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Murine embryonic stem (ES) cells are derived from the inner cell mass of the developing 
embryonic blastocyst. These cells can self renew which allows them to be propagated 
indefinitely in the laboratory and they can differentiate into cell types derived from all 
three germ layers.  Manipulation of the mouse genome using gene targeting techniques in 
conjunction with ES cell technology has provided valuable insights into embryonic 
development and cell lineage specification.   
 
KIT is a trans-membrane receptor tyrosine kinase (RTK) that dimerises upon binding to 
its ligand, stem cell factor (SCF) resulting in the auto-phosphorylation of intracellular 
kinase domains. This activity is crucial for the transmission of signals from the cell 
surface to the nucleus. KIT is expressed on stem and progenitor cells of many lineages 
and defects in the SCF/KIT signaling pathway causes detrimental effects at both the 
cellular and physiological level. This project aimed to investigate the role of the SCF/KIT 
signalling pathway during murine ES cell differentiation and survival.  
 
To assess the role of SCF/KIT signalling in ES cell proliferation and survival, we 





) cell lines. The self renewal and differentiation profile of these 
cell lines revealed an auxiliary role for SCF/KIT during ES cell self renewal and an 
absolute role in survival upon in vitro differentiation. This phenotype of apoptosis upon 
differentiation was recapitulated in wild type E14 ES cells treated with a KIT neutralising 
antibody (ACK2). Wild type cells that were treated with the JNK inhibitor, SP600125 
had a comparable phenotype to KIT null cells indicating that this could be one of the 
mediators of KIT signalling that has a protective role in the survival of differentiating ES 
cells.  
 
We hypothesised that blocking classical apoptotic pathways might prevent the death on 
differentiation observed in KIT null cells.  However, neither blocking the pro-apoptotic 
P38 pathway with the chemical inhibitor PD169316 nor over-expressing the pro-survival 
v 
 
protein BCL2 in KIT Null cells could prevent their apoptosis upon differentiation 
phenotype. This strongly suggests that these pathways are not involved in KIT mediated 
survival of differentiating ES cells.   
 
Although compensatory mechanisms are thought to exist for defective KIT signaling in 
vivo, an absolute role is assigned to KIT during ES cell differentiation. Further analysis of 
micro array data comparing gene expression from wild type E14 and KIT Null cell lines 
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1.1 THE DERIVATION OF EMBRYONIC STEM CELLS  
 
The first pluripotent cell lines, named Embryonic Carcinoma (EC) cells, were derived 
from the undifferentiated compartment of germ cell teratocarcinomas (Kleinsmith et al. 
1964; Martin et al 1981; Rippon et al. 2004).  These cells were employed as the early in 
vitro model for murine development (Kleinsmith et al. 1964) due to their ability to self 
renew and contribute to all tissues of the adult mouse after blastocyst injection (Illmensee 
et al. 1976). However, as EC cells are often aneuploid and harbor genetic abnormalities 
due to their teratocarcinoma origins (Andrews et al. 2005; Rippon et al. 2004), their 
contribution to medicinal therapy was severely compromised. This emphasised the 
requirement for a source of non- cancerous, pluripotent cells for clinical use.   
 
Pluripotent, murine embryonic stem (ES) cells were first derived from the inner cell mass 
of the pre-implantation blastocyst (Evans et al. 1981; Martin et al. 1981). Similarly to EC 
cells, ES cells have the ability to self renew (and therefore can grow continuously in 
culture) and differentiate into derivatives of all three embryonic germ layers; endoderm, 
ectoderm and mesoderm as well as contributing to the germ line as demonstrated by 
Bradley et al (1984) following blastocyst injection. ES cells differ from transformed 
tumour cell lines as they retain normal karyotypes, even after extensive passage (Evans et 
al 1981) and differ from adult stem cells as their self renewal potential allows the 
generation of large quantities of specific cells without the need for intrusive, surgical 
procedures.   
 
The ability of embryonic stem cells to differentiate into the three main germ layers, or 
pluripotency, has been of particular importance in many areas of research such as tissue 
engineering, drug discovery, regenerative medicine and the study of embryonic 
development and cellular differentiation (Keller et al. 1995; Keller 2005; Rippon et al. 
 3 
2004; Ronnstrand 2004; Thomson et al. 1998; Smith 2001). Manipulation of the mouse 
genome using gene targeting techniques in conjunction with ES cell technology has 
provided valuable insights into embryonic development, tissue lineage specification and 
specialised cells for therapeutic application. (Thomas et al. 1987; Beddington et al. 1989) 
 
 
1.2 THE MAINTENANCE OF UNDIFFERENTIATED ES CELLS  
Although pluripotent cells from the inner cell mass (ICM) are short lived in the 
developing embryo in vivo, murine ES cells can be maintained in their undifferentiated 
state for prolonged passage in vitro.  Initially, their self renewal capacity and successful 
prolonged growth was achieved upon co-culture with mouse embryonic fibroblast 
(MEFs) feeder layers (Evans et al. 1981; Martin 1981) indicating that MEFs not only 
acted as a matrix for ES cell growth but provided a source of growth factors and 
cytokines to maintain their proliferation and self renewal potential.  Further to this, 
analysis of MEF conditioned media and molecular examination of the ES cells 
themselves identified several key extrinsic and intrinsic factors for pluripotency 
maintenance. Identified extrinsic factors include the regulatory factor of Differentiation 
Inhibiting Activity (DIA) which is identical to the pleiotropic cytokine Leukaemia 
Inhibitory Factor (LIF) (Smith et al. 1988; Williams et al. 1988), Bone Morphogenic 
Proteins (BMP) Ying et al. (2003) and Wnts (Aubert et al. 2002; Sato et al. 2004) 
whereas intrinsic factors include OCT4 and NANOG (Chambers et al. 2004).    
1.2.1 Extrinsic factors 
LIF, a member of the IL6 family of cytokines, signals through the transmembrane 
receptor gp130.  Here, LIF binds to the LIF receptor and forms a trimeric complex with 
gp130 (Zhang et al. 1997) causing receptor dimerisation and signal transduction. The 
signal transducer and activator of transcription (STAT3) then phosphorylates to its active, 
dimeric form, locates to the nucleus to activate gene transcription for ES cell self-renewal 
(Yoshida et al. 1994; Niwa et al. 1998) 
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In the absence of serum, Bone Morphogenic Protein (BMP4) inhibits ES cell 
differentiation by the activation of SMADs which in turn, induce Id factors (Nakashima, 
Takizawa et al.2001; Ying et al. 2003). As BMP4 signalling primarily inhibits the 
differentiation of neuronal lineages and LIF signalling inhibits non-neural lineage 
development, both are required to maintain ES cell pluripotency in serum free ES cell 
cultures (Nakashima et al. 2001; Ruzinova et al. 2003).  WNTs are also implicated in 
short term ES cell pluripotency by suppressing neural differentiation (Aubert et al. 2002; 
Sato et al. 2004). 
 
1.2.2 Intrinsic factors 
OCT4 is a transcription factor which is expressed at various stages during embryonic 
development including the unfertilised egg, the embryo before ICM / trophoectoderm 
segregation, the ICM, the epiblast, the migratory germ cell and the gonadal ridge (Pesce 
et al. 2001; Chambers et al. 2004). Although OCT 4 alone can not prevent ES cell 
differentiation, continuous expression of OCT4 (Niwa et al. 2000) in conjunction with 
gp130 pathway activation (Chambers et al. 2004) is required in order to maintain 
pluripotency. In addition, the transcription factor SOX2 has been shown to enhance 
pluripotency by working in conjunction with OCT4 to synergistically activate the 
transcription of target genes E.g. FGF4 (Ambrosetti et al. 2000). 
 
 
Nanog is also a determinant of ES cell pluripotency (Chambers et al. 2003) and is only 
observed in cells that continually express Oct4 (Niwa et al. 2002). Within the developing 
embryo, Nanog is first observed in the morulae, then highly expressed in the early 
blastocyst but reduces prior to embryo implantation. Following implantation, Nanog is 
then re-expressed in epiblast cells and E9-13 migrating PGCs and PGCs of the genital 
ridge (Chambers et al. 2003). Although Nanog works separately form the STAT3 
pathway, it works in conjunction with LIF to provide ES cells with maximum self-
renewal potential (Chambers et al. 2004). 
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1.2.3 Intrinsic factors and iPs cells 
The importance of intrinsic factors becomes evident when considering the derivation of 
induced pluripotent stem (iPs) cells. iPs cells are generated from non-pluripotent adult 
somatic cells via the forced expression of retrovirally delivered transgenes involved in the 
intrinsic regulation of self renewal. During their derivation, iPs cells are cultured under 
conditions for self renewal and upon reaching a reprogrammed pluripotent state, forced 
transgene expression becomes silenced (Takahashi et al. 2007). iPs cells are similar to ES 
cells as they are able to self renew, express stem cell markers (murine ES cells SSEA-1 
Takahashi et al. 2006) (human ES cells SEA-3, SSEA-4, TRA-1-60, TRA-1-81, TRA-2-
49/6E, (Yu et al. 2007 ) and can be directed to differentiate into cell lineages of all three 
germ layers.    
Takahashi et al (2006) derived the first murine iPs cells by the forced expression of Oct-
3/4, Sox2, c-myc, and Klf4 by retrovirus transfection of mouse fibroblasts. Following this, 
human iPs cells were generated by 2 independent groups.  Takahashi et al (2007) induced 
pluripotency with the genes OCT3/4, SOX2, KLF4, and c-MYC with a retroviral system 
whereas Yu et al (2007) used OCT4, SOX2, NANOG, and LIN28 using a lentiviral 
system. (Takahashi et al 2007; Yu et al 2007) 
Although human ES cells differ form murine ES cells on several accounts e.g. human ES 
cells require bFGF for self-renewal (Amit. 2007) and differentiate in the presence of 
BMP whereas murine ES cells depend on the LIF/STAT 3 pathway in conjunction with 
BMP in order to maintain pluripotency (Matsuda et al 1999 ; Niwa et al 1998;Ying et al. 
2003) Takahashi et al (2007) have demonstrated that the transcription factors required to 
induce pluripotency in both human and murine models are consistent (OCT3/4, SOX2, 
KLF and c-MYC). Therefore, the system of transcription factors required for 
pluripotency maintenance is conserved between human and mouse. Interestingly, even 
though the same transcriptions factors can induce pluripotency in both species, transgene 
induced human cells grown under the culture conditions for murine ES cell/ iPs cell self 
renewal do not become reprogrammed.  Therefore, extrinsic factors and signals 
maintaining pluripotency are unique for each species. (Takahashi et al.  2007) 
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1.3 ES CELL DIFFERENTIATION 
 
Murine ES cells are directed to differentiate upon the withdrawal of LIF (Smith et al. 
1988; Williams et al. 1988) and lineage specific differentiation is achieved with a 
recognised differentiation system, defined culture conditions and the addition of known 
growth factor and cytokine cocktails. Universally employed differentiation systems 
include monolayer induction, co-culture with cell or matrix proteins, methylcellulose 
assays or the formation of embryoid bodies (EBs).  
 
When directed to differentiate in monolayers (LIF-), ES cells form mixed populations of 
cells from endodermal and mesodermal lineages (Mummary et al. 1990).  Under serum 
free conditions, the addition of retinoic acid initiates the formation of parietal endoderm 
(Smith et al. 1987) and in the presence of FGF-supplemented N2b27 media; neural 
precursors develop (Ying et al.  2003).   
 
Haematopoietic lineages can be induced via EB generation or by co-culture of ES cells 
with stromal cell lines (Nakano et al. 1994) or with explanted cells from the Aorta-
Gonad-Mesonephros (AGM) region (Medvinsky et al. 1996; Krassowska, Gordon-
Keylock et al. 2006).  Common stromal lines employed include OP9 and AM20-1B4 
(Krassowska, Gordon-Keylock et al. 2006) where both cell lines function to provide a 
microenvironment for haematopoietic differentiation and the development of 
multipotential haematopoietic lineages. Haematopoietic differentiation has also been 
observed with co-culture upon type IV collagen-coated dishes where haematopoietic 
lineages were derived from mesodermal precursors (Nishikawa et al 1998). 
 
 
EBs are aggregates of ES cells formed during their growth within a density rich medium 
such as methylcellulose or by „hanging drop‟ culture.  As methylcellulose formulation 
does not determine the number of cells per aggregate, the EBs produced by this system 
are often irregular in shape and size whereas, EBs generated from „hanging drop‟ cultures 
involve a defined cell number upon initial culture resulting in uniform aggregates. EBs 
uniformity is often required when comparing differentiation potential between cell lines 
or genetic modifications. EBs can generate cells expressing markers from all three germ 
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layers, (Itskovitz-Eldor et al. 2000) including hematopoietic cell lineages (Doetschman et 
al. 1985; Nakano et al. 1994; Nishikawa et al. 1998), endothelial cells (Risau et al. 1988; 
Yamashita et al. 2000), neuronal cells (Fraichard et al. 1995; Strubing et al. 1995) 
cardiomyocytes (Boheler et al. 2002) and bone derivatives (Buttery et al. 2001; Kramer et 
al. 2000). The 3D structure of EBs provides enhanced cell-cell and signalling interactions 
that are key to the generation of certain cell lineages that are otherwise unattainable by 
monolayer systems alone.  (Doetschman et al. 1985; Keller 1995).   
 
1.4 GENETIC MANIPULATION OF ES CELLS 
 
Modifications to the mouse genome arising from randomly integrated DNA or targeted 
DNA mutations in ES cells in vitro and subsequent generation of transgenic mice in vivo 
has greatly advanced our understanding of gene function, specifically in regard to 
mammalian development and disease progression. (Capecci et al. 1989, Beard et al. 
2006). The mutagenesis of ES cells has several advantages. Firstly, ES cells can be 
screened in vitro for the desired genetic alteration before being reintroduced into the 
embryo. Secondly, it is possible to study the effect of the genetic manipulation on ES cell 
differentiation using defined differentiation models in vitro. The third being their ability 
to contribute to the germline and thus allow direct analysis of the genetic modification in 
vivo by the generation of a mutant mouse.  
 
Both randomly inserted and targeted DNA can be introduced into the genome of ES cells 
by transfection, viral transfer or electroporation techniques (Capecci et al. 1989).  A 
random insertion event results in the indiscriminant incorporation of DNA (cloned or 
genomic) into the ES cell genome.  This method is generally employed to observe the 
effect of over expressing a desired gene during cellular differentiation or development. 
These sequences contain a selection cassette such as neomycin, puromycin or 
hygromycin to convey antibiotic resistance to resulting clones or contain reporter genes 
such as EGFP or LacZ to identify clones during selection (Gossler et al. 1989).  
Expression of these genes is driven by promoters such as the CMV promoter for 
constitutive expression (Schimidt et al. 1990) or an inducible promoter such as (CArG) 
for expression regulation (Worthington et al. 2005). 
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As ES cells are pluripotent in vivo and in vitro (Evans et al, 1981; Martin, 1981) and 
undergo homologous recombination, Thomas et al (1987) demonstrated that DNA could 
be integrated into the murine ES cell genome via homologous recombination and Bradley 
et al (1984) demonstrated that manipulated ES cells could contribute to the formation of 
chimeras and the germ line when reintroduced into murine blastocysts (Bradley et al., 
1984). Gene targeting relies on the site specific introduction of exogenous DNA into 
chromosomal DNA via homologous recombination. Gene alterations in this process 
include gene deletion, gene addition or subtle base pair alterations. Generally, vectors 
comprise of a gene or reporter sequence of interest flanked by 5‟- and a 3- regions of 
homology to the chromosomal loci of interest.  As targeting frequency is low, a positive 
selectable marker such as neomycin (neo) which confers resistance to the antibiotic 
kanamycin in bacteria and G418 in mammalian cells is employed to identify potential 
clones during selection. Other positive selection cassettes include hygromycin B (hygro)-
phosphotransferase and the puromycin (puro) gene. (Thomas et al. 1987; Lev. et al. 1994; 
Keller et al. 1995) 
 
1.5 THE IMPORTANCE OF SCF/KIT IN ES CELLS 
 
One signalling pathway associated with ES cell pluripotency (Palmqvist et
 
al., 2005; Lu 
et al 2007) and survival upon differentiation (Bashamboo et al. 2006) is the tyrosine 
kinase receptor KIT and its ligand SCF. Although there is some debate over the role of 
KIT signalling in ES cell self-renewal (Lu et al 2007, Palmqvist et al. 2005; Bashamboo 
et al. 2006) the research by Bashamboo et al associated the KIT receptor with a key role 
in murine ES cell survival upon differentiation and was the founding paper on which this 
study was based.  By employing a gene targeting strategy they ablated the Kit gene in ES 
cells and although the self renewal capacity of these cells was unaffected by the knock-
out mutation, they demonstrated that KIT Null ES cells perished by apoptosis upon 
differentiation in parallel with a reduced expression of the pro-survival protein BCL2. 
This research, for the first time, demonstrated an absolute requirement for KIT during ES 
cell differentiation via the pro-survival protein BCL2 and defined apoptosis as the 
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mechanism of cell death mediated by KIT ablation. To investigate the specific 
mechanisms by which SCF and KIT may promote ES cell self renewal as well as survival 
upon differentiation, it is of importance to understand the biology of this receptor-ligand 
pair including specific signalling events downstream and relate these events to cell 
survival upon differentiation, lineage specification and disease progression 
 
 
1.6 THE DISCOVERY OF THE KIT RECEPTOR AND ITS LIGAND STEM CELL FACTOR.  
 
The discovery of c-kit, its ligand SCF and their related function was nearly 70 years in 
the making. Primarily, investigations into spontaneous murine pigmentation defects lead 
to the discovery of the White spotting (W) and Steel (Sl) loci in 1920 and 1957 
respectively (Russel 1979).  These mutations were named in response to their resulting 
phenotypes where (W) heterozygotes displayed a characteristic white belly spot due to an 
inability of melanocyte migration from the neural crest to the ventral ectoderm and Sl 
heterozygotes were grey in colour and often white belly spots due to their overall 
deficiency of melanocytes (Mintz et al. 1957; Russel, 1979; Geissler et al. 1988).  
Following from this, many other W and Sl mutations were discovered and it was shown 
that these mutations affected three independent stem cell lineages; melanocytes, 
hematopoietic stem cells and primordial germ cells where phenotype severity depended 
on the nature of the mutation within each gene (Reith et al. 1991; Russell, 1979) (Table 
1).   
The striking phenotypic similarities between W and Sl mutations, even though located on 
two separate loci lead to the belief that these mutations were in some way related and 
could possibly encode a receptor ligand pair (Geissler et al. 1988). This hypothesis was 
supported by transplantation studies where W mutants were rescued by neural crest 
(Mayer et al. 1968) (site of melanocyte precursors) and bone marrow cells from wild-type 
embryos upon transplantation.  However, neural crest and bone marrow cells from wild-
type embryos did not proliferate or migrate in the Sl hosts. Similarly, when melanocyte 
and haematopoietic stem cells from W embryos were transplanted into irradiated wild-
type embryos, no stem cell proliferation or migration was observed whereas transplanted 
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Sl stem cells could both proliferate and migrate in wild-type environment (Bernstein et al. 
1968; Mayer et al. 1968).   Therefore, it was concluded that the W mutation affected the 
cellular constituent (receptor) whereas the Sl mutation affected the microenvironment in 




c-kit was originally identified as the viral oncogene v-kit which provided Hardy-
Zuckerman IV feline sarcoma virus with transforming activity (Besmer et al. 1986).  
Following from this, c-kit was cloned, sequenced and mapped to mouse chromosome 5 
and found to have genetic similarity not only to a tyrosine kinase region of v-kit but 
shared major structural features of with CSF1 and PDGF receptor subfamilies (Yarden et 
al. 1987).  Geissler et al (1988) then demonstrated an absence of c-kit expression in the 
W
19H 
cell line, a mutation in which the entire W locus has been deleted.  In comparison c-
kit expression was strong in the wild-type control mapping the location of c-kit to the W 
locus on chromosome 5. Further analysis of 2 other W mutants revealed gene 
rearrangements within c-kit gene (Geissler et al. 1988).  In 1990, Williams et al isolated 
the ligand for c-kit via immuno-precipitation techniques and reverse translation of this 
protein determined its identity as Stem Cell Factor (SCF).  Following from this, the gene 
encoding, SCF was cloned, sequenced and mapped to murine chromosome 10 (Copeland 
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Table 1. Phenotypes of W mutations.  
 
(aa=amino acid; E=Glutamine; K=Lycine; T = Threonine; N=Asparagine; D = Aspartic acid; 
V=Valine; M= Methionine) 
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1.7 KIT- A RECEPTOR WITH TYROSINE KINASE (RTK) ACTIVITY 
 
The development of many multicellular organisms is regulated by a combined 
arrangement of polypeptides, growth factors, differentiation factors, cytokines and 
hormones.  These factors act by binding to and activating cell surface receptors with 
protein tyrosine kinase activity (Ullrich et al.  1990).  There are approximately 20 RTK 
subgroups (Fantyl et al. 1993; Lemmon et al. 2010) with conserved molecular topology 
comprising of a signal sequence, a large glycosylated, extracellular ligand binding region, 
a hydrophobic transmembrane domain a juxtamembrane regulatory unit, a cytoplasmic 
domain with tyrosine kinase activity and a carboxy (C-) terminal. The evolutionary 
conserved structural components of RTKs and their associated signalling pathways, even 
between species, demonstrates their fundamental role in development and gene regulation 
(Lemmon et al.  2010).  
 
RTKs are activated upon specific ligand binding where upon binding, the extracellular 
region undergoes a conformational change causing two adjacent receptor monomers to 
dimerise. After dimerisation, ATP binds to the receptor where tyrosine kinase enzymes 
transfer a phosphate group from ATP to tyrosine residues on the receptor.  The receptor is 
then autophosphorylated and allows the phosphorylation of other cellular substrates 
downstream.  The conformation of the receptor‟s cytoplasmic domains determines 
molecule binding and these molecules are usually components of pre-existing signalling 
complexes that are found within the cytoplasm or located at the cell membrane. (Riedel et 
al. 1989).  The activity of ligand binding, receptor dimerisation and auto-phosphorylation 
is crucial for the transmission of a signal from the cell surface to the nucleus (Majumder, 
et al. 1988). After ligand binding and auto-phosphorylation, the receptor ligand complex 
is internalised by endocytosis and will continue to signal (Bergeron et al. 1995) until they 
enter into cell sorting pathways for degradation.  
 
 
1.7.1 KIT receptor structure 
 
KIT (also referred to as stem cell factor receptor or CD117) is a member of the RTK type 
III subfamily which also includes platelet-derived growth factor receptor (PDGFα and β), 
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the macrophage colony-stimulating-factor receptor (CSF-1), and the Fl cytokine receptor 
(Flk2/Flt3) (Fantyl et al. 1993). As well as containing the conserved features of RTKs, 
the Type III receptors are a distinctive subgroup with an extracellular region comprising 
of five immunoglobulin domains and an intracellular kinase domain separated into a 
proximal and distal regions by a kinase insert (Ullrich et al. 1990). Crystal analysis of 
KIT reveals that SCF binds to the first three extracellular, immunoglobulin regions of 
KIT and the „helix bundle‟ conformation of SCF facilitates dimerisation of the receptor 
upon binding (Lui et al. 2007).  The importance of the fourth extracellular 
immunoglobulin region was reported by Blechman et al (1995) who demonstrated that a 
deletion of this region destabilised receptor dimerisation and inhibited subsequent 
downstream signalling events (Blechman et al. 1995).  No definitive role has yet been 
assigned to the 5
th
 immunoglobulin region (Lui et al. 2007) but it is thought to be 
involved in proteolytic cleavage of the receptor from its membrane to its soluble form 
(Broudy et al.  2001).   
 
 
Alternative splicing in both human and murine mRNA can give rise to four different KIT 
isoforms in human and two in mouse.  Isoforms may lack a Gly-Asn-Asn-Lys (GNNK) 
sequence in the extracellular juxtamembrane segment (human and mouse) or lack a serine 
reside in the kinase insert region (human only) (Reith et al. 1991; Ashman, 1999). The 
isoforms have distinct characteristics where phosphorylation of
 
KIT and ERK1/2 
activation was more efficient in GNNK
– 
than for the GNNK
+
 isoform and GNNK
– 
promoted anchorage-independent growth, loss of contact
 
inhibition and increased 
tumorogenicity (Ashman, 1999) The function of the serine 
(–)
 isoform in the human is 
undefined but may be associated with PI3K signalling due its close proximately to the 
P13K binding site on the inter kinase site. (Crosier et al. 1993).  A truncated 3.3kb 
alternative- transcript of c-kit arising from a second promoter region in intron 16 and 
comprising of only the second part of the kinase domain (Rossi er al. 1992; Lennartson et 
al. 2005) has been detected in murine spermatozoa (Sakamoto et al. 2004) and murine 
hematopoietic stem cell and multipotent progenitors (Zayas et al. 2008).  Although tr-KIT 
lacks the ATP binding pocket, activation of the truncated form is thought to arise from 
interaction with the intracellular membrane protein FYN and activation is via kinase 
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phosphorylation and subsequent phosphorylation of PLCγ and mobilization of calcium 
from intracellular stores (Sette et al. 2002). 
 
The cytoplasmic region of KIT comprises of a juxtamembrane Region (JMR) and a 
tyrosine kinase domain that is split into a N lobe (proximal) and a C lobe (distal) by a 
kinase catalytic site (Figure 1).  The catalytic site is essential for enzyme function and 
stimulation of this site is regulated by an „activation loop‟ (A loop). This A loop is 20-25 
amino acid residues in length and inhibits kinase activity of the receptor by its location 
within the ATP binding pocket on the catalytic site. Upon ligand binding, dimerisation 
and conformation change of the receptor, the JMR becomes autophosphorylated on 
tyrosine residues (Tyr568 andTyr570), the activation loop moves from its inhibitory 
position and the conformation of the intracellular kinase domains extend and open 
allowing access to ATP to the ATP binding pocket in the kinase insert region. The 
receptor is now primed for phosphorylation on tyrosine residues and subsequent 
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Figure 1. A diagram of the KIT receptor outlining the main structural domains and 
corresponding amino acid codons. (adapted from Edling et al. 2007; Lennartsson 
et al. 2005) 
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1.7.2 Regulation of c-kit expression  
 
The Kit promoter is located approximately -124 and -83 base pairs (bp) from the 
initiation of translation site and contains binding sites for many transcription factors such 
as basic helix loop helix binding regions (bHLH) SP1, MITF AP-2, ETS, MYB, SCL and 
GATA-1. The major transcription start sites are located 62 and 58bp upstream of the 
translation site (Yamamto et al. 1993) and more distal positive and negative regulatory 
elements are found 5.5 kb upstream (Vandenbark et al. 1996; Ratajczak et.al 1998).   
 
 
Stem Cell Leukaemia (SCL also known as TAL 1) is a member of the basic bHLH family 
of transcription factors and plays a central role during haematopoiesis (Shivdasani et al. 
1995). SCL regulates gene expression by hetero-dimerising with E2A gene products (Hu 
et al. 1992) then binding to E-box DNA sequences (CANNTG) (Lécuyer et al. 2002). 
Using antisense Scl c-DNA or dominant negative SCL in TF-1 haematopoietic cell lines 
Krosel et al (1998) linked impaired SCL DNA binding to a reduction in c-kit expression 
and an increase in apoptosis progression.  Therefore, c-kit was identified as a potential 
down stream target of SCL. SCL and c-kit are co-expressed in primary haematopoietic 
precursors and an increase in SCL increases c-kit expression in B-cell precursors. 
Activation of the c-kit promoter during haematopoiesis requires a multifactorial ensemble 
of proteins including SCL, E2A, LMO2, LDB-1, and GATA1/2 and as assembly is 
driven by SCL, it is termed the SCL complex.  Activation of the c-kit promoter involves 
direct binding of the complex to promoter DNA via SCL and E2A and the assembly is 
secured to promoter DNA by specificity protein 1 (SP1) (Lécuyer et al.  2002) 
 
 
Huang et al (1998) demonstrated a direct correlation between AP-2 and c-kit expression 
over-expressing AP-2 in melanoma cells that were negative for both AP-2 and c-kit.  
Here, AP2 over-expression caused the induction of c-kit mRNA and protein with a 
concurrent reduction in metastatic potential of the cells indicating KIT mediated 




During erythropoiesis, the survival of early erythroid precursors is dependent on c-kit 
expression. Upon maturation, c-kit is down regulated by the transcription factor GATA 1 
and the mechanism of cell survival switches from c-kit to Epo expression (Pevny et al. 
1991; Munugalavadla et al. 2005). Although there are putative GATA 1 binding sites on 
the promoter region of c-kit, Munugalavadla et al (2005) did not relate the control of c-kit 
by GATA 1 to these sites on the promoter. However, Spinello et al (2009) have reported 
that GATA 1 and 2 associate with promyelocytic leukemia zinc-finger protein (PLZF) at 




1.7.3 The structure of Stem Cell Factor (SCF)  
 
The ligand for KIT, stem cell factor (SCF; also known as KIT ligand, mast cell growth 
factor, or steel factor) is expressed at varying stages during embryonic development and 
is expressed along the migratory pathways of primordial germ cells (De Felici et al.   
1994), melanocytes (Wehrle-Haller et al. 1995) and in sites of the developing 
haematopoietic system including the yolk sac, fetal liver, and bone marrow (Kallianpur et 
al. 1994 ; Silver et al. 1997 ; Bernex et al. 1996) as well as the brain, ovary, testis and 
retina (Toyooda et al. 2009; Ballow et al. 2006; McClanahan et al 1996; Wehrle-Haller 
1995; Blackshaw et al 2004; Wehrle-Haller et al. 2003) . Although SCF exists as a 
monomer under physiological conditions, dimerisation of SCF has been associated with 
KIT receptor activation and subsequent signal transduction. (Hsu et al. 1997; Zhang et al. 
2000; Xu et al. 2000).  Crystal analysis has determined that the SCF dimer complex 
comprises of two SCF monomers with head-to-head interaction to form an elongated 
homo-dimer stabilised by both polar and non-polar interactions (Xu et al. 2000; Zhang et 
al. 2000). SCF exists as both soluble and membrane bound forms arising from alternative 
mRNA splicing and proteolysis (Broudy et al. 1997). Both membrane and soluble 
isoforms have an extracellular region, a transmembrane component and an intracellular 
domain (Zhang et al. 2000).  The soluble form of SCF is created when the enzyme 
metalloprotease-9 cleaves after an alanine residue (ala189) in the extracellular region of 
SCF.  The membrane bound form is a result of alternative splicing within exon 6 which 
omits the cleavage site for metalloprotease  (Kridel et al. 2001).  The soluble form of SCF 
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causes the rapid activation and internalisation of the KIT receptor before it is 
endocytosed and degraded.  In contrast membrane bound SCF results in sustained 
receptor signalling possibly due to anchorage of the KIT/SCF complex and delayed 
ubuiquitination (Kissel et al. 2000). 
 
Deletion of both transmembrane and cytoplasmic regions of SCF has been observed in 
the steel mutant Sl
d
. Mice with this mutation only produce the soluble form of SCF and 
although viable, suffer from severe macrocytic anemia, reduced mast cell numbers, 
reduced melanocytes and are sterile. This implies that the soluble form of the ligand 
alone is insufficient for normal development. (Broudy et al.  1997) 
 
1.8 THE ROLE OF C-KIT DURING DEVELOPMENT 
 
As well as promoting ES cell self renewal and survival upon differentiation, the SCF/KIT 
pathway  has  been implicated in the survival of many stem and progenitor lineages 
including primordial germ cells (Dolci et al.
 
1991 ; Guerif et al. 2002) haematopoietic 
stem cells (HSCs) (Caceres-Cortes et al.
 
1999 ; Engstrom et al. 2003) neuronal stem cells 
(Erlandsson et
 
al. 2004) and melanocyte precursors (Ito et al. 1999; Wehrle-Haller
 
and 
Weston, 1995). Using a W 
lacZ/+
 transgenic mouse model,  Bernex et al (1996) 
demonstrated that KIT was expressed on a plethora of tissues throughout embryonic 
development which extended beyond those initially identified by W mutations.  
Following from this, specific point mutations in the KIT receptor identified downstream 
signalling proteins and events that were crucial to haematopoiesis (Agosti et al. 2004; 
2009), gametogenesis (Kissel et al. 2000), melanogenesis and mast cell development 
(Kimura et al. 2004).   
 
Observing the natural (wild type) progression of a developmental process in vivo and 
comparing these processes to developmental defects caused by aberrations in KIT 
signalling may provide insight into the specific periods at which Kit signalling is 
important during development.  This may be of importance when designing lineage 
specific ES cell differentiation strategies.  
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1.8.1 c-kit and melanogenesis 
In the dorsal region of the developing embryonic neural tube resides a population of 
pluripotent cells that have the potential to give rise to multiple lineages such as neurons, 
smooth muscle, bone, cartilage and melanocytes of the skin, inner ear and iris.  This 
population of cells is termed the neural crest (Bronner-Fraser et al. 1995).  Cells from this 
region undergo rapid proliferation and migrate to specific locations within the developing 
embryo dependent on cell lineage and environmental cues. Melanocytes are the pigment 
producing cells of the skin and melanoblast precursors are the first cells from the 
melanocyte lineage to appear from the neural crest.  Melanoblast precursors are defined 
from other cell populations in this region as they express c-kit, DOPA chrome 
tautomerase (Dct) and tyrosinase-related protein-2 (tryp-2) (Steel et al., 1992).   These 
cells first appear at E9.5 on the neural crest (Opdecamp et al.  1997) and by E10.5 
migrate to the basal layer of epidermis, hair follicles, the inner ear, uveal tract tail bud 
and leptomeninges. Melanocytes migrate from dorsal to ventral regions through the 
dermis to occupy the epidermis from E12.5-14 (Yoshida et al 1996). Epidermal 
melanocytes also expand in number and migrate through the epidermal basal layer 
between E13.0 and E15.5 (Yoshida et al. 1996).  Following birth, melanocytes are found 
as mature pigment cells in the skin, hair follicles, the choroid layer of the eye, the 
Harderian gland, the anal canal and the inner ear (Goding et al. 2000).  
Mice with W or S1 mutations or wild type mice treated with a KIT neutralising antibody 
lack coat pigmentation due to the failure of neural crest derived melanoblasts to survive 
and migrate to the skin and developing hair follicles (Bernex et al 1996; Nishikawaet al 
1991; Yoshida et al.1996; Hou et al. 2000). Melanocyes from Sl/Sl animals with no SCF 
are able to migrate from the neural crest but migration is terminated before reaching the 
dermis.  In contrast, melanocytes from Sl/Sl
d 
animals with no membrane bound SCF are 
able to migrate to the dermis but apoptose in this region soon after. This indicates that 
KIT signalling is not required for the initial stages of melanocyte migration from the 
neural crest but requires soluble SCF for their migration to the dermis where the 
membrane bound form become necessary for melanocyte survival (Wehrle-Haller et al, 
1995). 
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 Inoculation of a KIT neutralising antibody (ACK2) into pregnant mice at different 
periods throughout gestation have shown that KIT signalling becomes important at 
specific time points during melanogenesis. KIT is expressed on melanoblasts during their 
emergence to the neural crest at E9.5 and are required for dorso-lateral migration 
(Yoshida et al. 1996). Kit expression is not required for melanocyte entry to the 
epidermal layer at E12.5 but is regained at E13-15 (Yoshida et al. 1996; Bernex et al. 
1996; Nishikawa et al. 1991) during a proliferation stage in the epidermal layer where 
they become integrated into the hair follicles. Postnatal KIT dependence arises in 
proliferating and differentiating melanoblasts in hair follicles and proliferation is 
coordinated with the postnatal hair cycle (Nishikawa et al. 1991 Yoshida et al.1996). 
Neutralisation of KIT via administration of ACK2 into the peritoneal cavity of post natal 
animals resulted in loss of hair pigmentation that was not restored to the animal even 72 
days post injection. Inhibition of KIT signalling in melanoblasts located within the hair 
follicles interrupted their survival and differentiation potential and caused their demise by 
apoptosis.   
 
KIT mediated survival of migrating and differentiating melanoblasts to melanocyte 
lineages  is thought to arise from the activation of the Microphthalmia transcription factor 
(MITF) and the melanin catalising enzyme tyrosinase (Tyr), a down stream target of 
MITF (Gooding et al. 2000). MITF was also shown to promote survival of pigment cells 
by up-regulation of the major anti-apoptotic protein BCL2 (McGill et al. 2002). MITF 
has a basic helix loop helix structure and can bind to the E-box sequence contained 
within the KIT promoter to control transcription (Tsujimura et al.  1993).  During the 
early stages of melanogenesis MITF up-regulates c-kit  expression  in Melanoblasts 
(Opdecamp et al. 1997) but in later stage melanocytes and melanoma cells, KIT signaling 
leads to the activation of ERK 2 and (Hemesath et al. 1998) an increase in MITF 
phosphorylation. Analysis of neural crest cells from Kit 
W-LacZ/KitW-LacZ
 mice indicated that 
MITF alone is not sufficient for Tyr expression and that KIT signaling is needed not only 
for the proliferation and survival of melanoblasts but also later in development for Tyr 
induction and the transition of melanoblasts to mature Melanocytes (Hou et al. 2000) 
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1.8.2 c-kit and haematopoiesis  
Haematopoiesis arises from the continuous proliferation of stem cells, which upon 
differentiation form various cells of the haematopoietic system. These cell types have 
specialised function and include lineages such as erythrocytes, megakaryocytes 
granulocytes, monocytes and mast cells. (Bernstein et al. 1993; Paulson et al. 1995), 
Haematopoiesis occurs in two waves during embryonic development.  The first wave is 
termed primitive haematopoiesis and occurs within the yolk sac at E7.5. Following 
gastrulation, blood islands appear within the yolk sac which contains primitive 
erythrocytes that are morphologically distinct from their definitive adult counterparts. 
Although haematopoietic precursors found within the yolk sac have the potential to form 
definitive lineages they are unable to generate lymphocytes or HSCs prior to circulation 
onset (Cumano et al. 2001). The main function of the progenitors located at this site is to 
sustain the immediate requirements of the early embryo during early development 
(Medvinsky et al. 1996; Palais 1995; Palis et al. 1999; Keller, 2005) 
The second wave, termed definitive haematopoiesis, produces blood cell lineages that 
will create the adult haematopoietic system  Definitive haematopoiesis originates in the 
para-aortic splanchnopleura (P-Sp), which later becomes the developing aorta, gonads, 
and mesonephros (AGM) (Godin 1995; Medvinsky et al. 1996; Palis et al. 1999). 
Dissections of E8-9 embryos have attributed progenitors from this region with  
multipotent activity producing both lymphocytes and myeloid cells (Godin et al. 1995) 
and after E10 produces HSCs with long term repopulating potential (Medvinsky et al.  
1996). Subsequently, hematopoietic stem cells (HSCs) migrate from these regions to the 
fetal liver E11, thymus, and spleen.  Around the time of birth, the major site for 
haematopoiesis becomes the bone marrow, and this is maintained during adult life 
(Lennartson et al. 2005) 
 
Haematopoietic progenitors expressing KIT are primarily detected at E7.5 to E 9.5 in the 
blood islands of the embryonic yolk sac, from E9.5-E11.5 in the AGM (Palacious et al. 
1992; Bernex et al 1996; Silver et al. 1997) and by day E10.5 to E11.5
 
in the fetal liver 
(Palacious et al. 1992; Bernex et al 1996; Silver et al. 1997; Broudy et al. 1997) where 
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they progressively increase until day E15 and then decrease, (Palacious et al. 1992) 
paralleling the transition from yolk sac to fetal liver. Fetal thymus also contains KIT 
positive primitive T-lymphocyte and B-lymphocyte progenitors (Palacious et al.  1992
 
Hoang et at 1996; Broudy et al. 1997) where expression is down regulated upon terminal 
differentiation of the granulocyte-macrophage, B-,
 
and T-lymphoid lineages (Lécuyer et 
al.2002) (Figure 2). Although KIT expression is down regulated during haematopoietic 
cell differentiation to definitive blood lineages found in the adult, some haematopoietic 
cells (e.g. mast cells) maintain expression.   
 
W mutant mice display several haematopoietic defects which are restricted to erythroid 
and mast cell lineages which result in severe macrocytic anemia and mast cell deficiency 
respectively.  In particular, W/W
v
 mice are profoundly mast cell deficient containing no 
mast cells in the peritoneal cavity, gastrointestinal tract, respiratory system heart, brain or 
spleen.  In addition mast cell numbers in the skin are severely depleted in comparison to 
their wild type counterparts (Kitamura et al. 1978) and upon the removal of SCF from 
mast cells in vitro and in vivo, cells undergo rapid apoptosis (Iemura et al. 1994).  Sl/Sl
d
 
mutants contain reduced numbers of pluripotent haematopoietic stem cells contained 
within the yolk sac and fetal liver and mice homozygous for the W mutation die 
perinatally due to severe anemia (Russell, 1979). In the adult, anemia is induced when 
wild type mice are treated with the KIT blocking antibody ACK2 resulting in complete 
abolishment of haematopoietic progenitors from the bone marrow (Ogawa et al. 1991).  
 
 In the absence of KIT signalling other receptors have been shown to compensate for KIT 
e.g.The EPOr was shown to partially rescue erythroid formation in W/W mice (Waskow 
et al. 2002) and hepatocyte growth factor was shown to promote proliferation and 
















































Figure 2. KIT expression during the differentiation of haematopoietic stem 
cells.  Kit expression decreases upon terminal differentiation but expression 
remains high in megakaryocytes and mast cells (Lennartsson 2005).  Cell 
lineages that express KIT are depicted with a star.  
 24 
1.8.2 c-kit and germ cell development 
 
 
Primordial germ cells (PGCs) are the founding population of the germ cell lineage and 
develop concurrently with endoderm, mesoderm and ectoderm.  PGCs are first detected 
as alkaline phosphatase staining cells  (MacGregor et al. 1995) at E7 in the posterior  
primitive streak where they migrate to the allantois and then directly into the adjacent 
embryonic endoderm and the hindgut at E8, to reach the gonadal ridge at E9.5-11 
(Anderson et al. 2001).   
In the male, PGCs begin to rapidly proliferate within the developing testis and begin to 
differentiate to gonocytes which are mitotically inactive until a week after birth (Mclaren 
et al. 2003). After this time they migrate to the seminiferus tubuli and differentiate to A 
spermatogonia (De Rooij et al. 2001).  During their development, spermatogonia pass 
through stages of differentiation from A1-A4, and then differentiate to type b 
spermatogonia which are spermatocyte pre cursors. Spermatocytes then enter meiosis and 
differentiate into mature haploid spermatozoa by day 20 post partum. Males retain their 
type 1 stem cell like spermatogonia throughout life (DeRoojg et al.  1998) 
 
 
During female PGC development, PGCs begin to differentiate in the developing ovary 
upon reaching the gonadal ridge. They lose their motility, cease to proliferate and are 
termed oocytes which become enveloped in somatic granulosa cells. At E13.5, female 
germ cells initiate meiosis and pass through leptotene, zygotene and
 
pachytene stages of 
meiotic prophase before birth, then arrest
 
in the meiotic prophase diplotene stage until 
adulthood. Cells that are not surrounded by granulosa cells perish by apoptosis (Hutt et 
al. 2006; Pepling et al. 2001).  Upon reaching puberty a small number of primordial 
follicles are recruited into the growth and maturation phase of folliculogenesis whilst the 
remaining oocytes remain quiescent within the primordial follicles. Maturation onset is 
activated by a surge of pituitary Luteinizing hormone (LH) which recommences meiosis 
in the oocyte to metaphase II stage and the oocyte is ready for ovulation (Arnault et al. 
2008 ) 
c-kit is expressed in PGCs when they arrive at the base of the allantois at E7 (Manova et 
al. 1991).  c-kit mRNA is still present at E12·5 upon reaching the gonadal ridge in both 
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males and females (Orr-Urtreger et al. 1990). In the post natal mouse testis, c-kit is 
expressed in mitotic spermatogonia (Dolci et al. 2001), proliferating diploid 
spermatogonia with a reduction of expression in primary spermatocytes and is absent in 
post meiotic cells (Sorrentino et al., 1991). Round spermatids express a truncated version 
of c-kit during their differentiation into spermatoza and is also localised in the 
subacrosomal region of mature sperm (Sette et al. 1997). Injection of tr-kit into MII phase 
mouse oocysts results in reactivation of meiosis and triggers the calcium oscillations 
required for successful fertilisation onset (Sette et al.  2002) 
 
In the female, c-kit and SCF are expressed in zygotene/pachytene oocytes of the fetal 
mouse ovary at E 16.5- 17.5 (Doneda et al. 2002) and by E18.5, SCF expression is 
restricted to ovarian somatic tissue.   At birth SCF is high in the ovary then expression 
becomes associated with the granulosa cells (Manova et al. 1993).  Although present in 
migrating and mitotic PGCs, c-kit protein or mRNA is not present in germ cells 
undergoing first stage meiosis during fetal life (Manova et al. 1991).  c-kit expression is 
restored in diplotene oocytes (Manova et al. 1990), is expressed uniformly in primordial 
follicles and later stage follicles but expression decreases in antral follicles (Horrie et al 
1991; Hutt et al. 2006) 
 
 
SCF is expressed concurrently along the migratory pathways of the PGCs and is clearly 
expressed in the hind gut, ventral wall of the dorsal aorta, the mesentery and the genital 
ridge whereas c-kit is only expressed upon germ cells (Matsui et al 1990).  At this stage 
of migration and proliferation, the membrane bound form of SCF is most predominant 
(Manova et al 1993). In the testis SCF is produced by the sertoli cells (Ohta et al 2000) 




Mice homozygous for severe W and Sl mutations are sterile as the rapid proliferation of 
PGCs usually observed during E7-13.5 embryonic development fails to occur. 
Observations of mice with W or Sl mutations in one allele only has allowed the analysis 








have significantly reduced germ cell numbers and reduced germ cell development rates in 
both oocytes and spermatogonia (Reith et al. 1990). Using E8.5-10.5 pre-gonadal PGCs 
Dolci et al (1991) demonstrated the requirement for KIT signalling, with specific 
emphasis on membrane bound SCF, during PGC survival. Following this, Guerif et al. 
2002 evaluated the role of Kit during spermatogenesis onset and maintenance using a 
Kit
W-lacZ/+
 murine mode.  In comparison to their wild type counterparts, they found that 
Kit
W-lacZ/+
 mice had a reduction of several germ cell lineages ranging from type B 
spermatogonia to spermatozoa suggesting not only a smaller founding PGC population 
but also reduced proliferation rates in these mice. They also demonstrated that apoptosis 
was enhanced upon the first wave of spermatogenesis in Kit
W-lacZ/+ 
mice resulting in 
delayed meiosis, severely reduced sperm numbers and compromised fertility.  A similar 
result of reduced PGC number and inhibited sperm development was observed in Sl
17H
 
mutants during the first wave of spermatogenesis.  Although there was a significant 
reduction in female primordial and mature oocytes, female Sl
17H
 mutants remained fertile 
(Brannan et al. 1992). Yan et al.,
 
2000 showed that spermatogonia, spermatocytes and 
spermatids survival was positively correlated with increasing levels of SCF whereas 
blocking the KIT receptor with ACK2 was negatively correlated to cell survival where 




1.9 KIT MEDIATED SIGNALLING PATHWAYS 
 
Bashamboo et al (2006) reported a fundamental role for the SCF/KIT signalling pathway 
during ES cell differentiation and survival.  Although they highlighted BCL2 as a 
survival protein expressed during the differentiation process, they did not identify a 
specific down stream pathway or mechanism that was responsible for this survival.  An 
understanding of the signalling pathways and function of effectors mediated by KIT 
signalling would allow the identification and investigation of potential survival pathways 








The SRC family of tyrosine kinases, named after its founding member c-src, includes 
members such as BLK, FGR, HCK, LCK, and LYN which are primarily expressed in 
hematopoietic lineages (Abram et al. 2000). Linnekin et al 1997 demonstrated that LYN 
is the dominant SRC family member expressed in SCF responsive haematopoietic 
progenitor cells and treatment of these cells with an antisense Lyn specific 
oligonucleotide or a SRC inhibitor (PP1) reduced SCF induced proliferation, indicating a 
critical role for LYN in KIT mediated proliferation. Shivakrupa et al 2005 also showed 
that LYN deficient mice had reduced mast cell SCF induced proliferation rates when 
compared with the wild type control.  Using a KIT fusion protein Linnekin et al 1997 
demonstrated that the SRC Kinase interacts with phosphotyrosine residues 568 and 570 
in the KIT Juxtamembrane segment via a SH2 domain (Figure 3). Using a mutated KIT 
receptor that had point mutations at 7 different  residues, Hong et al demonstrated that 
mitogenic potential, survival and migration properties of  the 32D myeloid cell line was 
only rescued when tyrosines 568 and 570 were restored to the receptor. Restoration also 
reactivated the Ras/Erk and Rac/JNK pathways.   
 
1.9.2 Adapter proteins  
 
Adapter proteins have the ability to interact with multiple proteins simultaneously due to 
containing multiple binding domains.  APS is an adapter protein that binds to KIT at 
tyrosine 568, a residue that also binds CHK, SHC and SRC (Wollberg et al 2003). Upon 
phosphorylation APS binds to the ubiquitin E3 ligase CBL whose action links ubiquitin 
to the KIT receptor resulting in their internalization and degradation (Hu et al. 2005; 
Yokouchi et al. 1999) 
 
1.9.3 SHP1/2 phosphatase 
 
SHP1 and SHP2 are phosphotyrosyl phosphatases which are primarily expressed in 
haematopoietic and epithelial cells and comprise of two SH2 domains and a phosphatase 
domain.  Shp1 and Shp2 phosphatase bind to tyrosine 570 and 568 within the 
Juxtamembrane segment of KIT and have the ability to inhibit KIT signalling by 
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dephosphorylation of the receptor directly or by dephosporylating its downstream protein 































































Proliferation and Survival 
AKT 
Figure 3. The SCF/KIT receptor signalling pathway and associated downstream 
effectors (adapted from Lennartsson et al.  2005; Rönnstrand et al 2004) 
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1.9.4 Phosphatidylinositol 3-kinase activation (PI3K) 
 
Phosphatidylinositol 3-kinase (PI3K) represents a class of lipid kinases that 
phosphorylate the 3- hydroxyl group of phosphatidylinositol-4,5-bisphosphate (PIP2) to 
create phosphatidylinositol-3,4,5-trisphosphate(PIP3). PIP3 is able to bind with proteins 
containing a pleckstrin homology (PH) domain, resulting in their recruitment to the 
plasma membrane and subsequent activation (Foster et al. 2003).  There are three classes 
of PI3K (I,II and III).  Class I PI3K is most associated with intracellular RTK signalling 
and consists of a regulatory subunit (p85) and a catalytic subunit (P110).  The regulatory 
subunit contains a SH3 domain, a RHO-GTPase domain and two SH2 domains (Fruman 
et al. 1998) whereas the catalytic subunit contains a RAS binding domain and a 
phosphatidylinositol kinase accessory (PIKa) domain. The regulatory subunit binds to 
target proteins with SH2 homology causing PI3K to change conformation and become 
activated (Carpenter et al. 1993) as well as binding with adapter proteins CBL, CRKII 
and CRKL (Ronnestrand et al. 2004).  The p110 subunit contains enzymatic activity to 
phosphorylate phosphoinositides (Fruman et al. 1998). 
 
PI3K associates with activated RTKs by binding to phosphorylated tyrosine residues by 
one or both SH2 domains and interacts with KIT on tyrosine 721 (mouse 719) (Lev et al. 
1994).  Binding and activation of PI3K occurs at the plasma membrane where PI3K 
substrates such as AKT (also referred to as protein kinase PKB) are located.  AKT is a 
serine threonine kinase downstream of PI3K and is associated with cell survival. Blume 
et al (1998) demonstrated that binding of PI3K to KIT promotes survival in human 
embryonic kidney (HEK) cells via PI3K dependent activation of AKT resulting in 
phosphorylation and inactivation of the pro-apoptotic protein BAD.  KIT mediated 
activation of PI3K and AKT has also been implicated in the survival of haematopoietic 
progenitors by the phosphorylation and inactivation of pro-apoptotic forkhead 
transcription factors (Engstrom et al. 2003) as well as the survival and proliferation of 




A role for PI3K was first observed in ES cells via the generation of a PTEN (phosphatase 
and tensin homologue) null cell line.  PTEN dephosphorylates PIP3 to negatively 
regulate PI3K signalling.  PTEN null ES cells displayed increased levels of 
phosphorylated AKT with enhanced ES cell proliferation rates even under reduce serum 
conditions.  Survival in these cells was attributed to the phosphorylation and inactivation 
of the pro-apoptotic protein BAD (Sun et al, 1999).  Using  LY294002, an inhibitor of 
PI3K, Paling et al. 2004 demonstrated a reduction of AKT phosphorylation alongside a 
reduction in ES cell self renewal potential.  Concurrently, an up-regulation of ERK, a 
protein linked with ES cell differentiation in reduced levels of LIF (Burdon et al 1999), 
was observed.  When LY294002 was used in conjunction with the MEK inhibitor U0126, 
inhibition of self renewal was reversed associating the mechanism of PI3K mediated self 
renewal with ERK regulation.  In particular, the p110 catalytic sub unit of P13K appears 
to have a role in both the self renewal and proliferation of ES cells that is isoform 
dependent where the p110α isoform was involved with proliferation whereas the p110β 
subunit regulates self-renewal (Kingham et al. 2009). Upstream regulation of PI3K 





Phospholipase C-γ (PLC-γ) exists as two isoforms (1 and 2) which contain two SH2 
domains, a PH domain and a catalytic domain.  Isoform 1 is expressed ubiquitously 
whereas as 2 is expressed predominantly in the haematopoietic system (Carpenter et al. 
1999).  Activation of PLC-γ hydrolyses phosphoinositide PIP2, to create diacylglycerol 
(DAG) and inositol-1,4,5-trisphosphate (IP3).  DAG activates Protein Kinase C whereas 
IP3 interacts with the endoplasmic reticulum (ER) to release stored Ca2+ (Putney 2002).  
Using a mutant KIT receptor Gommerman et al (2000) demonstrated that PLCγ interacts 
with tyrosine 730 in 32D cells.  Interestingly, tr-KIT   which is present in haploid 
spermatozoa, associates with the SH2 domain of PLCγ and is essential for tr-KIT–





1.9.6 The Ras/Erk pathway 
 
RAS is a G-protein that switches from its inactive form when bound to GDP to an active 
form when bound to GTP (Lewis et al. 1997). This phosphorylation exchange and 
activation of RAS occurs at the inner cell membrane and is mediated by the guanine 
nucleotide exchange factor SOS, which exists in the cell as a protein complex with GRB2 
(Hancock et al. 2003).   The SOS-GRB2 protein complex binds to KIT via a SHP2 
domain at tyrosine residues 703 and 936 (Thömmes et al. 1999).  Upon phosphorylation, 
RAS activates RAF-1 which in turn, activates MEK1 and MEK2 whose downstream 
targets include ERK1 and ERK2.  Activated ERKs dimerise upon phosphorylation then 
translocate to the nucleus to phosphorylate transcription factors and modulate gene 





1.9.7 The JAK/STAT pathway 
 
The Janus kinases (JAKs) are cytoplasmic tyrosine kinases that activate the Signal 
Transducers and Activators of Transcription (STATS).  STATS are transcription factors 
with DNA binding domains and SH2 domains that dimerise upon phosphorylation 
initiating translocation to the nucleus for gene expression and regulation (Rawlings et al.  
2004).   Stimulation of the KIT receptor with SCF leads to the association of JAK2 with 
KIT, its subsequent phosphorylation then activation of STAT1α, 3, 5a and 5b (Gotoh et 
al. 1996). SCF induced JAK/STAT activation is reported to play a crucial role in the 
proliferation and differentiation of fetal liver haematopoietic progenitor cells. . (Linnekin 
et al, 1996; Radosevic et al. 2004).  
 
 
1.10 MAPK SIGNALLING 
 
Mitogen-activated protein kinases (MAPKs) are serine/threonine-specific protein kinases 
that regulate cellular response to extracellular stimuli such as mitogens, heat shock and 
pro-inflammatory cytokines to elicit alterations in gene expression, mitosis, 
differentiation, proliferation, and apoptosis (Pearson et al. 2001; Davis et al. 2000; 
Kyriaki eet al. 2001). Signaling via the MAPK pathway involves an intracellular and 
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sequential phosphorylation cascade where upstream MAPKKKs phoshorylate and 
activate MAPKKs then MAPKs downstream (Davis et al. 1993; Seger et al. 1993) 
Several MAPKs have been identified in mammalian cells including extracellular signal-
regulated kinases (ERK -ERK 1/2 or p44/p42), c-Jun N-terminal kinases (JNK/SAPK 1-
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Figure 4 After stimulation by growth factors, cytokines or stress, MAPK signalling 
pathways progress as three sequentially activated proteins; a MAPK kinase kinase 
(MAPKKK), a MAPK kinase (MAPKK) and a MAPK. Pathways are organised by 







ERKs 1/2 are activated by dual phosphorylation on threonine 183 and tyrosine 185 
residues on their conserved Thr-Glu-Tyr motif (Chong et al. 2003).  Upon activation, 
ERKs phosphorylate membrane proteins such as CD120a, Syk, and calnexin; the nuclear 
substrates SRC-1, PAX6, NF-AT, ELK-1, MEF2, c-FOS, c-MYC, and STAT3 and 
cytoskeletal proteins (Chen et al.  2001; Aouadi et al. 2006).  However, ERK signalling is 
not required for the self renewal or proliferation of ES cells (Niwa et al. 1998; Burdon et 
al. 1999; Burdon et al. 2002).  Furthermore, by deregulating SHP2 activation of ERK or 
using the MEK inhibitor PD098059, Burdon et al (1999) showed that inhibition of ERK 
activity enhanced ES cell self renewal and proliferation (Burdon et al. 1999).  Upon 
differentiation, both ERK1 and ERK2 have distinct roles during development and Pages 
et al (1999) demonstrated that ERK1 knockout mice, although viable and fertile, were 
defective in thymocyte maturation with reduced cell expression of CD4+CD8+ and T cell 
receptors. Mice with ablated ERK 1 also displayed reduced adipose tissue development, 
were resistant to a high fat diet and were protected against insulin resistance (Bost et al. 
2005).  Conversely, ERK2 knockout mice were embryonic lethal at E6.5due to 
trophoblast and placental tissue malformation in C57BL/6 mice (Saba-El-Leil et al. 2003) 
whereas a lack of ERK2 caused embryonic lethality in E6.5 BALB/C mice due to 






P38 is predominantly activated by MKK3 and MKK6 by dual phosphorylation of 
threonine 180 and tyrosine 182, which are separated by a glycine residue in the sequence 
Thr-Gly-Tyr (TGY) (Enslen et al. 1998). The activation of p38 is initiated by cytokines, 
hyperthermia, osmotic stress and radiation and upon activation contributes to 
inflammation, apoptosis and cellular transformation. (Zarubin et al. 2005).  In vivo, p38α-
deficient mice die at E10.5–11.5 due to of defective placenta formation and deficient 
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vascularisation.  In addition angiogenesis was abnormal in the yolk sac, the embryo 
proper myocardium and encephalon (Mudgett et al. 2000). 
 
Of the four p38 (α,β,γ and δ) isoforms only p38(which will now be referred to as p38) 
is expressed in ES cells (Allen et al. 2000) and is associated with early apoptotic events 
during ES cell differentiation.  Inhibition of this pathway in differentiating ES cells 
increases cell survival with an up regulation of BCL2 (Duval et al. 2004) and a reduced 
level of apoptosis. This phenotype is of particular importance as differentiating KIT Null 
ES cells apoptose upon differentiation with a down regulation of BCL2 (Bashamboo et 
al. 2006).  This correlative phenotype may attribute KIT signalling with a p38 inhibitory 
effect during ES cell survival.      
 
As well as mediating apoptosis in ES cells, p38 has been associated with lineage 
specification and its expression occurs in two waves during ES cell differentiation.  One 
wave occurs between 2-5 days LIF withdrawal (Aouadi et al.2006) and controls a switch 
between cardiomyogenesis and neurogenesis.  Using retinoic acid to induce neuronal 
differentiation and consequently inhibit cardiomyogenesis, Aouadi et al (2006) showed 
that RA inhibited the wave of p38 α activity at days 2-5 with neuronal lineage formation. 
They also showed that p38
-/-
 ES and p38 inhibitor (PD169316) treated cells 
spontaneously differentiated into neurons and did not form cardiomyocytes.   The second 





JNK, also known as stress related kinase (SAPK) is activated specifically upstream by 
MKK4 and MKK7 and participates in complex signaling pathways which result in a 
plethora of cellular processes from cell proliferation to differentiation and cell survival to 
programmed cell death (IP et al. 1998; Liu, 2004). MKK4 and MKK7 phoshorylate the 
Threonine -Proline-Tyrosine (Thr-Pro-Tyr) motif of JNK and dual phosphorylation is 
required to activate JNK and substantiate embryogenesis and cellular development (Wada 
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et al. 2004). Once activated, JNK translocates to the nucleus to regulate transcription 
through phosphorylation of several transcription factors such factors such as JUN, MYC 
and ATF2; AP-1 proteins, including JUNB, JUND (IP et al.  1998) as well as members of 
the BCL2 family (Davis et al. 2000; Nishina et al. 2003; Wada et al. 2004).  
 
JNK is encoded by 3 genes Jnk1, Jnk2 and Jnk3. Jnk1 and Jnk2 are expressed 
ubiquitously in many tissues but Jnk3 is expressed selectively in neurons (Davis 2000). 
Similarly to the ERK and p38 MAPK pathways, JNK is not required for the self-renewal 
or maintenance of ES cells in vitro (Xu 2010). Using ES cells derived from jnk1, jnk2 or 
jnk3 knockout mice Amura et al (2005) reported a requirement for JNK1 during RA 
induced neurogenesis.  JNK1
-/-
 ES cells failed to differentiate into neuronal lineages but 
were associated with enhanced epithelial induction as determined by increased expression 
of E-cadherin Wnt-4, Wnt-6 and BMP4. Therefore during ES cell differentiation, JNK1 
activity enhances neuronal lineages by repressing epithelial lineage signalling pathways. 
(Amuraet et al. 2005) 
 
The action of JNK throughout development is varied contributing to the differentiation of 
primitive endoderm (Kanungo et al. 2000; Lee et al. 2004), ectoderm and cardiac lineages 
(Xu, 2010). Although a single knock out of Jnk1, Jnk2 or Jnk 3 does not affect 
embryonic viability, double knock out of both Jnk1 and Jnk2 causes early embryonic 
lethality due to abnormal neuronal apoptosis (Davis et al. 2000; Kuan et al. 1999; 
Sabapathy et al.1999). Here, murine embryos lacking both Jnk1 and Jnk2 had reduced 
cell death during hindbrain development but increased cell death during forebrain 





1.10.4 KIT and MAPK 
 
c-kit has been associated with JNK expression via Src activation, where Src members 
bind to phosphorylated residues at positions 567 and 569, 567, and 569 (Hong et al, 
2004).  Here FYN activates JNK in the sequence; FYN-GAB2-SHP2-VAV-PAK-RAC-
JNK and plays an essential role in mast cell migration (Samayawardhena et al. 2008).  
JNK activation has also been observed down stream of KIT-mediated PI3K activation in 
the survival of 32D tumourigenic myeloid cell lines (Chian et al. 2001). ERK1/2 and  p38 
also associate with the KIT receptor via the SRC binding site tyrosine 567 to enhance 
Ca
2+
 influx and cell migration in the pro-B cell line BAF3 and human embryonic kidney 
cells 293T (Ueda et al. 2002).  Additionally ERK is activated via KIT-mediated 
recruitment of SOS - GRB2 protein complex which binds to KIT via a SHP2 domain at 






1.11.1 The anti-apoptotic role of SCF/KIT 
 
Relating KIT signalling with anti-apoptotic proteins has been demonstrated in several 
studies.  Kapur et al (2001) demonstrated that SCF/KIT was essential for the expression 
of BCL2, EPOr and STAT 5 in GATA1 deficient ES cells.  SCF-mediated up-regulation 
of STAT 5 results in enhanced BCL2 and BCL-xl expression in immature erythroid cells 
(Socolovsky et al. 1999).  Endo et al (2001) demonstrated that KIT-induced the 
phosphorylation of AKT which in turn phosphorylated and therefore inactivated the 
binding of BAD to BCL-XL.  BCL-XL is an important anti-apoptotic molecule in 
haematopoietic progenitors as it inhibits apoptosome formation and subsequently inhibits 
caspase cleavage and activation and mitochondrial pore formation (Jofesen et al.  2000).  
Hu et al 2008 associated a decrease in hepatocyte apoptosis with an increase in KIT-




Upon differentiation, ES cells are reported to under go a period of apoptotic crisis where 
only cells maintaining within a certain, undefined threshold are able to survive to 
differentiated lineages.  It has also been proposed that the signals required for ES cell 
survival upon differentiation are equivalent but require balance for survival (Duval et al. 
2000). Bashamboo et al (2006) reported an apoptotic phenotype in differentiating KIT 
Null ES cells; with a concurrent down regulation of BCL2 indicating that SCF-KIT is 
essential for the survival of differentiating ES cells in vitro by suppressing apoptosis via 
the pro survival protein, BCL2. To further investigate the role of KIT in ES cell survival 
it is of importance to understand the mechanisms of cell death, their consequences and 




1.11.2 Distinguishing the process of apoptosis from necrosis 
 
Apoptosis is a distinct and ordered program of energy-dependent, caspase-mediated cell 
death. Morphological features of apoptosis include cell shrinkage, membrane blebbing, 
organelle packing, nuclear fragmentation and chromatin condensation (Kerr et al. 1972.)  
Apoptosis can be distinguished from necrosis in several ways.  Necrosis is an irregular 
energy-independent, passive form of cell death where degradative processes include cell 
swelling, dissolution of chromatin, cell rupture and the recruitment of inflammatory cells 
(Manjo et al. 1995).  
 
Unlike necrosing cells, apoptotic cells do not rupture but form membrane bound cell 
fragments (apoptotic bodies) that express phagocytic markers for macrophages, 
parenchymal cells, or neoplastic cells resulting in their subsequent engulfment and 
degredation within phagolysosomes (Elmore, 2007). As apoptotic cells do not release 
cellular constituents but are quickly engulfed by phagocytic cells without the production 
of anti-inflammatory cytokines, the process of apoptosis occurs independently from 
inflammation (Kurosakaet al. 2003). Although there are specific differences between the 
two processes, an apoptotic process has the potential to convert to necrosis if the 
apoptotic stimulus is extended over a long time period in conjunction with a decrease in 
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1.11.3 Biochemical features of apoptosis 
 
Caspases are cysteine proteases whose activities arise via protein cleavage of specific 
aspartate residues (Thornberry et al. 1998). Caspases are ubiquitously expressed but are 
maintained as zymogens under physiological conditions. Caspases have been categorised 
according to function where “initiator” caspases such as caspase-8 and caspase-9 
proteolytically cleave and activate “executioner” caspases (caspase-3, caspase-6, and 
caspase-7) which subsequently target protein substrates for degradation (Shi et al. 2002).  
Caspase 12 is another mediator of apoptosis but is specifically involved with the stress 
response mediated by the endoplasmic reticulum (Nakagawa et al. 2000). At the cellular 
level both inactive pro-caspases and cleaved activated caspases can be detected in a 
number of ways including Western blot, immuno-histochemistry or fluorescently 
conjugated caspase inhibitors such as FAM-VAD-FMK (Grabarek et al. 2002).  
 
 
Apoptosis is often characterized by DNA fragmentation caused by calcium and 
magnesium ion dependent endonucleases which fragment DNA into segments of 180-200 
base pairs (Kerr et al 1972; Wyllie et al. 1980). Endonucleases selectively cleave DNA at 
sites located between nucleosomal units (linker DNA) to produce DNA fragments that 
form a distinctive ladder pattern when resolved on agarose gel during electrophoresis. 
Another detection method involves the TUNEL (Terminal dUTP Nick End-Labeling) 
assay where DNA end breaks are labeled with probe conjugated UTP to allow detection 
by light microscopy, fluorescence microscopy or flow cytometry. (Kressel et al. 1994).  
The apoptotoic phenotype of chromatin condensation and nuclear fragmentation can be 
envisaged using the fluorescent dye 4'-6-Diamidino-2-phenylindole (DAPI) and light 
microscopy.  This dye forms fluorescent complexes with natural double-stranded DNA 
and stains brightly in small, fragmented apoptotic nuclei whereas staining in viable cells 
is diffuse (Hamada et al. 1983). 
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Although membrane integrity is maintained during the early onset of apoptosis, 
disruption of membrane asymmetry occurs where exposure of phosphatidylserine (PS) 
from the inner to the outer lipid bilayer acts as a recognition and engulfment ligand to 
phagocytes (Bratton et al. 1997).  As Annexin V binds to PS in a Ca2+ dependent 
manner, Annexin V can be conjugated to fluorescent dyes and used in conjunction with 
Flow Cytometry to detect early apoptotic cells within a population. Loss of membrane 
integrity is a feature of necrotic cells and because of this, apoptotic cells can be 
distinguished from necrotic cells by exposing the cell population to a double stain of 
Propidium Iodide (PI) and Annexin V.  PI is a cell membrane impermeable dye that can 
only enter compromised cell membranes.  Upon double staining, cells in the early phase 
of apoptosis will express Annexin V only, cells under late phase apoptosis will express 
both Annexin V and PI; whereas necrotic cells with damaged cell membranes will be PI 
positive only.  
 
 
1.11.4 Mechanisms of Apoptosis 
 
There are three main pathways that a cell follows during the process of apoptosis; the 
„extrinsic‟ pathway which recruits death receptors; the „intrinsic‟ pathway involving the 
mitochondria; and the „perforin/granzyme A‟ pathway. All three processes converge to 
activate executioner caspase 3 to initiate cellular apoptotic degradation and debris 
clearance by phagosomes (Figure 5). The extrinsic pathway involves the recruitment of 
transmembrane death receptors and their corresponding ligands such as FASL/FASR, 
TNF-α/TNFR1, APO3L/DR3, APO2L/DR4 and APO2L/DR5.  These receptors contain a 
cytoplasmic death domain that is key for signal transduction and activation of the caspase 











































Figure 5 Schematic showing the 3 pathways associated with apoptosis; 
extrinsic, intrinsic as well as the perforin / granzyme pathway. Upon 
stimulation by specific ligands (extrinsic), cell stress (intrinsic) or Cytotoxic T 
cells, energy-dependent caspase cascades are triggered to activate the 
executioner pathways resulting in the morphological features associated with 
apoptosis. Adapted from Elmore, 2007 
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The intrinsic pathway of apoptosis is triggered in several ways including withdrawal of 
growth factors, loss of anti-apoptotic signal, hypoxia, radiation, hyperthermia or 
infection. As a result of intrinsic initiation, mitochondrial membrane potential is lost 
allowing the permeation of pro-apoptotic proteins from the mitochondrial inter-
membrane space to the cytosol (Saelens et al. 2004). Cytochrome c, Smac/DIABLO and 
HtrA2/Omi released from the mitochondria then cause the interaction and clustering  of 
APAF1 and caspase 9 to form an apoptosome which triggers  the caspase cascade 
(Adams 2003; Wang et al. 2001). Interestingly, the membrane potential of the 
mitochondria is also thought to be regulated, in part, by the Endoplasmic reticulum (ER). 
The ER is a major store of calcium ions and disruption of the endoplasmic reticulum 
results in an efflux of calcium ions into the cytosol. Uptake of these ions by the 
mitochondrion results in loss of mitochondrial membrane potential and cell death 
initiation. Hawkins et al (2000) have shown that Ca
2+
 signaling occurs between the 
mitochondrion and the ER and that the ER may provide a critical signal for mitochondrial 
disruption. 
In late apoptotic events, other pro-apoptotic proteins are released from the mitochondria 
and include AIF, endonuclease G and CAD.  AIF and endonuclease G translocate to the 
nucleus to cleave nuclear chromatin and cause DNA fragmentation independently from 
the caspase cascade (Susin et al. 2000) whereas CAD relies on caspase cleavage before 
translocation to the nucleus causing DNA fragmentation (Susin et al. 2000).   
 
Cytotoxic T -lymphocytes (CTLs) employ the perforin/granzyme pathway of apoptosis in 
order to eliminate virus-infected or transformed cells. CTLs use perforin to form a pore in 
target cells through wich they secrete the apoptosis inducing serine proteases Granzyme 
A and B (Trapani et al. 2002).  Granzyme B has the ability to cleave proteins at aspartate 
residues, activate both initiator and executioner caspases and the ensuing caspase 
cascade. (Goping et al. 2003).  On the other hand, Granzyme A activates caspase 
independent pathways and instead initiates apoptosis by activating NM23-H1, a 
chromosomal DNA damaging DNase (Fan et al. 2003; Martinvalet et al. 2005).  
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The execution pathway marks the activation of the execution caspases and the final 
stages of apoptosis.  Here, execution caspases initiate nuclear degradation and cleavage 
of cytoskeletal proteins such as PARP, cytokeratins and alpha fodrin via endonucleases 
and proteases. (Slee et al. 2001).  In particular caspase 3 activates the endonuclease CAD 
to degrade chromosomal DNA, cause chromatin condensation as well as the 
reorganization of cellular components into apoptotic bodies (Sakahira et al. 1998).  The 
exposure of PS on the cell surface of apoptotic cells and apoptotic bodies is key for 
phagocytic recognition and degradation and marks the final sage of the apoptotic process.  
 
 
1.11.5 The action of BCL2 
 
The control of apoptosis within the cell and the regulation of mitochondrial events occur 
via the Bcl2 family. The Bcl2 family consists of 20 apoptotic regulators that both 
contribute to and oppose apoptosis (Figure 6).  Members of this family fall into three 
categories, BCL2, BH3 or BAX (Figure 6) (Lindsten et al. 2000; Cuconati et al. 2002). 
The BCL2 group promotes cell survival by inhibiting pro-apoptotic members of the BAX 
group via inactivation of initiator caspases as well as inhibition of BAX and BAK  
mediated mobilization of Ca
2+
 from ER stores and its uptake into mitochondria (Nutt et 
al. 2002; Zong et al. 2003). BCL2 is located on the cytoplasmic face of the mitochondrial 
membrane, the endoplasmic reticulum and the nuclear envelope.  Upon apoptotic stimuli, 
pro-and anti-apoptotic members of the Bcl2 family congregate at these areas in order to 
mediate apoptotic events (Hsu et al. 1997). The BH3 group, in particular BAD, is 
activated upon dephosphorylation (Zha, et al. 1996) in response to developmental cues, 
insufficient growth factors and intracellular damage (Huang et al. 2000).  BAD elicits cell 
death by directly binding to and antagonising the action of BCL2 members as well as 
enhancing the activity of the BAX group. Both BAX and BAK form aggregates upon 
activation and have the ability to activate initiator caspases and pemeablise the outer 
mitochondrial membrane.  This permeabilisation allows the flow of apoptotic proteins 
and the release of cytochrome c from the mitochondrion to the cytosol (Wang et al. 2001; 
Adams. 2003).  
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Figure 6 A simplified flow diagram indicating the relationship between 
anti-apoptotic and pro-apoptotic proteins of the BCL2 family (Lindsten 
et al. 2000; Adams 2003).  
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1.11.6 Apoptosis in development 
 
Apoptosis not only proceeds in order to eliminate defective cells but is essential in 
maintaining homeostasis during normal development. Apoptosis is required during the 
process of spermatozoid and oocyte maturation and acts to remove germ cells that have 
undergone DNA damage or mutations during DNA replication Rodriguez et al. 1998) 
There are two waves of apoptosis during germ cell development.  The first being at E13 
during PGC migration to the gonadal ridge (Larsen et al. 1993) and the second at day 13 
post partum when the spermatogonia undergo a phase of rapid proliferation.  Apoptosis 
during oogenesis involves two main meiotic processes; an early phase involving the 
oogonia and oocytes in the preleptotene stage and a later phase concerning the oocytes in 
the pachytene stage (De Pol et al. 1998).  Apoptosis is present in the mammalian 
blastocyst and distortions of apoptosis during blastocyst formation results in embryonic 
death or fetus abnormalities (Brison et al. 1997; Brill et al. 1999). In the post implantation 
embryo apoptosis functions to eliminate redundant cells, control cell proliferation and 
sculpt structures such as the fingers (Zakeri et al. 1997) and removal of the pronephric 





1.12 KIT AND HUMAN DISEASE 
 
The association of KIT with human disease arises from receptor gain or loss of function 
mutations (Figure 7) and their resulting downstream signalling abnormalities. Loss of 
function mutations present human syndromes, such as autosomal-dominant piebaldism, 
displaying phenotypes in man that are similar to the W mutations described in mice. 
These defects include skin and hair pigment anomalies, deafness, megacolon and defects 
in the development of the interstitial cells of Cajal (ICC) (Spritz et al.1994) 
 
c-kit gain of function mutations can be divided into two classes; mutations that reside in 
the juxtamembrane region of KIT and those that reside in the distal kinase region (Sattler 
et al. 2004). X-ray crystallography indicates that the juxtamembrane domain negatively 
regulates KIT by inserting into and inactivating the proximal kinase domain by blocking 
formation of the active receptor conformation (Chan et al. 2003).  Mutations in the JMD 
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are responsible for disrupting the inhibitory effect of the JMD/kinase domain interaction 
allowing constitutive c-kit activation and dimerisation.  Human disease that arise from 
this mutation include GIST (Furitsu et al. 1993; Duensing et al. 2004) sinonasal 
lymphomas (Hongyo et al.  2000) and mastocytosis (Buttner et al. 1998) 
 
The second region that generates activating mutations is the distal kinase and codon 816 
which causes ligand independent activation of the receptor (Moriyama et al. 1996).  
Disease associated with gain of function in the distal kinase domain include mastocytosis 
(Nagata et al. 1995), mast cell leukemia, acute myeloid leukemia (Ashman et al. 1999; 
Ning et al. 2001), testicular germ cell tumors (Tian et al. 1999) and ovarian 
dysgerminomas (Pauls et al. 2004).  Additionally, Core binding factor (CBF)-acute 
myeloid leukemia (AML) arises through mutations of exon 8 which corresponds to the 
immunoglobulin loop 5 in the extracellular region.  Mutation within this region cause 
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Figure 7. A diagram of the KIT receptor and point mutations causing 
loss or gain of receptor function. (Nocka et al. 1991; Tsujimura et al. 
1993; Reith et al. 1990; Geissler et al. 1981; Lennartsson et al.  2006) 
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Gain of function mutations are typically treated with the chemical inhibitor Imatinib.  
Imatinib binds to the proximal kinase domain of the KIT receptor and locks the receptor 
in its inactive conformation. Prolonged exposure of KIT to Imatinib can result in acquired 
resistance due to secondary, activating mutations in the distal kinase. Severe side effects 
have also been reported with this inhibitor as Imatinib is not KIT specific but 
concurrently inactivates other receptors such as PDGFßR, BCR-ABL, ABL and ARG. 
(Demetri et al. 2002; Buchdunger et al. 2002).  Although Imatinib can inhibit both wild 
type and JMD mutant receptors (Frost et al. 2002), it is functionless in the treatment of 
constituently active mutations such as codon 816 in the distal kinase.  This mutant 
receptor is always in its activated conformation which impedes Imatinib binding.   
Distal kinase mutations have been alleviated by the KIT activation loop specific ATP 
based inhibitors AP23464 and AP23848. Although these drugs can also inhibit the 
function of JMD mutant receptors, efficacy was only reached at extremely high inhibitor 
concentrations (Corbin et al. 2005) Other drugs effective against both JMD and distal 
kinase mutations of KIT include the indolinone chemicals SU6577, SU11652, SU11654 
and SU11655 (Ma et al. 2000; Lennartsson et al. 2006) .  These drugs are currently under 
investigation to alleviate the problems of side effects and secondary receptor mutations. 
However, none of these drugs are effective against Loss of function mutations.   
ACK2 is a KIT specific monoclonal antibody that functions by binding to and 
inactivating the extracellular ligand binding region of the receptor and therefore inhibits 
receptor dimerisation and subsequent downstream signalling events (Yoshinaga et al. 
1991). At the cellular level and in experimental animal models ACK2 has been employed 
to demonstrate the effect of KIT inhibition during the development of the blood system 
and self renewal of haematopoietic progenitors (Ogawa et al. 1991), during peristaltic 
movement of the ICC within the gut (Maeda et al. 1992), apoptosis induction in c-Kit 
positive melanoblasts (Ito et al. 1995), melanocyte development (Nishikawa et al. 1991) 
and during spermatogenesis (Yoshinaga et al. 1991).  Therefore, gaining insight of KIT 
mediated development and disease progression at the molecular level will ensure optimal 
treatment determination and identification of potential targets for novel drug therapies. 
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1.13 PROJECT RATIONALE  
 
The SCF/KIT signalling pathway has been implicated in the survival of many stem and 
progenitor lineages during their proliferation, differentiation and survival.  Bashamboo et 
al (2006) also revealed a critical role for KIT during ES cell survival upon differentiation 
via the pro-survival protein BCL2.  However the specific signalling events involved with 
differentiating ES cell survival had not been elucidated. Characterisation of the signalling 
pathways regulated by KIT during ES cell differentiation will not only reveal essential 
pathways required during ES cell survival upon differentiation but also identify key 
signalling events during lineage specification.  This is of particular importance for 
understanding the process of embryogenesis and the generation of a consistent supply of 
defined cell lineages for regenerative medicine and cellular therapy.  Understanding the 
consequences of inappropriate KIT signalling will also identify targets for novel drug 





Three key hypotheses were addressed in this study to further the research of Bashamboo 
et al and elucidate the role of KIT during ES cell self renewal, proliferation and survival 




Hypothesis 1:   
KIT is not an essential factor in ES cell self renewal but becomes an essential survival 
factor upon ES cell differentiation 
 
 Bashamboo et al (2006) claimed that although KIT was an essential factor for ES 
cell differentiation it was not essential to the process of ES cell self renewal 
whereas Lu et al (2007) reported that KIT was involved in the maintenance of 
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undifferentiated ES cells and could serve as a marker of ES cells with optimal 
differentiation.  Can this discrepancy be addressed in this study? 
 Is the death upon differentiation phenotype specific to the Bashamboo KIT Null 
clone? Can this phenotype be recapitulated in a newly derived ES cell model?  
 How does a KIT Null mutation / KIT inhibition by ACK2 affect the self renewal 
and differentiation profile of ES cells? 






Hypothesis 2:   
KIT Null cells die by apoptosis upon differentiation and inhibition of these apoptotic 
processes may support cells through the apoptotic crisis to allow survival upon 
differentiation. 
 
 The mechanism of KIT Null ES cell death was previously reported as apoptosis. 
Can this be confirmed? 
 Can inhibitors of apoptotic pathways prevent the KIT Null death upon 
differentiation phenotype? 
 KIT survival upon differentiation has been associated with the pro-survival 













Hypothesis 3:   
KIT mediated survival of differentiating ES cells may act through activation of the JNK 
pathway. 
 
 JNK activity has been associated with both pro and anti apoptotic effects 
depending on cell lineage and stage of development.  What is the effect of JNK 
inhibition during ES cell self renewal and differentiation? 
 What downstream effectors are affected by a block in JNK? 
































































2.1 MOLECULAR BIOLOGY TECHNIQUES  
 
Standard molecular biology techniques and associated solutions were carried out and 
produced in accordance with the Molecular Cloning Laboratory Manual (Sambrook et al., 
1989) unless otherwise stated.  
 
2.1.1 Transformation of bacterial cells  
 
Chemically competent DH5α cells (TOP10, Invitrogen) were thawed and incubated on 
ice with 1μl of plasmid DNA or 5-20μl of ligation product for 20 minutes.  The heat 
„shock technique‟ facilitated DNA entry into DH5α cells where the cell/DNA mixture 
was incubated at 42ºC for 45 seconds and then directly transferred to ice and incubated 
for 2 minutes. The resulting transformation reaction was placed into a 15ml Falcon tube 
containing 500μl SOC medium (Super optimal culture broth - supplied with the 
competent cells, Invitrogen) and incubated at 37ºC for 1 hour in an orbital shaker at 
200rpm. A 50μl and 450μl aliquot of the transformation product was spread onto LB 
plates with an appropriate antibiotic and left to grow at 37ºC overnight.  
 
 
2.1.2 Plasmid preparation (Miniprep and Maxiprep) 
 
Single colonies picked from an overnight LB plate culture (described in 2.1.1) were 
grown in individual 5ml (Miniprep) or 200 to 400ml (Maxiprep) antibiotic containing 
medium and incubated at 37ºC overnight in an orbital shaker (200rpm). After 12-16 
hours the cells were harvested by centrifugation (Miniprep – 6, 000g for 5 minutes; 
Maxiprep - 3000 x g for 20 minutes at 4°C) and plasmid DNA was isolated from the cells 
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in accordance with the QIAgen kit Miniprep/Maxiprep manufacturers recommendations 
and protocol.  
 
 
2.1.3 Preparation of glycerol stocks 
 
5mls of LB (Luria-Bertani) broth was inoculated with one bacterial colony from an 
overnight LB plate culture (described in 2.1.1).  The bacterial cells were allowed to 
incubate for 8-12 hours at 37ºC at 200rpm in an orbital shaker then 800μl of the cells 
were added to 200µl of 80% autoclaved glycerol (in water).  The cell and 80% glycerol 
mixture was vortexed briefly before immediately freezing and storing at -80C in cryo-
tubes. To grow the cells from glycerol stocks, a pipette tip was gently touched onto the 
surface of the glycerol stock and placed immediately into 5mls of LB broth where it was 
incubated for 8 -12 hours at 37ºC at 200rpm in an orbital shaker. 
 
2.1.4 DNA extraction from animal tissue and ES cells  
 
Cells under investigation were grown to confluence in 25cm2 tissue culture flasks, washed 
twice with PBS before adding 2 mls of genomic DNA extraction buffer (4M Urea, 10mM 
CDTA, 0.5% sarcosyl, 0.1M Tris pH8 and 0.2M NaCl) supplemented with 1mg/ml 
Proteinase K and incubated with gentle agitation overnight at 55ºC. To precipitate the 
genomic DNA from the lysis reaction, 2mls of isopropanol was added directly to the 
flask and gently agitated at ambient temperature for 5 minutes. When visible, the white 
DNA precipitate was spooled from the flask using a pipette tip and placed into a 1.5ml 
eppendorf then resuspended in 500μl EB. To extract genomic DNA from ES cells grown 
on a 96-well plate, the cells were washed once with 100μl of PBS before adding 50μl of 
ES cell lysis buffer (10mM Tris pH7.5, 10mM EDTA, 10mM NaOH, 0.5% sarcosyl) and 
1mg/ml Proteinase K to each well. The plate was incubated in a pre-humidified chamber 
at 55ºC with gentle agitation overnight. After incubation, DNA was precipitated by 
adding 200μl of 7.5mM NaOH in 95% ethanol to each well of the plate using a multi-
channel pipette. The plates were then incubated at ambient temperature for 4-12 hours 
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before discarding the supernatant by up turning the plate onto absorbent material. The 
wells were then washed 3 times with 100μl of 70% ethanol and then air-dried 30 minutes. 
At this stage the DNA was enzymatically digested in preparation for Southern Blot (2.3) 
 
 
2.1.5 Polymerase Chain Reaction (PCR)  
 
PCR was used for the production of the Southern probe, generation of the EGFP-Flag-
BCL2 fusion protein PCR product isolated from the P513-kEGFP-Flag-BCL2 vector 
(Duval, Malaise et al. 2004), cDNA analysis and multiplex PCR for WT E14, 
heterozygous and KIT Null clones. A representative PCR reaction generally contained 10 
to 100ng template DNA along with 10μM of 2 primers each in 2x PCR buffer (Promega) 
containing MgCl2 (1.5mM) dNTPs (10μM) and 1unit of Taq DNA polymerase 
(Invitrogen) to a final volume of 25μl in nuclease free water (supplied with the Promega 
2 X buffer). The template DNA was amplified in a HYBAID PCR-Express machine. A 
typical PCR proceeded as follows: 2 minutes denaturing at 94ºC followed by 30-32 
cycles of 94ºC for 15 seconds, 55ºC for 30 seconds, 72ºC for 1 minute and a final 




Genomic DNA was extracted from 96 well plates cells are described above (2.1.4) and 
PCR was carried out using the parameter described (2.1.5). Multiplex PCR was carried 
out using the following primer sets;  
LacZ1 (5‟-GCATCGAGCTGGGTAATAAGCG-3‟, forward); 
LacZ2 (5‟-GACACCAGACCAACTGGTAATGGTAGCG-3‟, reverse); 
Kit1 (5‟-TCCTGTTGGTCCTGCTCC-3‟, forward);  
Kit2 (5‟-GTGGTAGGCATGGGAAAAG-3‟, reverse)  
The LacZ primer pair amplified an 800 bp-fragment of the LacZ gene and the Kit primer 
pair amplified a 148 bp-fragment of Kit.  Heterozygotes displayed both bands (Hou, 
Panthier et al. 2000) .  Resulting PCR fragments were run on a 0.75% gel with Ethidium 
bromide and visualized under UV illumination.  
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2.1.6 RT PCR 
 
Cells or Embryoid bodies (EBs) were harvested by trypsinisation or sedimentation 
respectively and given two washes in PBS before being snap frozen at -80 ºC.  The pellet 
was either stored at this stage or employed directly in the Quiagen RNeasy mini Kit for 
„mammalian cell RNA isolation‟ according to manufacturer‟s instructions (Quiagen).  
Simply, 10
7
 cells were disrupted with buffer RLT and homogenised using a pipette tip 
(cells) or passed through a 20-gauge (0.9 mm) needle attached to a sterile plastic syringe.  
An equal volume of 7% ethanol was added to the homogenate before addition to the spin 
colum and spun at 8000 x g for 15 seconds.  The supernatant was discarded and buffer   
RW1 was added to the spin column and centrifuged for 15 seconds at 8000xg.  Following 
this the supernatant was discarded and the column was washed a further two times with 
buffer RPE.  RNA was eluted from the column using RNAse free water. Keeping the 
resulting samples on ice, the concentration of the eluted RNA was determined by the 
nanodrop spectrophotometer (ND-1000) and associated software.  1U of DNAse 1 
(Roche) and 1 μl of DNAse buffer were added to 1 µg of RNA to make a final volume of 
10 µl.  This mixture was heated at 37°C for 15 minutes or 75°C or 10 minutes to 
inactivate the enzyme.  This was carried out in duplicate in order to produce a cDNA and 
a –reverse transcriptase (-RT) control.  Using the high capacity cDNA reverse 
transcriptase kit from AB Applied Biosystems, 1 µg of RNA was transcribed to cDNA 
according to manufacturer‟s instructions. –RT samples included RNAse free water  to 
replace the  reverse transcriptase enzyme and cycle conditions were as follows; 25°C for 
10 minutes; 37°Cfor 120 minutes; 85°C for 5 minutes and 4°C holding stage. 10ng of the 
resulting cDNA or –RT control was added to 2X Promega master mix with 10μM of 5‟ 
and 3‟ primers for c-kit and β-Tubulin to a final volume of 25μl.  The primers for c-Kit 
and β-Tubulin were as follows; 
 
c-Kit 1 (5‟- TCC TCA CTC ACG GGC GGA TC, 3‟ forward)  
c-Kit 2 (5‟-TGG AGG TGG GGT GGG GAA CT  3‟, reverse) 
β-Tubulin 1(5‟- GGAACATAGCCGTAAACT 3‟, forward)  
β-Tubulin 2(5‟- TCACTGTGCCTGAACTTA  3‟ reverse) 
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The c-kit primer pair amplified an 668 bp-fragment of the Kit gene and the β-Tubulin 
primer pair amplified a 300 bp-fragment of β-Tubulin gene.  Cycle conditions were 95°C 
5 min denature step; 25-35 cycles: 95°C 30 seconds denature step; 55°C  30 seconds 
annealing primer with single strand DNA template; 72°C 30 seconds extension step and 
72°C 8 minutes final extension step.  Resulting cDNA samples and controls were added 
to ethidium bromide stained 1% agarose gels and separated and visualized by gel 





RNA was isolated from cells as described (2.1.6) from heterozygous and KIT null clones 
developed by Bashamboo et al (2006) (Het1 and Null 1) and with newly derived 
Heterozygous and KIT null clones (Het 2 and Null 2). RNA was isolated from three 
independent experiments grown in the presence of LIF. TaqMan analysis was carried out 
by Gillian Cowan (2009 PhD thesis) and performed using the Roche Universal Probe 
Library with the primers   
 
Oct4 1 (5‟- TGAGGCTACAGGACACCTTTC 3‟forward) 
Oct4 2 (5‟-TGCCAAAGTGGGGACCT 3‟ reverse) 
Nanog 1  (5‟ –AGCCTCCAGCAGATGCAA  3‟forward) 
Nanog 2 (5‟ GGTTTTGAAACCAGGTCTTAACC 3‟ reverse) 
Relative expression, with error bars, was presented as bar charts. 
 
 
2.1.7 Restriction digest  
 
DNA was cut with an appropriate restriction enzyme and buffer then incubated for 2-16 
hours at an enzyme dependent optimal temperature. If restriction reaction required two 
enzymes, the buffer allowing maximum activity to both enzymes was selected.  Efficient 
restriction was visualized by fragment separation by gel electrophoresis.  
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2.1.8 Sequencing  
 
A sample (5μl) of purified plasmid DNA isolated by Miniprep (2.1.2) was combined with 
1μl of 10mM uni-direction primer then submitted for automated sequence analysis by the 
University of Edinburgh‟s School of Biological Sciences Sequencing Service. 
Sequencing reactions were carried out according to the manufacturer‟s specifications, 
using the ABI PRISM Big-dye terminator premix sequencing kit (Perkin-Elmer) where 




2.2 ES CELL ELECTROPORATION  
 
2.2.1 DNA preparation for electroporation 
  
20μg of targeting vector was linearised with an appropriate enzyme overnight (2.1.7) at a 
temperature optimal to the enzyme. The restriction reaction was subsequently purified 
using an equal volume of 50:50 phenol: chloroform solution. The mixture was vortexed, 
spun at full speed in an Eppendorf 5415D microfuge for 10 minutes before recovering the 
aqueous phase.  This purification step was repeated. The purified and linearised vector 
DNA was then precipitated with ammonium acetate and isopropanol, washed with 70% 




2.2.2 Electroporation Technique 
 
3x107 cells were pelleted by centrifugation (1000rpm for 5 minutes) then resuspended in 
600µl of sterile PBS.  This suspension was then gently mixed with 20μg of linearised and 
purified targeting vector DNA (as described 2.2.1) and transferred into an electroporation 
cuvette (Invitrogen, 0.4cm gap). The cells were electroporated in a GenePulserTM (Biorad) 
with one pulse of 250V set at a capacitance of 500μF. After a recovery period of 5 
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minutes on ice,  the electroporated cells were resuspend in 110mls (10mls per plate) of 
LIF containing ES cell growth media and placed into 11 pre-gelatinised 10cm tissue 
culture grade Petri-dishes. An additional plate containing only WT E14 cells was set up 
concurrently as a non-electroporated cell control. The cells were allowed to adhere to the 
plates overnight before replacing the media with antibiotic and LIF containing media.  Of 
the 11 electroporated plates, 10 were treated with antibiotic/LIF containing media to 
identify resistant cell clones.  The remaining plate was treated with LIF containing media 
only, to identify any contaminants arising from the electroporation process that would be 
masked on addition of the antibiotic.   The non-electroporated control cells were grown in 
the presence of the antibiotic to validate the efficacy of the antibiotic. Cells were treated 
for approximately 9 days with the antibiotic with daily fluid and media changes after 
which time individual resistant clones were picked and placed into individual wells of a 
96 well plate in the presence of Antibiotic /LIF containing media.  Upon reaching 70-
80% confluency the cells were trypsinised and re-plated in triplicate, into fresh pre-
gelatinised 96 well plates using a multichannel pipette with a fresh tip per clone. When 
reaching 70-80% confluency, 2 plates were cryopreserved for further expansion upon 
identification of correctly targeted clones.  To cryopreserve, cells were trypsinised with 
50μl of trypsin and then agitated into single cells suspension on addition of 50μl of 20% 
DMSO in fetal calf serum. The plate was sealed with parafilm, placed into an insulated 
polystyrene container and stored at -80ºC. The remaining plate was allowed to grow to 
100% confluency for DNA extraction and Southern blot analysis.   
 
 
2.2.3 Generation of heterozygous and KIT Null clones  
 
To generate the heterozygous (KitW
-lacZ/+
) cell line, wild type ES cells were 
electroporated (as 2.2.2) with 20μg of NotI- linearised and purified pGN Δ-Kit targeting 
vector DNA. To generate the KIT Null (Kit 
W-lacZ/W-lacZ
) cells, the heterozygous Kit 
W-lacZ/+
 




tissue culture grade Petri-dishes then selected 
with 2mg/ml G418 for 15 days (Lefebvre, Bai et al. 2001). Resistant colonies were 
picked, replicated in 96-well dishes and genomic DNA was isolated from expanded 
colonies for screening, using established protocols (Laird, Zijderveld et al. 1991)  
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2.2.4 X-gal stain of targeted clones. 
 
This assay was designed to envisage the in situ detection of cells carrying the lacZ gene. 
lacZ encodes the β-galactosidase enzyme which catalyses the hydrolosis of the β-
galactoside, X-gal. This reaction results in the release of galactose and 5-bromo-4-chloro-
3-hydroxyindole. 5-bromo-4-chloro-3-hydroxyindole is then oxidised to 5,5'-dibromo-
4,4'-dichloro-indigo, a blue insoluble product that easily distinguishes the presence of a 
functional lacZ gene by light microscopy.   
Media was aspirated from targeted clone monolayers grown in 96 well plates (as 2.2.2).  
100µl of 0.05% glutaraldehyde in PBS (Sigma) was added to each well using a 
multichannel pipette and incubated for 5 minutes at RT. The supernatant was discarded 
by aspiration and the monolayers were gently washed twice with 100μl of PBS. On the 
final wash, the PBS was left to contact the cells for 10minutes at RT.  After the 
incubation the PBS was aspirated and replaced with 200μl of X-gal solution. (sigma).  
Cells were incubated at 37°C at 5% CO2 for 2-24 hours. Positive clones with functional 
lacZ turn blue. 
 
2.2.5 ACK2- APC detection of targeted clones. 
 
 KIT Null (Kit 
W-lacZ/W-lacZ
 ) were screened for KIT protein expression by flow cytometry 
using the ACK2-APC conjugated antibody (eBioscience),  an APC- conjugated Rat 
IgG2b isotype control and unstained cells.  6x10
5
 WT E14 and KIT Null cells were 
resuspended in 450µl of PBS.  150 µl of each cell line was divided between 3 separate 
15ml falcon tubes and labeled „stained‟(ACK2-APC), „unstained‟ or „isotype control‟ 
(APC-Isotype control).  5 µl of the appropriated antibody (0.015μg) or PBS (for 
unstained sample) was added to each tube and incubated under foil at +4°C for 20 
minutes.  After this incubation period, 5mls of PBS was added to each tube and 
centrifuged at 1200rpm for 5 minutes.  The supernatant was discarded and 400µl of PBS 
was added to each tube then transferred to fresh appropriately labeled FACS tubes.  
Samples were then analysed using Flow cytometry with the FACS Caliber cytometer 
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(633 nm laser) and analysed using CellQuest software (Becton Dickinson). Resulting data 




2.3 SOUTHERN BLOT 
 
2.3.1. The Southern Blot Technique 
  
Genomic DNA (10μg) was digested with an appropriate enzyme overnight (EcoRI) at a 
temperature optimal to the enzyme. DNA was precipitated with ammonium acetate and 
isopropanol then resuspended in 30μl of nuclease free water. 
 
Genomic DNA isolated from a 96-wellplate was restricted using a cocktail containing 1x 
buffer, 1mM spermidine, 100μg/ml RNAse and 10units of restriction enzyme.  30μl of 
this restriction cocktail was added per well using a multi-channel pipette then incubated 
overnight in a pre-humidified chamber at a temperature optimal to the restriction enzyme. 
10X loading buffer was added to each well before adding the restriction fragments to a 
0.7% agarose gel alongside a 1KB+ genomic ladder (Invitrogen). The fragments were 
resolved on gel at 20V overnight and the resulting gel picture was captured using a UV-
doc system (Uvitec).  A ruler placed next to the DNA ladder allowed sizing of the DNA 
fragments upon Southern Blot development. Following this, the gel was depurinated for 5 
minutes in depurination solution (10.25ml HCl in 500ml H2O) and denatured for 45 
minutes in 0.5M NaOH and 1.5M NaCl then further 15 minutes incubation in 10XSSC 
neutralisation solution.  DNA from the denatured gel was then transferred Hybond N+ 
membrane (Amersham) by wet Southern Blotting Capillary Transfer as described in 
(Sambrook et al., 1989). The DNA was blotted onto the membrane overnight and upon 
disassembly, the location of each well was marked lightly onto the membrane with 
pencil. The membrane was rinsed in 2XSSC and air-dried then the DNA was cross linked 
to the membrane by exposing the membrane to UV light for 2 minutes using the UVdoc 




2.3.2 Probe generation, radioactive labeling and purification 
 
Procedures involving radioactive materials and reagents were carried out in a designated 
radioactivity area in accordance with The University of Edinburgh‟s Working with 
Radioactivity guidelines.  The Southern probe DNA was generated by high fidelity PCR 




Probe 1 (5‟- CAAGAGGAAAGTGTAGCTCGATG 3‟ forward) 
Probe 2 (5‟ CAAGAGGAAAGTGTAGCTCGATG 3‟ reverse) 
 
The probe was generated by PCR amplification (Invitrogen, Platinum Taq Polymerase 
High Fidelity kit) with the following settings: 94C for 5min then 30 cycles of 94C for 
15sec, 55C for 30sec, and 72C for 1min followed by 72C for 10min. The resulting PCR 
fragment was gel purified with a Quiagen gel purification kit in accordance with 
manufactures instructions and 100ng of purified DNA was denatured by adding nuclease 
free water to a final volume of 11μl and incubated at 100ºC for 5 minutes. The resulting 
DNA was then was snap-cooled on ice and 4μl of HighPrime mix (Roche) containing 1 
unit/μl Klenow polymerase; 125μM dATP, dGTP and dTTP each in 50% glycerol was 
added. Following this, 5μl of radioactively labeled [α-32P] dCTP (10mCi/ml) was added 
to the labeling mix (on ice) and the reaction was incubated at 37ºC for 1 hour. On 
incubation completion, the reaction mix was applied to a 1.5ml Sephadex G50 (Sigma) 
column. The column was washed with 1ml dH2O and the labeled probe was eluted from 
the column into an eppendorf and diluted with 800μl dH2O. Finally, the probe DNA was 
denatured for 5 minutes at 100ºC.   
 
 
2.3.3 Pre-hybridisation and hybridisation  
 
The Southern blot membrane was pre-hybridised for 30 minutes at 65ºC in an evenly 
rolling Techne hybridisation bottle in a Techne Hybridiser HB-1D oven. The denatured 
radioactively labeled probe was added to 10mls of pre-warmed (65ºC) ExpressHyb 
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solution (Clontech) pre-hybridisation solution and the blot was further incubated at 65ºC 
overnight.  
 
2.3.4 Washing  
 
After incubation with the probe, the pre-hybridization solution was discarded from the 
blot in accordance with the University of Edinburgh‟s radioactivity disposal guidelines.  
The blot was then washed three times with  100ml of pre-warmed (65ºC) 2XSSC/ 1% 
SDS and incubated for 15 minutes in a rolling Techne hybridisation bottle in a Techne 
Hybridiser HB-1D oven at 65ºC. The blot was then washed a further 3 times in 0.2XSSC/ 
1%SDS for 15 minutes at 65ºC. The washing procedure was terminated when the level of 
background radioactivity, measured by Geiger counter, reached a low localised 
radioactive level. If the signal remained high, the washing procedure (0.2XSSC/ 1%SDS) 
was repeated.  The blot was then mounted in Saran-wrap inside an X-ray cassette and 




2.4 CELL AND TISSUE CULTURE 
 
2.4.1 Culture conditions 
 
The feeder-independent mouse WT E14 tgt2a parental ES cell line was obtained from 
Smith (1991) and grown in ES cell media comprising of; Glasgow‟s Minimal Essential 
Medium (GMEM) supplemented with 20% fetal calf serum, 0.25% sodium bicarbonate 
(Gibco), 0.1% non-essential aminoacids, 2mM L-glutamine (Gibco), 1mM sodium 
pyruvate (Gibco), 0.1mM β-mercaptoethanol (Sigma) and 100 U/ml Leukaemia 
Inhibitory Factor (LIF) (Jackson et al., 2002). Cells were grown on tissue culture grade 
plastic pre-coated with 0.1% gelatin and incubated at 5% CO2 in a 37ºC humidified 
incubator (Galaxy S, Wolf Laboratories). LIF was produced on site at the John Hughes 
Bennett Laboratories and involved the collection of conditioned medium from COS7 
cells transfected with the pDR10 LIF-DIA expression construct (a gift from Austin 
Smith) (Smith. 1991) LIF-containing supernatant that detectably inhibited ES cell 
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differentiation via clonal assay was defined as 10 U/ml then 100 U/ml was used in 
standard maintenance medium. 
2.4.2 Thawing cells 
 
Cryopreserved cells stored at -140ºC were thawed rapidly in a 37ºC water bath and 
transferred to a universal tube containing 10mls of pre-warmed growth media. The cells 
were pelleted by centrifugation at 1000rpm for 3 minutes, the supernatant was removed 
and the cell pellet was resuspended in fresh culture medium and transferred into a pre-
gelatinised 25cm2 culture flask with 10ml culture medium. The culture medium was 
replaced after 4 to 12 hours upon cell adherence to the flask. 
 
 
2.4.3 Passage and expansion of ES cells  
 
Cells were seeded into pre-gelatinised flasks at a seeding density of 1x10
6 
cells per 10ml 
and were passaged every 2 days upon reaching 70-80% confluency. Cells were never 
allowed to overgrow. To passage, medium was aspirated from the flask then the cells 
were washed twice with PBS and incubated (5% CO2 at 37ºC) with 2mls of trypsin 
solution ( 1% trypsin, 1% chick serum and EDTA in PBS).  After 5 minute incubation in 
trypsin solution, the cells lifted off the tissue culture plastic and were gently 
disaggregated into a single cell suspension using a 10ml pipette. Trypsinised cells were 
then neutralised with a 5X volume of culture medium in a Falcon tube and cells were 
centrifuged at 1000rpm for 5 minutes. The cell pellet was resuspended in 10ml fresh 
medium and cell number was determined using a haemocytometer on a Leitz Labovert 
microscope. 1x10
6 
cells per ml in 10ml were transferred to a new pre gelatinized 25cm2 
flask, 3x10
6 




 cells in 80ml of culture 
medium to a 225cm
2 
flask and incubated at 5% CO2 in a 37ºC until required or reaching 














2.4.4 ES cell clonal assay  
500 ES cells per well were plated in pre-gelatinised 6-well plate with ES cell medium 
containing LIF. Cells were added to the plates in a swirling motion in order to avoid 
clumping and gain an even distribution of cells in the wells. The following day the wells 
were gently rinsed with PBS and the medium was replaced to the wells. LIF was only 
added to wells if stem cell colony growth was required. Cells under differentiation were 
grown without LIF.  After 5 days in these culture conditions the ES cell colonies were 
fixed and stained for alkaline phosphatase activity in accordance with the Alkaline 
Phosphatase Kit (Sigma-Aldrich).  Primarily, cells were fixed in the fixative solution 
(67% acetone, 25% citrate solution, 8% formaldehyde) for 30 seconds, then gently rinsed 
in water and subsequently incubated with the colour substrate solution for 15 minutes in 
the dark. After a final rinse, the plates were left to air dry and alkaline phosphatase 
staining of individual colonies was analysed using an inverted Zeiss Axiovert25 
microscope. Colonies were scored as stem cell (pink), mixed (dense central core of pink 
surrounded by a periphery of unstained cells) and differentiated (unstained) (Figure 2.1). 
Statistical analysis was carried out by t-test
 


































































Figure 2.1 Classical morphologies of Stem cell, Mixed and Differentiated colonies.  
The colour coding above the pictures represents stem cell (blue); mixed (red) and 
differentiated (yellow) represent the bar colours in subsequent clonal assay 
histograms.  
 
Differentiated  Mixed  Stem cell  
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2.4.5 Preparation of embryoid bodies (EB) and cardiomyocyte assay  
 
A suspension of ES cells at 6x10
5
/20mls of growth media (LIF+) was poured into the lid 
of a square Petri dish (120mm
2
) an used as suspension reservoir.  Using multichannel 
pipette 10μl drops of this ES cell suspension was pipetted onto the lid of a fresh square 
Petri dish (120mm
2
) to produce a sequence of equally sized and distributed „hanging 
drops‟. The petri dish lid, containing the hanging drops was gently placed onto the base 
of the sterile water filled (10mls) petri dish.  The drops were then incubated at 37ºC in a 
humidified incubator for 2 days and then harvested by tapping the dishes and collecting 
the EBs in solution with a pipette. EBs from all dishes were pooled into a universal then 
spun at 800 rpm for 3 minutes.  After discarding the supernatant, the EBs were 
resuspended fresh medium without LIF and supplemented with Penicillin/Streptomycin 
solution (Sigma) at 1:100.  Following this, the EBs were cultured in suspension in a 
bacteriological 100mm
2
 dish for a 5 days with medium changes every two days. After 5 
days, single EBs were transferred into a pre-gelatinised 24 well plate and analysed for 
beating foci.  
 
2.4.6 Growth rate determination 
WT E14 and KIT Null cells were seeded into 25cm
2
 tissue culture grade flasks at 
1x10
6
/10mls in ES cell growth media with the inclusion of LIF.   After 2 days in culture, 
cells were trypsinised, pelleted and counted using a haemocytometer.  Resulting cell 
numbers were presented as histograms and statistical analysis was carried out using a 
student‟s t-test.  
 
2.4.7 Colony size determination 
WT E14 and KIT Null cells were cultured in a clonal assay as described (2.4.4) .  After 5 
days, the colonies were, fixed stained and colony size was determined using a calibrated 
Zeiss Axiovert microscope scale.  
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2.4.8 Karyotyping of ES cell clones  
 
ES cells were seeded into 25cm
2
 flask at 2x10
6
 cells and allowed to adhere to the flasks 
overnight. The next day 100μl of KaryoMAX (Invitrogen) was added to the flask and the 
cells were incubated at 37ºC for 2 hours.  Cells were then trypsinised, placed into 15ml 
falcon tubes and pelleted by centrifugation (1000 rpm for 3 minutes).  The supernatant 
was removed and 8mls of 0.56% KCl solution was added drop by drop to resuspend the 
pellet.  The pellet was being continually and gently vortexed throughout this time to 
avoid clump formation. Following this, the cell suspension was incubated in a 37ºC water 
bath for 12 minutes then fixed with 2ml of freshly prepared fixative (methanol 3:1 acetic 
acid). After gently mixing by inversion, the cells were then spun at 1000 rpm for 5 
minutes (1000rpm), the supernatant was removed and the cells were again resuspended in 
8mls of fixative. This spin and re-suspension was repeated 3 times.  After the final 
centrifugation, step the cells were resuspended in 1ml of fixative and one drop of this cell 
fixative mixture was dropped onto a sterile slide which had been pre-cooled at 4ºC in 
ethanol. To stain the karyotype spreads, DAPI (Sigma) was used at a concentration of 
1:2,500 dilution, then 10µl was added to the slide and cover slip mounted. 20-30 
karyotyping spreads were obtained for each clone and images were captured under 
fluorescent light on a Zeiss Axioskop2 microscope using a 63x oil emulsion objective. 
The camera used was a ProgRes C14 from Jenoptik and images modified and saved using 
OpenlabTM software. The number of chromosomes in each of the spreads was counted 
manually using Adobe Photoshop by marking each counted chromosome on the image 
with a red dot.  
 
 
2.4.9 G418 Concentration Kill Curve 
  
Heterozygous ES cells were plated at 4x10
3
 cells into each well of a pre gelatinized 6-
well plate and left to adhere to the plastic overnight in an incubator at 5% CO2 /37ºC in 
5ml of LIF containing ES cell medium. After approximately 12 hours, the growth 
medium was discarded and replaced with 5mls of fresh, antibiotic (G418 ; Geneticin, 
PAA) containing medium. Several antibiotic concentrations (0, 100, 150, 200, 250, 300, 
350 and 400μg/ml) were employed to determine the concentration at which WT E14 cells 
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perished over the course of 7-9 days. Media from each antibiotic condition was replaced 
on a daily basis and cell death was monitored. The optimal G418 concentration at which 
all heterozygous cells perished within 9 days was 260-280μg/ml.  
 
 
2.4.10. Puromycin concentration Kill Curve 
 
KIT Null and WTE14 cells were plated at 4x10
3 
cells into each well of a pre gelatinized 
6-well plate and left to adhere to the plastic overnight in an incubator at 5% CO2 /37ºC in 
5ml of LIF containing ES cell medium. After approximately 12 hours, the growth 
medium was discarded and replaced with 5mls of fresh, antibiotic containing medium. 
Puromycin was added at various concentrations 0, 0.5, 0.75, 1.00, 1.25 or 1.5 µg/ml to 
determine the concentration at which KIT Null/ WT E14 cells perished over the course of 
7-9 days. Media from each antibiotic condition was replaced on a daily basis and cells 
death was monitored. The optimal Puromycin concentration at which all WT E14 / KIT 






2.5 WESTERN BLOT PROCEDURE 
 
 
2.5.1 Protein extraction from cells  
 
Media was carefully removed from ES cell monolayers and washed twice with ice cold 
PBS containing protease (Sigma) and phosphatase inhibitors (Sigma).  300µl of ice cold, 
RIPA buffer (Pierce scientific), containing protease and phosphatase inhibitors, was 
added to 25cm2 flasks monolayers and cells were harvested on ice using a rubber 
policeman.   Harvested cells were placed into an appropriately labeled eppendorf and 
centrifuged at +4ºC for 15 minutes at 14,000g.  Protein yields were increased by 
sonicating the pellet for 30 seconds with a 50% pulse. The supernatant was collected in a 
fresh tube (on ice) and protein concentration was determined using a Bradford Assay 
(Bio-Rad). 
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2.5.2 Gel electrophoresis and Western blotting procedure  
 
Running buffer (including antioxidant) and transfer buffer (including 10% methanol) 
were prepared in accordance with the Invitrogen NU Page 1D electrophoresis protocol. 
Extracted protein samples were also prepared in accordance with the Invitrogen NuPage 
1D electrophoresis protocol.  In brief 50µg of protein sample was prepared with NuPage 
LDS sample buffer, reducing agent and glycerol then denatured by boiling at 70ºC for 10 
minutes. Samples and molecular weight ladder (Prestained Marker-Invitrogen) were then 
loaded onto pre-cast gels 10% (BIS-Tris) gels (Invitrogen) and run in the NuPAGE Xcell 
surelock Mini cell electrophoresis module at 200V for 35 minutes (Mes) or 200V for 50 
minutes (Mops).  Mops running buffer was used for proteins between 14-200 kD whereas 
Mes running buffer was used for proteins 2.5 – 60kD.  After running the proteins on the 
gel, proteins were transferred (wet transfer) onto nitrocellulose membranes (Whatmann) 
in accordance with Invitrogen Xcell surelock Mini cell electrophoresis manufacture‟s 
instructions and using the Xcell surelock Mini cell electrophoresis equipment.  Transfer 
was carried out at 30V for 1 hour. 
 
To eliminate background staining, unbound sites on the membrane were blocked for 1 
hour at RT or at 4ºC overnight in 5% milk or 5% BSA in 1X TBS -0.05% Tween20 with 
gentle rocking. Primary antibody at an appropriate dilution (0.5% BSA in 1XTBS with 
0.05% Tween) was then added to the membrane and incubated for 2 hours at RT or 
overnight at 4ºC depending on antibody binding efficacy. Following this, the membranes 
were washed in three times for 10 minutes in 1XTBS with 0.05% Tween then incubated 
for 1 hour in secondary antibody conjugated to HRP diluted in 0.5% BSA in TBS with 
0.05% Tween according to manufacturer‟s instructions. The membrane was then washed 
a further 3 times to remove unbound antibody in 1XTBS with 0.05% Tween. All 
incubations and washes were performed on a shaking platform. Protein bands were 
visualised by incubation with ECL reagents for I minute (Luminol-Fluka / Coumarc acid 
Sigma) then mounted in Saran-wrap inside an X-ray cassette and exposed photographic 
film (Kodak) at RT for 1 minute, 2minutes and 5 minutes. Primary antibodies include 
anti-GAPDH monoclonal antibody (AbCam) anti-Bcl2 (N-19) Anti JNK1 and anti p-c-
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Jun (Santa Cruz Biotechnology), anti-Flag (UBI Company, 2EL-1B11 mouse 
monoclonal), anti-EGFP (BD company, JL-8 mouse monoclonal); Secondary antibodies 







2.6.1 Sorting cell populations 
 




 based on their level of KIT 
expression using the ACK2-APC KIT antibody (e-Bioscience).  Cells falling between 
categories were eliminated from analysis. Cells were sorted using FACS analysis on the 
FACSVantage cytometer (laser 633nm) and gated using unstained and isotype control 
stained cells.  Sorted cells were then grown in their individual categories for 3 passages 
(6 days) with the inclusion of LIF then re-analysed for KIT expression with an ACK2-
APC antibody via flow cytometry with the FACS Calibur cytometer (laser 633 nm) 
analysis.  WT E14 and KIT Null cells were tested concurrently as controls. This was 
carried out in triplicate and KIT expression was recorded as a percentage and presented a 
histogram.  
 
To observe the effect of KIT expression, sorted cells, WT E14 and KIT Null cells were 
placed into a clonal assay and their ability to form stem, mixed or differentiated colonies 
was recorded.  Cells were grown under both self renewal (+LIF) and differentiation  
(LIF-) conditions and fixed, stained and analysed as described (2.4.4).  
 
2.6.2 ACK2 Dose dependency 
 
500 WTE14 ES cells were plated per well in a pre-gelatinised 6-well plate with ES cell 
medium containing LIF. The following day the wells were gently rinsed with PBS and 
the medium replaced LIF+/- ; ACK2 +/- (Insight Biotechnology) or isotype control +/-.   
ACK2/isotype control was added at a final concentration of 0, 5 10 and 15μg.  After 5 
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days the assay fixed and stained for alkaline phosphatase activity, and colonies were 
scored as stem mixed or differentiated as described above. The assay was carried out in 
triplicate and analysed by student‟s t-test.  
 
2.6.3 Prolonged exposure to ACK2 
 
WT E14 cells were passaged once (2 days) twice (4 days) or > 10 times (>20days) in the 
presence of the KIT neutralising antibody ACK2.  Following from this, clonal assays 
were performed (2.4.4), fixed stained and analysed (2.4.4).  To observe the effect of 
neutralisation reversal, cells previously exposed to the antibody were placed into assay 
without antibody or given one clear passage (2 days) without antibody before being 
placed into assay.  
 
2.6.3.1 Assessing ACK2 induced apoptosis  
 
WT E14 cells were cultured ACK2 +/-  or isotype control  +/-  for one passage (2days) in 
the presence of LIF.  Following this, cells were re-seeded at 0.5 x 10
6
 in fresh 25cm
2
 
tissue culture grade flasks with ACK2 +/-  or isotype control  +/-   in the presence or 
absence of LIF.  Flasks were incubated at 37°C at 5% CO
2
 for 3 days before staining with 
Annexin V-FITC as described (2.6.4).  
 
 
2.6.4 AnnexinV- FITC / PI staining 
 
Annexin-PI staining was carried with the BD Pharmingen Annexin V-FITC Apoptosis 
KIT II in accordance with BD Bioscience‟s manufacturer‟s instructions. Briefly, 1x10
6
 
KIT Null cells, WTE14cells, BCL2 overexpressing clones or PD169316/ACK2 
/ZVAD/SP600125/ isotype control treated cells were resuspended in 1X Annexin V 
binding buffer (Ca
2+
).  100μl of this suspension was transferred into each of 4 FACS 
tubes labeled „unstained‟ „Annexin only‟ „PI only‟ and „Annexin V-FITC /PI‟.  5μl (5μg) 
of ready made Annexin V-FITC dye was added to the appropriate tubes an incubated for 
15 minutes under foil at room temperature. To account for background staining, Annexin 
V-FITC was added at 2.5 and 1.25 μl (2.5 and 1.25μg respectively).  The effect of non-
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specific binding was alleviated by pre blocking the cells with recombinant Annexin V 
(5μg) (BD Bioscience) for an incubation period of 15 minutes at RT before a subsequent 
stain in Annexin V-FITC. The cells were then gently vortexed half way through this 
incubation to disperse the dye through out the sample.   After incubation, 300μl of 
binding buffer was added to each tube. Flow cytometry was carried out using FACScan 




2.6.5 DAPI staining 
 
WTE14, KIT Null or BCL2 over-expressing cells were centrifuged at 1200rpm for 5 
minutes then resuspended at 5000 cells/μl in 4% PBS buffered paraformaldehyde 
solution containing 10 μg/ml 4'6-diamidino-2-phenylindole (DAPI, Sigma). 10 μl of this 
suspension was placed onto a glass slide and covered and secured with a coverslip. The 
morphology of the cells' nuclei was observed using fluorescence microscopy under 
fluorescent light on a Zeiss Axioskop2 microscope using a 63x oil emulsion objective. 
The camera used was a ProgRes C14 from Jenoptik and images modified and saved using 
OpenlabTM software at an excitation wavelength 350 nm. Nuclei were considered to 
have the normal phenotype if displaying diffuse and homogenous fluorescence. 
Apoptotic nuclei were identified by condensed chromatin gathering at the periphery of 
the nuclear membrane or by a fragmented morphology of nuclear bodies. More than 150 
cells were counted for each cell line and the percentage of apoptotic nuclei was 
determined. This experiment was carried out in triplicate.  
 
 
2.6.6 FLICA staining 
 
FLICA staining was carried out in accordance with Immunochemistry Technologies‟ 
PolyCaspase detection kit and manufacturer‟s instructions.  Briefly, 1x10
6
 KIT Null cells, 
WTE14 cells, BCL2 over-expressing clones or PD169316 /ACK2/ZVAD/SP600125/UV/ 
isotype control treated cells were resuspended in 1ml of PBS.  300μl of this suspension 
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was placed into fresh 15 ml falcon tubes and 10μl of 10X FLICA reagent was added to 
each tube.  Stain was dispersed throughout the cells by flicking the tube several times.  
Cells were incubated with the FLICA stain for 1 hour at 37°C at 5% CO2.  The cells were 
gently flicked several times throughout this incubation.   Following this, 1 ml of 1X wash 
buffer was added to the tube and spun at 1000rpm for 5 minutes.  The supernatant was 
discarded.  This was carried out a further two times. After the final wash, the cells were 
resuspended in 400μl of wash solution and were ready for flow cytometry analysis.  
Unstained cells were prepared concurrently for cytometer gating controls. Fluorescein 
was measured on the FL1 channel with the FACscan cytometer (laser 488nm). 
 
 




 flask of confluent cells was exposed to maximum intensity UV light for 10 
minutes.  Following from this, the cells were placed back into an incubator at 37°C at 5% 
CO
2




2.7 APOPTOSIS REGULATION 
 
2.7.1 ZVAD  
 
2.7.1.1 Annexin V-FITC/PI/FLICA staining 
 




 tissue culture grade flasks 
with ZVAD +/-  (Biomol Research) in the presence or absence of LIF.  Flasks were 
incubated at 37°C at 5% CO
2
 for 3 days before staining with Annexin V-FITC (WT E14 
only) or FLIKA (WT E14 and KIT Null) as scribed above.  
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2.7.1.2 Clonal assays 
 
500 WTE14 or KIT Null ES cells per well were plated in pre-gelatinised 6-well plates 
with ES cell medium containing LIF. The following day the wells were gently rinsed 
with PBS and the medium replaced LIF +/- and ZVAD +/- (40µM). The assay was 
carried out for further 5 days with a fluid change including ZVAD replenishment on day 
3. On completion of the 5 day incubation, ES cell colonies were fixed and stained for 
alkaline phosphatase activity as 2.2.4. ). The assay was carried out in triplicate (with two 




2.7.2 P38 inhibitor PD169316 
 
2.7.2.1 P169316 dose dependency assay 
 
500 WTE14 ES cells per well were plated in pre-gelatinised 6-well plate with ES cell 
medium containing LIF. The following day, wells were gently rinsed with PBS and the 
medium replaced LIF+/- ; PD169316 +/- (Calbiochem) or DMSO control +/-.   
PD169316/DMSO control was added at a final concentration of 0, 5 10 and 15μM 
(PD169316) / 0, 0.1%, 0.2% and 0.3% (DMS0).  After 5 days the assay fixed and stained 
for alkaline phosphatase activity, and colonies were scored as stem, mixed or 
differentiated as described (2.4.4). ). The assay was carried out in triplicate (with two 
replicates per test) and analysed by either Student‟s t-test or one way analysis of variance 
(ANOVA).  
 
2.7.2.2 PD169316 and Annexin/FLICA  staining 
 




 tissue culture grade flasks 
with PD169316 +/- (10µM ) in the presence or absence of LIF.  Flasks were incubated at 
37°C at 5% CO
2
 for 3 days before staining with Annexin V-FITC (WT E14 only) or 




2.7.2.3 PD169316 and clonal assays 
 
500 WTE14 or KIT Null ES cells were plated per well in pre-gelatinised 6-well plates 
with ES cell medium containing LIF. The following day the wells were gently rinsed 
with PBS and the medium replaced LIF +/- and PD169316 +/- (10µM). The assay was 
carried out for further 5 days with a fluid change including PD169316 replenishment on 
day 3. On completion of the 5 day incubation, ES cell colonies were fixed and stained for 
alkaline phosphatase activity as described above (2.4.4).  
 
 
2.7.2.4 SP600125 dose dependence assay 
 
500 WTE14 ES cells were plated per well in pre-gelatinised 6-well plates with ES cell 
medium containing LIF. The following day the wells were gently rinsed with PBS and 
the medium replaced LIF+/- ; SP600125+/- (Calbiochem) or DMSO control +/-.   
SP600125/DMSO control was added at a final concentration of 0, 2.5 5, 10, 15 and 20μM 
After 5 days the assay was fixed and stained for alkaline phosphatase activity, and 
colonies were scored as stem, mixed or differentiated as described above (2.4.4). ). The 
assay was carried out in triplicate (with two replicates per test) and analysed by either 




2.7.2.5 SP600125 Western blot analysis 
 
Western blot analysis was carried out a described above (2.5) but specifically, protein 
lysates were isolated from WT E14 cells grown in the presence or absence of LIF and the 
presence or absence of the inhibitor SP600125 (5μM) for three days. Proteins were tested 









 cells were grown overnight at 37°C at 5% CO
2
 on pre-gelatinised 6 well plates 
with the inclusion of LIF.  The following day, the ES cell media was removed and the 
cell monolayers were washed twice with PBS.  The ES cell media was then replenished 
with fresh media with serum+/- ; ACK2 +/- ; Isotype control +/-.  All cells, except 
controls, were starved of serum for 12 hours and incubated at 37°C at 5% CO
2
. SCF at 
50ng/ml was added to the appropriate wells for 15 minutes at 37°C at 5% CO
2
 to 
stimulate KIT signalling.  After this incubation, cell lysates were immediately removed 
on ice as described above and proteins were prepared for Western blot analysis.  
 
 
2.7.2.7 SP600125 Annexin/FLICA stain 
 




 tissue culture grade flasks 
with SP600125 +/- (5µM ) in the presence or absence of LIF.  Flasks were incubated at 
37°C at 5% CO
2
 for 3 days before staining with Annexin V-FITC (WT E14 only) or 
FLIKA (WT E14 and KIT Null) as scribed above (2.6.4 and 2.6.6. ) 
.  
 
2.7.2.8  SP600125 clonal assays 
 
500 WTE14 or KIT Null ES cells were plated per well in pre-gelatinised 6-well plates 
with ES cell medium containing LIF. The following day the wells were gently rinsed 
with PBS and the medium replaced LIF +/- and SP600125 +/- (5µM ). The assay was 
carried out for further 5 days. On completion of the 5 day incubation, ES cell colonies 
were fixed and stained for alkaline phosphatase activity as described above (2.4.4) 
 
 
2.7.2.8 SP600125 Prolonged exposure 
 
WT E14 cells were passaged untreated or passaged with the inclusion of SP6001225 once 
(2 days) twice (4 days) or 20 times (40 days) before placing into a clonal assay.  
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Following this assays were fixed stained and analysed as described above (2.4.4).  To 
observe the effect of JNK inhibition reversal, cells previously exposed to antibody were 
placed into assay without antibody or given one clear passage (2 days) without antibody 
before being placed into assay. The assay was carried out in triplicate (with two replicates 
per test) and analysed by one way analysis of variance (ANOVA).  
 
 
2.8 BCL2 OVER-EXPRESSION 
 
2.8.1 Generation of the EGFP-FLAG-BCL2 PCR insert  
 
The EGFP-FLAG-BCL2 PCR insert was generated using the P513-kEGFP-Flag-BCL2 
vector kindly donated by Helen Boeuf (Duval, Malaise et al. 2004) as a template.  A PCR 
product was generated with Not1 and Xho1 restriction ends using the primer pair; 
 
Bcl2 F (5‟- GCGGCCGCATGGTGAGCAAGGGCGAGGAGCTGT T 3‟ forward) 
Bcl2xho (5‟- CTCGAGTCACTTGTGGCCCAGGTATGCACC 3‟ reverse) 
 
PCR was carried out with PCR reagents from Cambio Epicentre and included a 
proofreading polymerase enzyme with buffer J.  Specifically, PCR was carried out with 
the following protocol; (95°C for 5 minutes/ (94ºC, 55 ºC, 72 ºC) for 30 minutes and 
72ºC for 15 minutes.  
 
2.8.2 Topo cloning 
 
Fresh PCR product was used to carry out the TOPO cloning (poly A tail to combine with 
linearised vector with T overhangs) in the PCR 8 GW TOPO vector (Invitrogen) in 
accordance with Invitrogen‟s cloning instruction manual. Topo clones were transformed 
into chemically competent Dh5α cells (Invitrogen top 10 K4750-10) and grown over 
night at 37°C on spectinomycin plates. Resulting clones were picked and Minipreped 
using QIAprep Spin Miniprep Kit as described above (2.1.2).  Plasmid DNA (100ng) was 
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sent for sequencing as described above (2.1.8) with the inclusion of 10% DMSO due to 
the sequence being G-C rich. Sequencing was carried out using the following primers; 
 
GW1 (5´- GTTGCAACAAATTGATGAGCAATGC-3´ forward) 
GW2 (5‟ - GTTGCAACAAATTGATGAGCAATTA-3´ reverse) 
 
The resulting correctly identified clone was called Topo clone 2–BCL2 which was maxi 
prepped as described above (2.1.2) then stored as a glycerol stock (2.1.3) (Appendix 1).   
 
2.8.3 The Gateway Reaction 
 
The plasmid RFCA Pcagsip- Ires Puro was designed and developed by Melany Jackson 
(Appendix 2) JHBL and was used as the destination vector during the gateway reaction 
(Figure 2.2).  This vector includes ccdB F plasmid encoded gene that inhibits the growth 
of e-coli (Bernard and Couturier 1992). The entry clone was Topo clone 2-BCL2. A 
mixture of 150 ng of Clone 2-bcl2-puro-topo, 150 ng RFCA pCagsip, 5X LR clonase 
reaction buffer, 1μl of Gateway LR clonase II enzyme mix (invitrogen) and TE to a final 
volume of 20 microlitres was briefly vortexed and then incubated at 25°C for 2 hours. 
After incubation Proteinase K was added to the sample to terminate the enzyme reaction. 
The resulting product was transformed into DH5α cells and selected on LB plates 
containing ampicillin (37°C overnight). Colonies were picked and streaked on ampicillin, 
spectinmycin and chlramphenicol plates.  Clones that were resistant to ampicillin only 
were miniprepped and sequenced. Bcl2 gateway clones were sequenced using the 
primers.  
 
Oligo 164 (5‟ TGC TGG TTG TTG TGC TGT 3‟ forward) 
Bcl2 Xho(5‟ CTC GAG TCA CTT GTG GCC CAG GTA TGC ACC 3‟ reverse)  
 
Confirmed clones, called BCL2 Gateway (Appendix 3), were maxi-prepped and made 
























2.8.4 BCL2 Gateway Electroporation 
 
Electroporation was carried out as described above (2.2) but specifically, BCL2 Gateway 
was linearised with Pvu1 and electroporated into NNC1cells and WTE14 cells. 
Linearised PCagsip was also electroporated into WT and KIT null cells as an empty 
vector control. KIT Null cells and WT E14 cells were grown in the presence of 
puromycin for selection (0.7 µg/ml) and were picked on their ability to form colonies 











Att L1 EGFP-FLAG-BCL2 Att L2 
Att R1 ccdB / Camr Att R2 
+ LR 
clonase 
ENTRY clone  
Topo clone2-BCL2 
Destination vector RFCA 
Pcagsip- Ires Puro 
 
Att P1 ccdB / Cam
r Att R2 







LR clonase reaction 
Figure 2.2 LR clonase reaction. The plasmid RFCA PCagsip is the destination vector during 
the gateway reaction and the entry clone is topo clone2-BCL2. Crossover at attL1 and attL2 
sites for recombination transfers the gene of interest into any Gateway destination vector. 
Specifically designed primer binding sites within the att 1 and att 2 sites are used for 
sequencing with the GW1 and GW2 primers.  Only Ampicillin resistant clones were selected 
and sequenced (diagram adapted from(Villefranc, Amigo et al. 2007) 
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2.8.4.1 BCL2 EGFP Screen 
 
Unstained BCL2 over-expressing clones and unstained empty vector control clones were 
screened initially by Flow Cytometry for EGFP expression using the FACScan flow 
cytometer on the FL1 channel (laser 488nm).  EGFP positive clones were tested 
alongside WT E14/NNC1 control cells as well as empty vector control by Western blot as 
described above (2.5).  
 
2.8.5 BCL2 over-expression and Annexin/FLICA staining 
 





tissue culture grade flasks in the presence or absence of LIF and incubated at 37°C at 5% 
CO
2
 for 3 days before staining with Annexin V-FITC or FLICA as scribed above (2.6.4 
and 2.6.6. ) 
.  
2.8.6 BCL2 over expressing clonal assays  
 
500 WT E14, KIT Null or BCL2 over-expressing ES cells per well were plated in pre-
gelatinised 6-well plate with ES cell medium containing LIF. The following day the wells 
were gently rinsed with PBS and the medium was replaced with LIF +/- . The assay was 
carried out for further 5 days and completion of the 5 day incubation; ES cell colonies 
were fixed and stained for alkaline phosphatase activity as described above (2.4.4). ). The 
assay was carried out in triplicate (with two replicates per test) and analysed by either 
student‟s t-test or one way analysis of variance (ANOVA).  
 
 
2.9 MICRO ARRAY ANALYSIS 
 
RNA was isolated from WTE14 and two independent KIT null cells lines (KitW-lacZ/W-
FKB and KitW-lacZ/W-lacZ) lines grown in the presence of LIF and 36 hours after LIF 
withdrawal.  This RNA was hybridised onto an Affymetrix chip and analysed by micro 
array (Bashamboo, unpublished data) in accordance with Schulz, et al 2009 and the 
Affymetrix Genechip Expression Analysis Technical Manual. Each cell line from each 
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condition was tested in triplicate and pair-wise comparisons were performed using 
GeneChip® Operating Software (GCOS) 1.4. Arrays were normalized by the log scale 
robust multi-array analysis (RMA) (Schulz, Kolde et al. 2009).  The mean of each gene 
signal was calculated for each condition and differentially expressed genes were 
identified using the Student‟s t-test. The resulting data was managed using the KIT/SCF 
database generated by The University‟s of Edinburgh Bioinformatics.  A gene was only 
included into the analysis if the differential fold change value was ≥1.5 and p value ≤0.05 
when comparing the WTE14 cell line with the KIT Null cells lines.  To ensure 
reproducibility, a gene had to be significantly up or down regulated in both KIT Null 
cells lines before their inclusion to the analysis and resulting gene lists. From the 
microarray analysis, a total of 45101 genes were returned of which 1,101 were 
differentially expressed when comparing WTE14 cells with both KIT Null cell lines. 
Complete gene listings can be found in Appendix 4-9. A low fold change indicates low 
gene expression in KIT Null cells when compared with WTE14 expression and the 
converse holds for genes with a high fold change. Genes were sorted into categories 
dependent on low and high fold changes in the presence or absence of LIF.  Genes that 
were always high or low, regardless of LIF inclusion, were also identified (Appendix 10 
and 11).  Genes were also sorted on account of speculative compensatory mechanisms 
(Appendix 12), membrane perturbation (Appendix 13), apoptosis (Appendix 14), and 
JNK signalling (Appendix 15). 
 
2.10 STATISTICAL ANALYSIS 
 
Data from self renewal assays were initially performed using a Student‟s t-test and were 
reanalysed using one way ANOVA to confirm significance and increase sensitivity where 
p-values were borderline.  The specific statistical analysis performed for each test 
condition was described in each figure legend. Self renewal assays were carried out in 
triplicate to obtain three independent replicates (n=3) where each replicate was carried 
out in duplicate to assess variance. Confidence intervals were calculated as the standard 
error of the mean (SEM) and were depicted as error bars on each graph.  Statistical 




































































KIT and its ligand SCF play an important role in the self renewal and differentiation of 
various stem and multipotent progenitor cell types. Bashamboo et al (2006) have 
previously reported a role for the SCF/KIT pathway in the early stages of ES cell 
differentiation. Using gene targeting techniques they generated a KIT null cell line that 
was able to self renew in the presence of leukaemia inhibitory factor (LIF) but was 
unable to survive when directed to differentiate via 2D monolayer culture. Following this, 
they hypothesised that the SCF/KIT signalling pathway was required for the survival of 
differentiating ES cells but was not essential for self renewal maintenance.  
 
Conversely, Lu et al (2007) claimed that the KIT signalling pathway was involved in the 
maintenance of undifferentiated ES cells and could serve as a marker of ES cells with 
optimal differentiation. Their cell sorting experiments indicated that a KIT 
hi
 fraction 
displayed enhanced expression of pluripotency markers, produced increased stem cell 
numbers in clonal assays and gave enhanced differentiation in 3D culture when compared 
with their wild type, unsorted counterparts. 
 
To determine if KIT signalling is important in maintaining the undifferentiated state of 
murine ESC, Bashamboo et al (2006) grew wild type (WT) E14 ES cells for one passage 
(2 days) in the presence of the KIT blocking antibody ACK2.  Although these ACK2 
treated cells exhibited a comparable death upon differentiation phenotype to KIT Null ES 
cells, both ACK2 treated cells and KIT Null cells displayed a non-significant reduction of 
 86 
stem cell colonies when compared to their WT counterparts in the presence of LIF.  This 
contrasted with the results reported by Lu et al (2006) where a 1.7 fold reduction in the 
number of stem cell colonies was observed when KIT signalling was blocked with the 
ACK2 antibody. 
 
To further these investigations, the experiments described in this chapter were designed 
to assess the role of KIT signalling in ES cells and address the discrepancy between the 




3.3 EXPERIMENTAL STRATEGY 
 
To assess the level of KIT expression during self renewal and differentiation, WT E14 
cells were grown in the presence of LIF and then directed to differentiate via monolayer 
culture (2D) or Embryoid Body (3D) formation.  Expression was semi-quantified using 
RT-PCR.  
 
To confirm the KIT Null death upon differentiation phenotype reported by Bashamboo et 
al, we derived novel KIT null cell lines using gene targeting techniques and assessed their 
ability to maintain genetic stability, self renew and differentiate via monolayer culture.  
Self renewal and differentiation profiles of KIT Null cells were then compared with both 
WT E14 and Heterozygous cell lines.  
 
To address the discrepancy shown between the studies carried out by Bashamboo and Lu, 
we neutralised the KIT receptor in WT E14 cells with ACK2 to analyse the effect of 
prolonged antibody exposure during the self renewal and differentiation process. To 
determine how different levels of KIT expression affects undifferentiated and 




 and KIT 
neg
  






3.4.1 KIT is expressed in both 2D and 3D differentiation systems 
 
To determine the expression of c-kit in ES cells during self renewal and differentiation, 
RNA was isolated from WT E14 ES cells grown in the presence of LIF and from ES cells 
directed to differentiate via 3D EB formation or 2D monolayer culture.  The products of 
semi-quantitative RT-PCR were normalised using β-tubulin (Figure 3.1).   
 
c-kit is expressed by self renewing ES cells and upon differentiation, distinct patterns of 
c-kit expression are observed when comparing 2D and 3D cultures. Under monolayer 
conditions, c-kit expression remains consistent over a 5 day culture period regardless of 
LIF inclusion whereas c-kit expression during EB differentiation is consistent until day 2 
(D2 -LIF) where expression is lost and is not regained until day 4 (D4 -LIF).  The initial 
reduction of c-kit expression during EB formation may reflect a loss of pluripotency 
occurring with the onset of cellular differentiation and resulting functional changes as 
described by Glover et al (2006) who observed the development of specific cell types 48-
72 hours after LIF withdrawal. The re-expression of c-kit in the EB system may represent 
the occurrence of differentiated cell lineages that are dependent on c-kit expression such 
as haematopoietic precursors or germ cells (Edling et al. 2007; Kehler 2007; McClanahan 
et al. 1993; Mckinny-Freeman et al. 2009).  Each differentiation system provides specific, 
environmental cues to the ES cell population which may explain the discrepancy in 
timing and expression of c-kit between the two systems. The formation of EBs in vitro 
mimics embryonic development in vivo and provides a 3D framework with cellular 
interactions to support the differentiation of multiple cell lineages.  Monolayer 
differentiation lacks this framework and the resulting cell lineages are likely to be 
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Figure 3.1 Semi-quantitative RT-PCR analysis of c-kit expression from RNA isolated during EB 
formation (3D culture a,c) and monolayer differentiation (2D culture b,d) of ES cells visualized by 
ethidium bromide stained gels.  RNA was isolated from cells at daily time points (D0- D5) in the 
presence or absence of LIF as indicated.  β-tubulin was used to normalise the concentration of 
DNA for semi Quantitative PCR for Embryoid body formation and monolayer differentiation (c,d). 
The expected band for c-kit is 668bp and 300bp for  β-tubulin. This is a representative experiment 
of two independent experiments. RT=Reverse Transcriptase; -RT = -Reverse Transcriptase 
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3.4.2 Gene targeting and the generation of KIT Null cell lines  
 
To confirm the KIT Null phenotype described by Bashamboo et al (2006) we knocked 
Kit out of WT E14 cells using the same gene targeting strategy employed by Bernex et al 
(1996) and Bashamboo et al (2006) (Figure 3.2a).   Here, we employed a replacement 
vector (pGN- Δkit) which consisted of a 1.2 kb arm of 5‟ homology, a nlslacZ-neo 
cassette  and a 6.1 region of 3‟ homology. Electroporation of this vector into WT E14 ES 
cells resulted in homologous recombination and a targeted deletion of codons 7 to 22 of 
Kit exon 1 and the first 200 bp of intron 1.  This deleted region corresponded to the 
membrane signal peptide of c-kit and was replaced by the coding region of a nlslacZ-neo 
cassette which was in frame with the first coding bases of c-kit including the ATG 
(Figure 3.2 a).  If targeted correctly, the nlslacZneo cassette is under the control of the c-
kit promoter and lacz expression and neomycin resistance can select for correctly targeted 
events. Of the 192 clones resistant to G418 only 48 stained positively (blue) by X-gal 
(Figure 3b and c). These clones were tested further by a multiplex PCR screening 
strategy to detect integration of the nlslacZneo cassette as well as the unaltered WT allele 
(figure 3.2 d). To eliminate the possibility of random vector integration into an open, 
expressed chromosome region and therefore random gene expression, the precise 
genomic structure of resistant clones was analysed by Southern Blot (figure 3.2 e).  
Southern Blot confirmed that only 1 of the 48 screened clones successfully targeted the 
Kit locus to produce a heterozygous (Kit 
w-lacZ/+
) cell line.   Karyotypic analysis indicated 
that this Kit
w-lacZ/+
 clone was genetically stable and was employed to generate new KIT 
Null cell clones by initiating a gene conversion event via exposure to high G418 
concentrations.  Highly resistant clones were screened by multiplex PCR and genomic 






































































148 bp  
Figure 3.2 A targeting strategy 
to generate a heterozygous Kit 
w-
lacZ/+ 
cell line and novel Kit 
w-lacZ/ 
w-lacZ
 cell lines from WT E14 ES 
cells (Kit 
+/+ )
. (a) Wild Type 
allele (WT) of c-kit which 
includes a region of DNA 
external to the coding region, 
exon 1, the ATG site and part of 
intron 1. The targeting vector 
(pGN- Δkit ) containing a nls-
lacZ neo cassette and the 
resulting targeted allele are also 
shown. The WT allele and 
targeting vector share a 5‟ 1.2 
arm of homology and 3‟.1 arm 
of homology as depicted by the 
broken lines. Multiplex PCR 
primers and resulting band 
lengths, EcoR 1 (E1) restriction 
points, Southern blot external 
probe and resulting Southern 
band lengths are displayed. X-
Gal staining of (b) E14 control 
cells and cells targeted with (c) 
pGN- Δkit. (d) Multiplex PCR 
analysis of DNA isolated from 
Kit
+/+
 (148 bp), and Kit 
W-lacZ/W-
lacZ
 ( -/- ,800 bp) and Kit 
W-lacZ/+
 
(-/+,  800 and 148 bp). NTC, no 
template control. 
(e) Southern blot analysis of 
EcoR1-digested DNA isolated 
from previously derived   Kit
W-
lacZ/W-lacZ
 cells (lane 1, 
Bashamboo et al. 2006), E14 ES 
cells (lane 3), newly derived KIT 
null clones (lanes 4,5,6,7,8,9 and 
10 band size 6.4Kb as shown by 
asterik) and newly derived Kit 
W-
lacZ/+
  clone (lane12).  WT bands 
are shown in lanes 11, 13 and 14 
(9.1Kb). Band lengths were 
determined on the southern blot 
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3.4.3 KIT protein analysis of KIT Null cells 
 
To ensure that our targeting strategy was effective in ablating the Kit gene and its 
associated protein, we stained the newly derived KIT Null clones with an APC 
conjugated anti-KIT antibody (APC-ACK2) and analysed APC fluorescence using Flow 
Cytometry.  WT E14 cells acted as a positive control whereas the KIT Null clone derived 
by Bashamboo et al (2006), named Clone 1, acted as a negative control.  An APC 
conjugated isotype control was employed to eliminate the effect of non-specific 
immunoglobulin binding or background staining (Figure 3.3).  
 
WT E14 cells express the KIT protein as demonstrated by a positive shift in APC-ACK2 
staining when compared to unstained and isotope control populations.  Conversely, KIT 
Null clones (Clone 1, NNC1, NNC2 and NNC3) do not express the KIT protein on the 
cell surface. Histograms of APC-ACK2 stained KIT Null populations are un-discernable 
from their unstained and isotype-APC stained counterparts. As the anti-KIT antibody 
ACK2 is specifically directed against the extracellular ligand binding region of KIT and 
Flow Cytometry  has demonstrated that this region is absent in the KIT Null clones, we 
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Newly derived KIT Null clones 
Key 
Figure 3.3 Flow cytometry histograms of APC-KIT stained New Null Clones NNC1, 
NNC2 and NNC3.  WT E14 cells were stained as a positive control whilst Clone 1 Nulls 
(Bashamboo et al, 2006) were used as a negative control and an APC-isotype control 
antibody eliminates the effect of nonspecific staining.  Unstained, APC-KIT stained and 
APC- isotype control stained populations are represented as individual histograms as 
defined by the accompanying coloured key.  The histogram area represents the total cell 
number in each category and the mean fluorescence intensity (MFI) defines where the 




3.4.4 Karyotypic analysis of parental and targeted cell lines 
Mortensen et al (1992) reported that heterozygous ES cells expressing a single neo 
resistance gene can spontaneously duplicate the neo-targeted locus with a loss of 
heterozygosity of the WT allele to generate homozygous mutant cells.  As G418 
resistance correlates with neo expression (Paludan et al. 1989), spontaneous homozygous 
mutants can be selected if grown in culture with high G418 concentrations (Mortensen 
1992). Lefebvre et al (2001) demonstrated that spontaneous homozygosity of the neo 
gene can occur through gene conversion events, mitotic recombination or chromosome 
loss and duplication. As these events can lead to genetic abnormalities such as aneuploidy 
which become evident after prolonged passage due to accumulation of chromosome 
abnormalities (Cooper et al. 2007; Corbet et al. 1999; Lefebvre et al. 2001), we subjected 
our newly derived KIT null cells to crude karyotypic analysis to determine their genetic 
status after gene targeting, high G418 selection and extended passage.   
 
WT E14, Het and KIT Null cell lines were grown in prolonged culture and their 
chromosome numbers were counted after passage 5 (day 10), passage 10 (day 20) and 
passage 15 (day 30).  At each passage interval, thirty chromosome spreads were counted 
per cell line and the proportion of euploid (n=40 figure 3.4 a) and aneuploid (n=41 figure 
3.4 b) cells was recorded as a percentage (figure 3.4 c). A clone was considered euploid if 
greater than 75% of the metaphases displayed 40 chromosomes (Longo et al. 1997). After 
analysis of chromosome spreads, it became evident that the parental E14 cells were able 
to maintain a normal, euploid karyotype even after prolonged passage and these cells 
maintained genetic stability up to passage 36 (data not shown).  The Kit 
w-lacZ/+
 
heterozygous cell clone was able to maintain a normal karyotype when analysed at 
passage 15.  However, it was evident that serial passage gave rise to the accumulation of 
an additional chromosome within the cell population. The effect of serial passage 
extending beyond 15 passages has not yet been investigated for this clone.    The most 
striking effect of serial passage and genetic instability was observed for the three 
independently derived KIT Null clones.  Although KIT Null cells are initially genetically 
stable, all three KIT Null cell clones lost euploidy, gaining an additional chromosome 
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(trisomy), on serial passage.  This phenomenon was also displayed by the KIT Null clone 
derived by derived Bashamboo et al (2006) (data not shown).  
 
At passage 5, WT E14 cells have a significantly greater proportion of karyotypically 
normal cells when compared with the heterozygous and all newly derived KIT null 
clones (p<0.05).  However, there is no significant difference when comparing 
chromosome spreads from the heterozygous clone with the KIT Null clones. At this 
stage, all clones are regarded as euploid. Upon serial passage (P15), again WT cells are 
significantly more euploid than the heterozygous and KIT null clones (p<0.05).  
However, at this passage interval the heterozygous clone maintains euploidy whereas all 
three KIT Null clones do not (with a significant reduction of KIT Null euploidy at 
p<0,001). Although this may associate a role for KIT or partial KIT expression with the 
maintenance of cellular karyotypic stability, it is difficult to separate this effect from 
accumulated genetic abnormalities arising as a response to adverse growth conditions 
over prolonged passage. 
 
Several reports have demonstrated that prolonged murine ES cell in vitro culture results 
in an accumulation of chromosome abnormalities (Liu et al. 1997; Longo et al. 1997) and 
of theses abnormalities, trisomy of chromosome 8 and 11 are the most common.  This 
additional chromosome is thought to give a growth advantage to the aneuploid cells (Liu 
et al. 1997; Sugawara et al. 2006) causing the rapid outgrowth and replacement of 
euploid cells in the culture (Liu et al., 1997; Sugawara et al., 2006). This theory 
corresponds with the report from Nichols et al (1990) who demonstrated that euploidy in 
an ES cell culture can deteriorate from 100% to 16% in only 5 passages (Nichols et al. 
1990).   This may account for the rapid reduction of euploid cells on serial passage of the 
KIT null cell clones which was exacerbated by targeting and selection in high G418 
conditions (Corbet et al. 1999). All subsequent experimentation was carried out on KIT 
Null ES cells at low passage with a normal karyotype ensuring that all reported 






































































































































































































Figure 3.4. Karyotype analysis of c-kit targeted ES cell clones derived from E14 cells. DAPI 
stained chromosome spreads with (a) a euploid karyotype where n=40 and (b) an aneuploid 
chromosome spread showing 41 chromosomes. (c) WT E14 cell s (Kit 
+/+
), Heterozygous (Kit 
w-lacZ/+
) 
and newly derived KIT Null Clones (NNC) (Kit 
w-lacZ/ w-lacZ
)1,2 and 3 were grown for 5, 10 and 15 serial 
passages. At each passage interval, 30 chromosome spreads were counted per cell line. The 
proportion of ES cells cell displaying a euploid karyotype of 40 chromosomes or an aneuploidy 







3.4.5 Self renewal analysis of parental and targeted cell lines 
 
OCT4 and NANOG are key intrinsic factors that are essential for the self-renewal and 
maintenance of pluripotent ES cells (Chambers et al. 2004).  We assessed the expression 
of Oct4 and Nanog in newly derived heterozygous and KIT Null cells using QRT-PCR 
techniques (These experiments were performed by Gillian Cowan PhD thesis 2009 
Figure 3.5). In three independent replicates, there was no significant difference in Oct4 or 
Nanog expression when comparing targeted cells with control WT E14 cells (P<0.05).  
Even with reduced or ablated c-kit expression, ES cells have the potential to express the 
genes associated with self renewal. However, we did observe a distinct, yet non 
significant, reduction in Nanog expression when comparing KIT null clones with their 
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Figure 3.5 QRT-PCR analysis of Oct4 and Nanog expression in WT E14, 
Heterozygous and KIT Null clones. All cells were grown in the presence of LIF 
and WT E14 control cells were compared with heterozygous and KIT null clones 
developed by Bashamboo et al 2006 (Het1 and Null 1) and with newly derived 
Heterozygous and KIT null clones (Het 2 and Null 2). In each case, the average 
relative gene expression from three independent replicates was represented as a 
histogram and standard deviations are represented by the error bars (n=3).  The 
newly derived Kit null clone used in this assay was NNC1 (Cowan PhD thesis, 
2009). (n=3. Error bars represent SEM.  Analysed using a student’s t-test where p>0.05) 
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3.4.6KIT Null cells die upon differentiation 
 
Although the genes Oct4 and Nanog were expressed in KIT null cells and levels of 
expression were comparable to WT E14 control cells, gene expression levels do not 
always relate to biological function. To analyse self renewal at the biological level, we set 
up 2D monolayer clonal assays to test the ability of newly derived KIT Null cells to self 
renew in the presence of LIF and their ability to form differentiated colonies upon LIF 
withdrawal (Figure 3.6).  
 
In the presence of LIF, Heterozygous (Het) and KIT Null clones (Clone 1, NNC1, NNC2 
and NNC3) cells were able to self renew and although there was a trend for the total 
number of stem cell colonies to reduce when comparing WT E14 cells to the targeted 
clones, this difference was not significant (Het p=0.1; Clone 1 p=0.07; NNC1 
p=0.07;NNC2 p= 0.06 and NNC3 p= 0.06).  When the cells were directed to differentiate 
on the removal of LIF only ES cells with full (WT E14) of partial KIT (Het) activity were 
able to form differentiated colonies.  All targeted clones, whether Het or KIT Null, 
showed a significant reduction in their ability to form differentiated colonies when 
compared to the control WT E14 population (Het p<0.001) and Clone 1, NNC1, NNC2 
and NNC3 (p<0.001). The KIT Null clones were unable to form differentiated colonies 
and appeared to die upon differentiation (Figure 3.6a). It is interesting to note that while 
total stem cell colony numbers do not decrease significantly, the size of the individual 
colonies were visibly and significantly (p=0.03 Appendix 16) reduced when comparing 
WT E14 cells with the KIT Null clones (Figure 3.6b and c). This would imply that the 
ability of single cells to form self renewing colonies was not impeded by the loss of the 
KIT receptor but the rate at which the cells self renewed was reduced.  The effect of 
reduced proliferation rates in the absence of functional KIT signalling was further 
demonstrated when equal cell numbers (1x10
6
) of each cell line were seeded in to flasks 
and the resulting cell numbers were compared after two days in culture (Figure 3.6d). 
Every KIT Null clone had significantly lower total cell numbers when compared with 
their WTE14 counterparts (Clone 1 p=0.02; NNC1 p= 0.04; NNC2 p=0.02 and NNC3 
p=0.03) whereas heterozygous cells were non significantly reduced in comparison to the 

























































WT E14 Het Clone 1 NNC1 NNC2 NNC3
Figure 3.6 (a) Clonal assays showing the ability of control (WT E14) and targeted cells (Het, Clone 1, NNC1, NNC2 and NNC3) to self renew in the 
presence of LIF and their ability to differentiate in the absence of LIF(WT E14 vs Het p<0.001) and WT E14 vsClone 1, NNC1, NNC2 and NNC3 (p<0.001).  
Colonies were scored as Stem cell (blue bars) mixed (red bars) or differentiated (yellow bars).  In each case, total colony numbers were recorded and 
presented as a series of histograms. A significant difference in colony number when comparing WT E14 control cells with  targeted clones is 
represented by the pink bar and asterisk (*).   Stem cell colonies of WT E14 cells (b) and KIT null cells (c) grown in the presence of LIF.  Scale bar 
represents 100µM. (d) Histograms of total cell number from WT E14, Het and KIT Null clones after being seeded at a concentration of 1x10
6
 and 
grown for a two day period (n=3) WT vs Clone 1 p=0.02; NNC1 p= 0.04; NNC2 p=0.02 and NNC3 p=0.03.  Error bars represent Standard error of the mean 
(SEM). Analysed using a Student’s t-test.                                                                                                          
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3.4.7 KIT Null cells have limited differentiation in 3D culture. 
 
As EB formation provides differentiating ES cells with a 3 dimensional framework and 
complex signaling networks that are not present in monolayer cultures, we tested the 
hypothesis that signaling molecules occurring throughout EB formation may compensate 
for a lack of KIT and prevent the death phenotype in differentiating KIT Null cells. 
Briefly, undifferentiated WT E14 and KIT Null ES cells were directed to differentiate 
under EB formation conditions and the resulting bods were placed  into bacteriological 
grade Petri-dishes from days 0 (D0) to day (D5).  At this point, EBs were either allowed 
to grow on the Petri-dishes until day 10 (D10) or individual EBs were placed into pre-
gelatinised 24 well plates and were analysed for beating foci via cardiomyocyte assay 
(Figure 3.7 a).   On D0 –D3 EB differentiation (Figure 3.7 b), KIT Null EBs were visibly 
smaller than their WT E14 counterparts and by D3 did not form dense central cores as 
shown by WT E14 EBs.  By D5, WT E14 EBs has diffuse boundaries and adhered to 
other EBs in the culture dish whereas KIT null EBs, although forming dense cores, 
maintained their tight, spherical structures and did not attach to other EBs in the culture 
vessel.  By D10, WT E14 EBs began to develop into complex, bubble like structures that 
began to beat whereas the KIT null EBs formed modest, motionless structures.   
 
Under cardiomyocyte stimulating conditions, WT E14 EBs flattened onto the culture 
dish, differentiated extensively and approximately 90% of the EBs produced beating foci.  
Even though KIT Null EBs formed limited differentiation on the periphery of the 
flattened bod, none of the EBs formed beating foci in three independent experiments 
(Figure 3.7c). This differs from the monolayer differentiation system which did not 
sustain any KIT Null differentiation. Therefore, passing the KIT Null cells through an EB 
stage may provide the cells with additional signals that can aid differentiation but not 

















































































































Figure 3.7 Differentiation of WT E14 cells and KIT Null cells via EB formation.  (a) A flow diagram outlining the 
differentiation strategy of ES cell to cardiomyocyte assay. (b) Images taken at various time intervals during EB 
formation day 0 (D0); Day 3 (D3); day 5 (D5) and day 10 (D10). (c) Percentage of beating foci from three independent  
cardiomyocyte assays comparing  WT E14 and KIT Null cells.Scale bar = 400µM. (n=3. Error bars represent SEM.  
Analysed using a Student’s t-test where WT E14 vs Kit Null = p<0.001) 
c 
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3.4.8 Recapitulation of the KIT Null phenotype using ACK2 
 
WT E14 cells were cultured in the presence of a of a KIT neutralising antibody called 
ACK2.  ACK2 binds specifically to the extracellular ligand binding region of the KIT 
receptor and blocks SCF from binding to the receptor and therefore, blocks all associated 
signalling downstream of KIT (Yoshinaga et al. 1991). WT E14 cells were grown in the 
presence of varying concentrations of ACK2 to determine an optimal antibody 
concentration for subsequent experimentation that was efficacious and did not cause any 
adverse reaction to the cells. Any non-specific immunoglobulin binding effect was 
eliminated by parallel testing with an isotype control. The initial dose-dependency assay 
involved a 2D monolayer self renewal and differentiation assay spanning antibody 
concentrations of 0-15μg where antibody was added directly to the cells on assay (Figure 
3.8 a). Under self renewing conditions (+ LIF), there was a trend for the stem cell 
colonies to reduce in number as antibody concentration increased.  However, this 
reduction in colony number was not significant when comparing each antibody 
concentration to the cell control (p>0.05).  As the cells were directed to differentiate on 
the removal of LIF, increasing antibody concentration resulted in extensive cell death. 
This inhibition of differentiation become significantly different from the control at 10µg-
15µg (p=0.01). There was no effect on self renewal or differentiation when the isotype 
control was added to the cells on assay (Figure 3.8 b). As ACK2 at 10µg caused no effect 
to the self renewal capacity of the WT ES cells (+LIF) and significantly reduced their 
ability to survive on differentiation (LIF-), similarly to the KIT Null phenotype, ACK2 
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Figure 3.8 Monolayer self renewal (+LIF) and differentiation (-LIF) assay of WT 
E14 cells grown in the presence of ACK2 or an Isotype control. (a) ACK2 was 
added to the cells at a concentration of 5-15μg. A significant colony reduction (p=0.001) 
was only observed in differentiating WT E14 cells when ≥10μg of antibody was added 
on assay.  This significance is shown by the pink bar and asterisk. (b) WT E14 cells 
were grown in the presence of an Isotype at a concentration of 5-15μg. 0 refers to a cell 
control where no antibody or isotype control was added to the cells on assay (n=3. 



















3.4.9 Prolonged exposure to ACK2 significantly reduces ES cell self renewal.  
 
 
Lu et al (2007) reported a 1.7 fold reduction in stem cell colony number when ES cells 
were grown in the presence of ACK2 and LIF whereas, Bashamboo et al found a non-
significant reduction in stem cell colony number when cells were grown for one passage 
(2 days) in ACK2.  To investigate this discrepancy further and to observe the effect of 
prolonged ACK2 exposure, WT E14 cells were grown in the presence of ACK2 for one 
passage (2 days), 2 passages (4 days) and greater than 10 passages (>20 days) and stem 
cell, mixed and differentiated colonies were counted and compared to cell and isotype 
controls (Figure 3.9) 
 
After one passage (P1 +LIF) of the cells in ACK2, self renewal was unaffected but when 
LIF was removed (P1 LIF-) a significant reduction in differentiated colonies (P=0.03) 
was observed which was comparable to that previously described by Bashamboo et al 
2006.  This block on differentiation can be prevented if ACK2-treated cells were placed 
into the monlayer assay in the absence of antibody (ACK2-).  After two passages in 
ACK2 (P2+LIF), self renewal is significantly reduced in comparison to controls (ACK2; 
P= 0.02) and self renewal is not restored on removal of ACK2 in the assay (ACK2 –; P= 
0.006).  Treated cells required one clear passage in the absence of ACK2 (P1 ACK2-) in 
order to restore stem cell colony numbers to control levels.  On LIF withdrawal (P2 LIF-
), a similar pattern was observed where differentiation was significantly blocked by 
ACK2 (ACK2; P=0.008) and was not restored (ACK2-; P=0.02) until treated cells were 
passaged for at least one ACK2-free passage.   We also observed this effect for cells that 
were passaged in ACK2 for >10 passages (P>10) where ACK2 significantly reduced the 
ability of the ES cells to self renew (ACK2; P=0.01 and ACK2 - ; P=0.01) and self 
renewal was not restored until one ACK2-free passage.  On removal of LIF, again ACK2 
significantly inhibits the survival of differentiating WT E14 cells (ACK2; P=0.001 and 
ACK2-; p= 0.004) and survival was only restored with one ACK2-free passage.   We 
believe that technical artefacts such as non-specific toxicity can be excluded as an 
explanation for this phenomenon because the cells were able to self renew albeit at a 
slower rate than their WT counterparts and that the isotype control with the same 
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conformation as ACK2 displayed no phenotype.  It is also of interest to note that the 
morphology of the stem cell colonies grown in the presence of both LIF and ACK2 
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Figure 3.9 Clonal monolayer assay of WT E14 cells exposed to ACK2 (10μg).  Cells were grown under 
self renewal (+LIF) and differentiation (-LIF) conditions.  Cells were grown in ACK2 for 1 passage (a. P1), 2 
passages (b. P2) and greater than 10 passages (c. P>10) before being placed into the clonal assay.  
Significant reductions (p<0.05) in colony number are denoted by the pink bars and asterisk. Refer to text for 




3.4.10 ES cells can be sorted into distinct populations dependent on KIT expression 
 
Even under self renewal growth conditions, ES cell populations are a dynamic mixture of 
cell types which spontaneously self renew and differentiate into specific cell lineages 
dependent on expressed cell surface markers (Toyooka et al. 2008).  Lu et al (2007) 







resulted in a KIT 
hi
 population with an increased capacity to self renew and differentiate. 
To investigate this finding and determine the role of the KIT receptor in our system, we 




 and KIT 
neg
 fractions dependent on KIT 
expression using FACS analysis and an APC-KIT conjugated antibody (Figure 3.10 a).  




 population, the intermediate cell 
population, which minimally expressed KIT, was excluded from the analysis.  To observe 
the effect of serial passage on KIT expression, each population was passaged once (2 
days) twice (4 days) or three times ( 6 days) after the initial sort and their level of KIT 
expression was re-determined by Flow Cytometry (Figure 3.10b).   
 
Even after serial passage, cells sorted by KIT expression remained in their specific 
compartments where KIT expression was significantly greater in the KIT 
hi
 population 
when compared with WT E14 cells (p<0.001), the KIT lo population (p<0.001), the kit 
neg population (p<0.001) and the KIT null clone NNC1 (P<0.001). Similarly to the 
results shown by Lu, the population of KIT neg cells began to re-express KIT post sort. 
This may be due to a cell population with extremely low KIT expression that were 
inadvertently included into the sorted KIT neg population or it could indicate that KIT 
expression fluctuates in an ES cell population grown under self renewing conditions and 
may represent different stages of early differentiation.  
 
To address the function of KIT expression level during self renewal and differentiation, 
each sorted fraction was analysed by clonal assay (Figure 3.10c). In the presence of LIF, 
self renewal of the KIT 
hi
 fraction was significantly greater than the KIT 
lo
 (p=0.01), KIT 
neg
 (p=0.02) and NNC1 (p=0.02) cells. Although there was an increased level of self 
renewal when comparing KIT 
hi
 cells with WT E14 cells, this difference was non 
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significant.  WT cells self renew significantly greater than KIT 
Neg
 (P=0.004) cells but 
similarly and non significantly different from KIT 
lo
 or KIT null cells.   
 
The KIT Neg cells also showed a skewed clonal profile where significantly more cells 
were differentiating (p<0.03), even under self renewal conditions, when compared with 
the WT E14 cell control. This high level of differentiated and mixed colonies may imply 
that KIT Neg populations are representative of early differentiating cells rather than KIT 
Null equivalents. Unlike the KIT Neg fraction, KIT Null cells have a self renewal profile 
similar to and non significantly different from the WT E14 cells and are unable to survive 
upon differentiation.  
 
In the absence of LIF, both KIT 
hi 
and WT E14 cell populations have significantly greater 




 and KIT Null cells (p<0.001 in all 
comparisons).  Both KIT 
lo
 and KIT 
neg
 cells have a significantly greater ability to 
differentiate than the KIT Null cells which may suggest that a reduction in KIT 
expression results in a reduction in cell survival upon differentiation similarly to the KIT 
Null phenotype. This would agree with the report from Lu et al (2007) who showed that 
an increase in KIT expression resulted in enhanced self renewal of the cells which, in 
turn, improved the ability of the cells to differentiate.    However, it should also be noted 




) are potentially in the early stages 
of differentiation as shown by their skewed clonal profile and their ability to differentiate 




 fractions to differentiate on the removal 
of LIF may be due to inadequate growth conditions provided by the clonal assay which 
cannot sustain their requirements for survival upon differentiation. Therefore, KIT 
neg
 
cells are not equivalent to KIT Null cells as KIT Null cells are unable to sustain 
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Figure 3.10 Sorting WT E14 ES 
cells according to KIT expression 
level.  (a) FACS analysis of WT E14 
cells grown under self renewing 
conditions and sorted with an ACK2-
APC conjugated antibody into 






 cells.  Cells with minimal 
KIT expression were excluded from 
the analysis to avoid overlap of the 
KIT 
lo
 and KIT 
Neg
 categories. (b) 
Sorted cells grown under self 
renewing conditions (LIF +) were 
passaged for 6 days after the initial 
sort and then re-analysed for KIT 
expression with an ACK2-APC 
antibody via FACS analysis.  WT 
E14 and KIT Null cells were tested 
concurrently as controls.  KIT 
expression was recorded as a 
percentage. (c) Sorted cells, WT 
E14 and KIT Null cells were placed 
into a clonal assay and their ability 
to form stem, mixed or differentiated 
colonies was recorded.  Cells were 
grown under both self renewal 
(+LIF) and differentiation (-LIF) 
conditions. Significant reductions 
(p<0.05) in colony number are 
denoted by the pink bars and 
asterisk. Refer to text for exact p-
values. (n=3. Error bars represent 








3.5.1 KIT and ES cell maintenance and proliferation 
Abrogation of KIT signalling via gene targeting techniques allowed the investigation of a 
KIT Null mutation and its affect on ES cell self renewal and differentiation. We report 
that KIT ablation did not affect the ability of KIT knock-out clones to express gene 
markers associated with self renewal or have an altered self renewal profile when 
compared with the parental WT E14 cell line. This is in agreement with the study 
conducted by Bashamboo et al (2006).  Initially this may appear to contrast with the 
report by Lu et al (2007) who associated KIT signalling with enhanced ES cell self 
renewal and functionality, our extended analysis  using a KIT Null neutralising antibody, 
FACS analysis and clonal assays allowed us to address this discrepancy.  
 
Bashamboo et al (2006) reported that ACK2 treated WT E14 cells displayed a similar 
phenotype to KIT Null cells where stem cell colony numbers were non-significantly 
reduced when compared with non treated controls.  However, Lu et al (2007) describe 
only a 1.7 fold reduction in stem cell colony number in the presence of the antibody.  
Similarly to Bashamboo et al (2006), we employed the WT E14 cell line in our study and 
found that on initial passage (2 days) with ACK2 only a slight and non significant 
reduction in stem cell colony number was observed.  A significant reduction became 
evident after prolonged exposure (>4 days) of the cells to ACK2.  It is conceivable that 
WT E14 cells require sustained exposure to ACK2 before a self-renewal phenotype is 
evident and that this phenotype was not observed by Bashamboo et al due to reduced 
cell-antibody exposure.  Lu et al (2007) did not use the WT E14 cell line but the R1 ES 
cell line in their study, which may account for the difference in sensitivity to the antibody 
and the non-essential requirement for prolonged ACK2 exposure. The data presented in 
this study and the study by Lu et al (2007) showed that inhibition of KIT signalling by 
ACK2 in WT E14 cells reduced but did not completely prevent the process of self 
renewal.  This implies an auxiliary role for KIT signalling during ES cell maintenance.   
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However, there is now a discrepancy in the self renewal profile displayed by WT E14 
cells treated with ACK2 and the self renewal profile of KIT Null cells.  The significant 
reduction in stem cell colony numbers when KIT is artificially blocked in WTE14 cells 
that is not displayed by the KIT knock-out clones may be explained by compensatory 
mechanisms that have arisen during the selection of KIT Null clones. Compensatory 
mechanisms for reduced or ablated KIT signalling by receptor/ligand pairs that converge 
with KIT associated downstream signalling pathways have been previously observed in 
other proliferating cell lineages such as the EPO receptor in erythroid cell development 
(Wu et al. 1995); the Cytokine receptor γ chain (γc) in thymocytes (Rodewald et al.  
1997) and the
 
c-fms receptor during blastocyst implantation (Arceci et al, 1992) as well as 
c-fms in mast cell mitosis and survival. (Dubreuil et al. 1991) 
 
The distinct reduction in stem cell colony size upon clonal assay, the reduced cell number 
after passage with an initial 1x10
6
 cell seed and the reduction of EB diameter when 
comparing the KIT Null clones with WT E14 controls, may associate KIT signalling with 
a pronounced role in ES cell proliferation and rate of self renewal rather than the process 
of self renewal itself.  This theory is supported as a similar effect on stem cell colony size 
and cell number was observed with WT E14 cells treated with ACK2.   
 
 
3.5.2 The effect of KIT upon differentiation 
 
Upon LIF withdrawal and the initiation of differentiation, it became evident that there 
was an absolute requirement for KIT signalling in order to sustain cell survival. This was 
demonstrated by complete cell death in differentiating KIT Null cells, inhibited 
differentiation in ACK2 treated WT E14 cells and limited differentiation during KIT Null 
EB development. This finding correlates with data described by Bashamboo et al (2006) 
who reported a cell death phenotype in differentiating KIT Null ES cells and WT E14 
cells treated with ACK2. Although Lu et al (2007) did not recapitulate such a pronounced 
cell death phenotype (-LIF) using the ACK2 antibody (only a 1.6 fold reduction) they 
used it at a concentration of 10 ng/mL rather than 10μg/ml as employed by the 
present study and by Bashamboo et al (2006).  It may be that ACK2 reduces in 
efficacy with reduced concentration.  However, they achieved a 5.7 fold reduction in 
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EB formation when using the tyrosine kinase inhibitor Imatinib.  Imatinib does not 
exclusively block KIT (Heinrich et al. 2000) but blocks related RTKs such as Abelson 
protein tyrosine kinase (abl) and platelet derived growth factor (PDGF) (Carroll et al 
1997).  Lu et al (2007) argued that this inhibitor was acceptable to use in their system as 
the R1 ES cell line employed in their experimentation did not exhibit abl or PDGF 
expression in the undifferentiated state as demonstrated by their microarray data.  
 
Although cell lineages such as germ cells (De Miguel et al. 2002; Dolci et al. 1999; 
Yoshida et al. 1997) mast cells (Galli et al., 1995; Lemura et al. 2002) haematopoietic 
stem cells (Engstrom et al. 2003; Keller et al., 1995; Young et al. 2006) , interstitial cells 
of cajal  (Maeda et al. 1992) and melanocytes (Ito et al. 1999) show an absolute 
requirement for KIT signalling for their migration, proliferation , survival or function, 
other in vivo signalling pathways have demonstrated KIT compensatory mechanisms. 
Wasow et al 2002 showed that over-expression of Epo in c-Kit
W/W
 mice rescued this 
previously embryonic lethal phenotype by partial rescue of the red blood cell lineage.  In 
this study, we demonstrated the partial differentiation of KIT Null cells as they were 
passed through EB culture which suggests that signalling pathways supplementary to 
rather than compensatory for KIT signalling may exist in vitro. Certainly in vivo, even the 
most severe W mutations affecting the kinase activity of c-kit and therefore reflect loss of 
KIT function, allow the progression of cell and tissue differentiation.  However, affected 
animals often die perinatally due to severe macrocytic anaemia (Russell, 1979; Reith et 
al. 1990).  Therefore, compensatory mechanisms for KIT signalling must exist in vivo 
which may be recapitulated in vitro.  
 
 
3.5.3 Cell sorting with KIT expression level 
 
Even under optimal self renewal growth conditions, a population of ES cells comprises of 
a dynamic range of cell types at different stages of the self renewal or differentiation 
process. (Toyooka et al. 2008).  Sorting WT E14 cells based on KIT expression level 






 populations which remained in their 




 population had a positive effect on the self renewal and differentiation ability of 
the ES cells by enhancing stem cell colony and differentiated colony formation upon 
clonal assay. Again, the increase in stem cell colony formation may reflect a KIT 
mediated effect on cell survival or increased proliferation rate rather than a direct effect 
upon self renewal. 
 
Although Lu et al (2007) claim that undifferentiated ES cells with low KIT expression 
have reduced ability to self renew and differentiate, their clonal analysis only considered 
the formation of stem cell colonies and did not mention the clonal profile of the KIT Neg 
cells which was skewed towards differentiation as shown by our analysis.   The 
comprehensive study of KIT expression throughout embryonic development by other 
groups (Edling et al.  2007; Keller et al. 2007; McClanachan et al. 1993 Mckinny-
Freeman et al. 2009) and the crude analysis of KIT expression during EB formation by 
RT-PCR in our study demonstrated that KIT is expressed in waves and expression 
switches on and off dependent on differentiation model and stage of development.  It is 
more likely that the KIT 
neg
 ES cells described by Lu et al (2007) are not a true KIT 
Neg
 
population of undifferentiated ES cells but represent a population of ES cells that are in 
the initial stages of differentiation.  This may account for their skewed differentiation 
profile under self renewing conditions in clonal and EB formation assays; their reduced 
expression of pluripotency markers and their reduced level of KIT expression.  Our KIT 
Null clones and the Kit Null clone derived by Bashamboo et al (2006) expressed the gene 
markers associated with self renewal and were able to self renew within limits of control 
WT E14 cells. Therefore, a population of KIT 
neg
 cells is not equivalent to an 
undifferentiated KIT Null ES population which may account for the discrepancy in self 
renewal in potential on comparison of the two studies.  
 
 
3.5.4 Karyotypic analysis of KIT Null clones  
 
Upon serial passage, targeted cells both heterozygous and Null began to lose euploidy.  
The most striking and rapid loss of euploidy was observed in the in three independently 
derived KIT Null clones where each clone gained an extra chromosome. It is difficult to 
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discriminate if this effect was due to a loss of the KIT receptor and associated signalling 
events, accumulated genetic abnormalities in response to adverse growth conditions 
during prolonged passage or a growth advantage given to a particular cell population 
containing the additional chromosome.  In the present study we have established that KIT 
Null cells although able to self renew, do so at a reduced rate when compared with the 
parental WT E14 cell line.  During gene targeting events, cells were exposed to a high 
G418 concentration which had the potential to induce and select for genetic abnormalities 
such as trisomy.  Upon serial passage, it is possible that a genetic abnormality, either 
arising spontaneously or induced via G418 exposure could give rise to a population of 
rapidly proliferating cells that would outgrow a slowly proliferating, euploid KIT null 
population. Therefore, it is essential that KIT null cells and stocks of KIT Null cells are 
maintained at minimal passage during subsequent experimentation and all experiments 
performed in this thesis were done on early passage, karyotypically normal cells.  To 
determine if KIT signalling has a direct influence on karyotype instability, WT E14 cells 
which maintain a normal karyotype up to and potentially beyond 36 passages, could be 
passaged in the KIT blocking antibody ACK2 and karyotypic of analysis of untreated 




In summary, this study indicates the auxiliary role of KIT during the self renewal and an 
absolute role for KIT on cell survival during the onset of ES cell differentiation.  KIT is 
involved in enhancing ES cell proliferation under self renewing and differentiation 
conditions as shown by colony size in clonal assay, increased cell number on passage and 
EB size and function upon cardiomyocyte assay analysis. The following chapter will 
explore the means by which the KIT Null cells perish upon differentiation and observe 
the effect of enhancing some of the previously reported survival pathways associated 















































Apoptosis is a complex genetic programme by which the body eliminates damaged, 
redundant or infected cells in order to maintain an effective immune system (Murray et 
al. 2001) and allow the body to function at optimum (Kerr et al. 1972; Adams 2003). The 
activation of caspases, mitogen activated protein kinases (MAPK) and endonucleases 
contribute to the apoptotic process and recent publications suggest that the signals 
required for apoptosis are also required to trigger cell differentiation.  Therefore, 
differentiation and cell survival depends on a balance between anti- apoptotic and pro-
apoptotic factors (Duval et al. 2000; 2004; 2006).  The protein family BCL2 consists of 
20 apoptotic regulators that both contribute to and oppose apoptosis. (Lindsten et al. 
2000; Cuconati et.al 2002).  The founding member of this family is a pro-survival protein 
called BCL2 whose over-expression has been associated with malignancies via cell death 
inhibition which contrasts to other oncogenes that typically cause malignancies via 
promotion of cell proliferation (Vaux et al. 1988; Mead et al. 2008). 
 
One of the classical methods of apoptosis detection is membrane asymmetry 
identification via Annexin V staining. This dye binds preferentially to phosphatidyl serine 
(PS) a phospholipid that resides on the inner leaflet of the cell plasma membrane. During 
the initial stages of apoptosis, PS is exposed to the outer layer of the membrane without 
loss of membrane integrity. As a result, Annexin V can be conjugated to a fluorescent 
marker and used in conjunction with an exclusion dye such as Propidium Iodide (PI) to 
distinguish early apoptotic cells from necrotic cells. It was using this apoptosis detection 
method that Bashamboo et al discovered that KIT Null cells (Clone 1) were constitutively 
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Annexin V positive. To investigate whether this Annexin V positivity was due to KIT 
null cells being predisposed to apoptosis or an anomaly of nonspecific staining we carried 
out a series of investigations using Clone 1 as well as the newly derived KIT Null clones 
(NNC1,NNC2 and NNC3) to analyse their apoptotic state under both self renewing and 
differentiating conditions.  
 
MAPK such as c-Jun N-terminal Kinase (JNK) and p38 have been associated with both 
pro and anti-apoptotic programmes. Duval et al (2004) demonstrated that a third of 
differentiating ES cells apoptose due to P38 signaling and subsequent activation of the 
caspase cascade. (Takekawa et al. 2000; Duval et al 2004; Duval et al. 2006).  As 
inhibition of the P38 pathway using the anti-apoptotic drug PD169316 significantly 
prevents cell death without affecting differentiation via an up regulation of BCL2 (Duval 
et al. 2004) we tested the hypothesis that inhibition of the P38 pathway could prevent the 
death associated with the KIT Null phenotype.  
 
Bashamboo et al previously demonstrated that KIT signaling was required to support 
cells through the apoptotic crisis on the induction of differentiation via the pro-survival 
protein BCL2 (Bashamboo et al 2006) and in 2004, Duval et al showed that over-
expression of the pro-survival protein BCl2 prevented apoptosis in differentiating ES 
cells. To test the hypothesis that BCL2 was implicated in KIT mediated survival, we 
over-expressed this protein in WT E14 and KIT null cells to observe its effect on cell 
survival during differentiation.  
 
 
4.3 EXPERIMENTAL STRATEGY 
 
Using Flow Cytometry analysis, Clone 1 cells were tested alongside the newly derived 
KIT Null clones NNC1, NNC2 and NNC3 to confirm the previously described 
constitutively Annexin V positive phenotype of the KIT null cells.  
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To asses if KIT Null Annexin V positivity was related to a predisposition to apoptose, 
self renewing and differentiating cells were analysed for apoptotic features such as 
caspase activation, nuclear fragmentation and chromatin condensation.  
 
To determine whether KIT Null Annexin V positivity was due to a lack of KIT signaling 
or membrane asymmetry, KIT signaling was blocked in WT E14 cells using ACK2 in 
order to recapitulate the KIT Null phenotype. 
 
To ascertain if KIT Null cell death followed the classical pathway of apoptosis, cell death 
was blocked in differentiating KIT Null and WT E14 cells using the broad range caspase 
inhibitor ZVAD.   
 
To determine the effect of P38 inhibition during WT E14 and KIT Null differentiation, 
the P38 pathway was blocked in these cells using the chemical inhibitor PD169316.   
 
To establish the role of BCL2 during WT E14 and KIT Null cell differentiation, BCL2 
was over-expressed in both WT and KIT Null cells and its effect cell survival was 





4.4.1 Confirmation of the KIT Null Annexin V Positive phenotype 
 
Several newly derived KIT null clones (NNC1, NNC2 and NNC3) were employed to 
investigate Annexin V positivity and determine whether this phenotype was due to Kit 
ablation or a feature unique to the Bashamboo cell line, Clone 1 (Bashamboo et al. 2006).  
Clone 1 cells were employed as an Annexin V positive control whereas WT E14 cells 
acted as a negative control. All cells were grown under self renewal conditions with the 
inclusion of LIF. 
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Analysis of Flow Cytometry scatter plots of Annexin V-FITC and PI stained cells 
showed that every KIT Null clone was annexin positive with the majority of cells 
distributed to the lower right hand „Annexin V positive‟ quadrant (Q3) similarly to the 
Clone 1 positive control (Figure 4.1a). Conversely, WT E14 cells have the majority of 
their distribution in the lower left „Annexin V negative‟ quadrant (Q4). Quadrants 1 and 2 
represent cells that are stained with Propidium Iodide (PI) a dye that is excluded from 
viable cells but stains cells in the late stags of apoptosis (Q2) and during necrosis 
(Q1)(Moore et al. 1998).  As PI positive cells represent a non-viable population, these 
cells will be excluded from the analysis.  On direct comparison WT E14 cells show 
significantly lower staining (p<0.05) than every Null clone indicating that Annexin V 
positivity is a specific and reproducible effect of c-kit ablation (Figure 4.1 b). Under usual 
circumstances this extent of Annexin V positivity would indicate that each KIT Null 
clone had entered an early phase of apoptosis.  However, their ability to self renew and 















































Figure 4.1 Annexin V-FITC Staining of KIT Null cells.  (a) Scatter plots of newly derived KIT Null cells (NNC1, NNC2 and 
NNC3) stained with Annexin V-FITC (5μg) (x-axis) and Propidium Iodide (PI) (y-Axis) in the presence of LIF and analysed by 
Flow Cytometry.  WT E14 cells and previously derived KIT null cells (Clone 1) acted as negative and positive controls 
respectively.  All clones were analysed using the same gate. (b) Histograms depicting Annexin V positivity of WT E14 cells vs 
KIT Null clones in the presence of LIF.  Significant differences (p<0.05) are shown as an asterisk and pink bars. (n=3. Error 


















































































To ensure that the KIT Null Annexin V positive phenotype was due to specific staining 
of Annexin V rather than an artefact of non-specific staining caused by residual FITC, 
WT E14 and NNC1 cells were analysed with varying concentrations of Annexin V-FITC.  
Previously, (Figure 4.1a) WT E14 cells and NNC1 cells were stained with 5µg of 
Annexin V-FITC as recommended by the manufacturer. However, reducing the 
concentration of the stain by 50% (2.5 µg) and 75% (1.25 µg) still maintained the KIT 
Null Annexin V positive phenotype (figure 4.2).  To elucidate if this staining was specific 
to Annexin V binding, WT E14 and KIT Null cells were pre-incubated and blocked with 
recombinant, un-conjugated Annexin V before counterstaining with Annexin V-FITC.   
In the pre-adsorbtion step, recombinant annexin binds to all available PS sites, Annexin 
V-FITC is unable to bind on counter stain and fluorescence is blocked. As fluorescence 
was blocked in both WT E14 and NNC1 cells, we can conclude that Annexin V binds 
specifically to these cells and the effect of non-specific fluorescence can be eliminated. 
 
4.4.2 Assessing the apoptotic status of KIT Null cells. 
 
As PS exposure, membrane asymmetry and Annexin V positivity are phenomena 
associated with early apoptosis, it may be hypothesised that KIT Null clones are either 
apoptotic or predisposed to apoptose and are awaiting the appropriate death signal. 
However, KIT Null cells have the ability to self renew in culture, clonal assays and 
remain viable in the presence of LIF.  Furthermore, under self-renewing conditions they 
do not express other biochemical or morphological features associated with apoptosis 
such as nuclear fragmentation or chromatin condensation and activation of the caspase 
cascade, (Figure 4.3 ad 4.4).  When comparing DAPI stained WT E14 cells with NNC1 
(Figure 4.3a) cells under self- renewing conditions (day 0; LIF +), cell nuclei of both 
cells types are large, intact and refractile with minimal signs of apoptosis (Figure 4.3b).  
The onset of apoptosis is only triggered when KIT Null cells are directed to differentiate 
in the absence of LIF. Three days after LIF withdrawal NNC1 cells begin to show 
extensive signs of chromatin condensation and nuclear fragmentation (Figure 4.3c) and 































Figure 4.2 Reducing and blocking Annexin-V staining. Scatter plots of WT E14 cells and KIT Null 
cells (NNC1) stained with Annexin V-FITC (x-axis) and PI (y-axis) in differing concentrations of 
Annexin stain (a.2.5µg or b.1.25µg).  Annexin V staining was blocked using recombinant Annexin V at 


















As KIT Null cells are constitutively annexin positive, another method of apoptosis 
detection was employed to quantify cell death. Caspases (cysteine, aspartic acid specific 
proteases) are a family of proteases that are present but inactive in viable cells. In 
response to apoptotic signals, initiator caspases (caspase -2,-8,-9,-10) are cleaved then 
form heterotetramers which in turn cleave, activate and amplify effector caspases 
(caspase -3,-6 and 7).  Effector caspases cleave proteins within the cell that regulate cell 
survival ultimately resulting in cell death.  (Arends et al.  1991, Salvesen et al. 1997. 
Sleeet al. 1999).  
 
To detect activated caspases within the cell, we employed the cell permeable 
Fluorochrome Inhibitor of Caspases reagent (FLICA).  FLICA is cell permeable, non-
cytotoxic inhibitor which comprises of three main units; carboxyfluorescein (fam), 
Valine-Alanine- Asparagine (VAD) and fluoromethylketone (fmk). VAD is a protein 
sequence that is recognised by and binds to many activated caspases (caspase-1, -3, -4, -
5, -6, -7, -8 and -9) and fmk is a protein moiety that covalently binds to a cysteine residue 
located within the activated caspase to inhibit its enzymatic function (Figure 4.4 a-e).  As 
the FLICA reagent covalently binds to the activated caspase, it is retained within the cell 
and any unbound reagent is washed away during assay.  The remaining signal is a direct 
measure of activated caspase within the cell (Bedner et al. 2000; Grabarek et al. 2002). 
 
WT E14 and NNC1 cells grown in the presence of LIF (LIF +; day 0) or the absence of 
LIF (LIF-; day 3) were analysed by Flow Cytometry with the FLICA reagent (Figure 
4.4f).  In the absence of LIF there was a significant increase in activated caspases in both 
WT E14 and NNC1 when compared with their self-renewing counterparts (p<0.01 in 
both cases) indicating that a proportion of cells enter apoptosis on differentiation.  A 
similar result was reported by Duval et al (2004) who showed that 30% of cells enter 
apoptosis on differentiation.  When comparing differentiating WT E14 cell with 
differentiating NNC1 cells (day 0; LIF-), WT E14 cells have significantly lower activated 
caspase levels than NNC1 cells (P<0.01). This implies that the KIT null cells have 
enhanced apoptosis induction, even at early stages of differentiation. To act as a positive 
control for apoptosis and to ensure FLICA reagent functionality, WT E14 cells were 
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exposed to UV in the presence of LIF to induce apoptosis before staining.  UV induced 
apoptosis was significantly greater than all other conditions regardless of cell type or 
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Figure 4.3 Detecting apoptotic features. (a) DAPI staining of WT E14 and KIT Null cells 
in the LIF+(day 0) and under differentiating conditions LIF- day1-day3.  (b)Viable cells 
have large nuclei with uniform staining whereas (c) apoptotic cells have small brightly 
stained nuclei determined by nuclear fragmentation and chromatin condensation. Three 
days after LIF withdrawal NNC1 cells begin to show extensive signs of chromatin 
condensation and nuclear fragmentation and the percentage of apoptotic cells is 
significantly greater than their WT counterparts (p<0.01) . (n=3. Error bars represent SEM.  


































Figure 4.4 FLICA detection of activated caspase (a) inactivated caspases exist in viable 
cells in 3 subunits; an N-terminal prodomain, a 20 kD catalytic subunit and a 10 kD subunit. 
(b) Upon apoptosis induction, caspases are cleaved at an asparagine residue to release the 
10kD subunit and then at  a second asparagine residue (c) to release the pro-domain. (d) The 
10kD and 20Kd subunits re-assemble to form heterotetramer and the activated caspase 
enzyme.  The active centers containing the reactive cysteine residue to which the fmk protein 
moiety binds is depicted by the excised triangular ends.  (e) VAD contains a sequence that is 
recognised by activated caspases and covalent binding of fmk to active caspase centres 
inhibits caspase enzymatic activity. Carboxyfluorescein acts a a green fluorescent tag for Flow 
Cytometry detection and analysis. (f)  FLICA staining of WT E14 cells KIT null cells and UV 
treated cells grown in the presence (LIF+, day 0) or absence (LIF–, day3) of LIF. Significant 
differences between each condition are depicted by the asterisk and by pink bars (p<0.05) 
refer to the text for exact p-values . (n=3. Error bars represent SEM.  Analysed using a 
Student’s t-test) 
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4.4.3 The effect of ACK 2 on the KIT Null Annexin V Positive phenotype. 
 
Under self-renewing conditions, NNC1 cells display minimal signs of apoptosis where 
levels of activated caspases and nuclear fragmentation were comparable to control WT 
E14 cells. (DAPI/FLICA staining Figure 4.3 and 4.4). This conflicts with the Annexin V 
positive state of the KIT Null cells which implies the onset of cell death. However, it may 
also suggest that KIT Null Annexin V positivity is a phenomenon that occurs 
independently from apoptosis as reported to occur in viable B-cells (Dillon et al, 2000) 
and activated platelets (Thiagarajan et al. 1990).  To investigate this further, ACK2 
(10µg) treated WT E14 cells were compared with isotype control treated cells (10µg) and 
untreated cells to observe the effect of a block in KIT signaling on Annexin V staining 
(Figure 4.5). Under self renewal conditions, ACK2 has no effect on Annexin V positivity.  
However, ACK2 significantly enhanced apoptosis in differentiating cells when compared 
with untreated and Isotype control cells where p= 0.02 and p= 0.04 respectively.  As WT 
E14 cells treated with ACK2 did not display the constitutively Annexin V positive 
phenotype of the KIT Null cells, Annexin V positivity may be due to membrane 
perturbation caused by a physical loss of the KIT receptor to the membrane rather than a 
lack of KIT signaling. As expected, a block in KIT signaling enhanced apoptosis which 







































Figure 4.5 ACK2 inhibition of KIT signalling and Annexin V –FITC staining. Histograms of 
percentage annexin staining of WT E14 cells grown in the presence (LIF +) and absence  
(LIF-) of LIF with the inclusion of the KIT blocking antibody ACK2 or an Isotype control (iso) 
(both antibodies at 10µg).  Significant differences between each condition are depicted by the 
asterisk and by pink bars (p<0.05). ACK2 significantly enhanced apoptosis in differentiating 
cells when compared with untreated and Isotype control cells where p= 0.02 and p= 0.04 
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4.4.4 Caspase inhibition and ES cell survival 
 
As KIT Null cells appear to follow the classical pathway of apoptosis upon 
differentiation, we wanted to test the hypothesis that blocking apoptosis with the broad 
range caspase inhibitor, ZVAD would enhance KIT Null survival upon differentiation.  
To ensure that the ZVAD reagent was efficacious, differentiating WT E14 cells were 
tested in the presence and absence of ZVAD (40µM) and analysed by Flow Cytometry 
for Annexin V positivity (Figure 4.6a).  As expected, differentiating WT E14 cells have 
greater annexin positivity than WT E14 cells grown under self renewing conditions 
(p<0.01).  On ZVAD inclusion, Annexin V positivity is significantly reduced on 
comparison to both self-renewing (P<0.01) and differentiating cells (P<0.01) indicating 
inhibitor efficacy. To determine if ZVAD prevented the KIT Null death upon 
differentiation phenotype, ZVAD was added to differentiating KIT Null cells and 
analysed by Flow cytometry with FLICA staining (Figure 4.6b). WT E14 cells were 
tested concurrently as a staining control.  When ZVAD was added to differentiating cell 
cultures, caspase activation was significantly reduced in both differentiating WT and KIT 
null cells (p<0.01 in both instances) when compared with controls. Therefore, ZVAD was 
able to prevent apoptosis in KIT Null cells.  
 
However, apoptosis inhibition upon differentiation onset may not equate to successful, 
late stage differentiation. To observe if blocking apoptosis with ZVAD allowed KIT null 
cells to form differentiated colonies, clonal assays were established to observe the effect 
of ZVAD on cell survival (Figure 4.6 c and d).  Under self-renewing conditions, ZVAD 
had no effect on WT E14 cells but as the cells were directed to differentiate, ZVAD 
significantly increased the proportion of surviving differentiated colonies (p<0.01) on 
comparison to controls.  Although ZVAD significantly increased the proportion of KIT 
Null stem cell colonies in the presence of LIF (p=0.01), KIT Null cells were unable to 
survive when directed to differentiate.  
 
Even though caspase activation was not completely inhibited with ZVAD, WT E14 cells 
treated with ZVAD displayed a significant increase in differentiated colonies when 
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compared with controls (p<0.01) indicating inhibitor efficacy.  This effect was not was 
not observed in KIT Null cells grown under the same conditions. This data implies that 
KIT provides a pro-differentiation signal to cells which is not compensated with a block 
in apoptosis and may suggest that both pro -differentiation signals and anti-apoptotic 























































Figure 4.6 Caspase inhibition with ZVAD (40µM) and its effect on apoptosis.  (a) WT E14 cells grown in the presence or 
absence of LIF and the presence or absence of the broad range caspase inhibitor ZVAD.  Cells were tested by FLOW 
cytometry with Annexin V FITC staining and the result was depicted as a histogram of percentage Annexin V positivity. (b) WT 
E14 and KIT Null cells (NNC1) were tested for caspase activation then caspase activation inhibition using ZVAD in the 
presence and absence of LIF. Cells were tested by Flow Cytometry with FLICA and percentage caspase activation 
(fluorescence) was displayed as histograms. Clonal assays of WT E14 cells (c) and KIT null cells (d) grown under self 
renewing conditions (LIF+) and differentiating (LIF-) conditions with the inclusion or absence of ZVAD.  Stem cell Mixed and 
differentiated colonies are depicted as histograms. Significant differences between each condition are depicted by the asterisk 
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4.4.5 Inhibition of P38 in ES cells  
 
Duval et al (2004) showed that 30% of differentiating ES cells died by apoptosis via 
activation of the mitogen activated protein kinase (MAPK) p38 pathway.  Inhibition of 
this pathway using the inhibitor PD169316 resulted in an up regulation of BCL2 
expression and survival of the differentiating cells. As KIT null cells apoptose on 
differentiation with a decrease in BCL2 expression (Bashamboo et al. 2006) we tested 
whether KIT-mediated survival upon differentiation was through inhibition of the P38 
pathway.  To test inhibitor efficacy and witness any dose dependent effect or toxicity, 
varying inhibitor concentrations were added to WT E14 cells on clonal assay.  DMSO 
was added as a diluent control and tested concurrently (Figure 4.7a).  Under self renewal 
conditions (LIF+), the P38 inhibitor had no effect on the ability of the cells to self renew. 
As the cells were directed to differentiate (LIF-), a significant increase in the number of 
differentiated colonies was seen only when the inhibitor was used at 10µM (p=0.02).  
Increasing volumes of the diluent control did not affect the self renewal or differentiation 
potential of the cells in this clonal assay.   
 
To test the efficacy of the inhibitor further, untreated WT E14 cells and WT E14 cells 
treated with the inhibitor were directed to differentiate and their Annexin V positivity 
was analysed by Flow Cytometry (Figure 4.7b).  As expected, differentiating WT E14 
had significantly greater Annexin V positivity (p<0.01) than WT E14 cells grown under 
self-renewing conditions.  When the PD169316 was added to differentiating cells, not 
only was Annexin V staining significantly reduced (p<0.01) in comparison to untreated 
differentiating cells, it was also significantly lower than the cell control under self 
renewing conditions (P<0.01).   A similar effect was also displayed when activated 
caspases were investigated (Figure 4.7c).  The inhibitor significantly reduced activated 
caspases on differentiation significantly lower than the cell controls in both WT E14 
(P<0.01) and NNC1 KIT null cell clone (P<0.05).  Although Duval et al experienced a 
30% survival using this inhibitor our survival was 20% reduction on clonal assay, 65% 
reduction of Annexin V staining and a 60% reduction in caspase activation. This 





























Figure 4.7 P38 inhibitor (PD169316) dose dependency assay.  (a) Clonal assays of WT cells grown in 
the presence (5µM, 10µM or 15µM) or absence (0) of the P38 inhibitor PD169316 under self renewing 
(+LIF) of differentiating conditions (LIF-) Stem mixed and differentiating colonies were represented as 
histograms.  As a diluent control, DMSO was added to the cells at the same volume as the inhibitor.  (b)  
Annexin V-FITC staining of self renewing (LIF+) WT E14 cells or differentiating WT E14 cells (after 3 days, 
LIF-) with the presence or absence of PD169316 as shown by the key. (c)  FLICA staining of WT E14 cells 
and NNC1 cells grown in the presence or absence of LIF or PD169316 as shown by the x-axis key. 
Histograms from (b) and (c) were generated from Flow Cytometry data and significant differences between 
each condition are depicted by the asterisk and by pink bars (p>0.05). Refer to text for exact p-values. (n=3. 
Error bars represent SEM.  Analysed using a Student’s t-test)  
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To determine if P38 inhibition was able to support KIT null cells through the apoptotic 
crisis and allow them to differentiate, clonal assays were performed on KIT Null and WT 
E14 cells under self-renewal and differentiation conditions (Figure 4.8).  In the presence 
of LIF, PD169316 had no effect on the population of self-renewing WT E14 cells but in 
the absence of LIF, PD169316 treated cells had significantly higher survival rates than 
both cell and diluent controls (in both comparissons p<0.001) (Figure 4.8a).   
 
Although KIT Null cells are unaffected by inhibitor inclusion under self-renewal 
conditions, there is a slight but non-significant prevention of apoptosis when PD169316 
is added to the differentiating KIT Null cells on assay (Figure 4.8b and c).  As this rescue 
was non-significant, we can conclude that KIT mediated survival does not act through 
inhibition of the P38 pathway. While P38 was able to prolong the survival of 
differentiating KIT Null cells, its inclusion was unable to prevent cell death providing 
further support for the requirement of both anti-apoptotic and pro-differentiation signals 











































Figure 4.8 P38 inhibition (PD169316) and effect on apoptosis.  Clonal assays of (a) WT E14 
cells and (b) NNC1 cells grown in the presence or absence of PD169316 (10 µM) under self 
renewing (LIF+) or differentiating (LIF-) conditions.  DMSO was added as a diluent control.  (c) 
The magnified panel describes a slight but non-significant (p<0.05) prevention of apoptosis when 
the p38 is added to differentiating KIT null cells (NNC1). Significant differences between each 
condition are depicted by the asterisk and by pink bars (p<0.05). In the absence of LIF, 
PD169316 treated WTE14 cells had significantly higher survival rates than both cell and diluent 
controls (in both comparissons p<0.001) (n=3. Error bars represent SEM.  Analysed using one 
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4.4.6 The Generation of BCL2 over-expressing ES cells 
 
To confirm the involvement of BCL2 in KIT mediated survival (Bashamboo et al. 2006), 
WT E14 and KIT Null ES cell clones over-expressing the fusion protein EGFP-Flag-
BCL2 were established (Figure 4.9 a). WT E14 and KIT Null ES clones containing only 
the vector backbone and no fusion protein insert were concurrently generated and 
employed as empty vector controls. Electroporated clones were selected in puromycin 
(0.7 µg/ml) and unstained clones were screened by Flow Cytometry for EGFP expression 
(Figure 4.9 b).  EGFP positive clones were further analysed by Western blot using ant-
Flag, anti-EGFP and anti-BCL2 antibodies (Figure 4.9 c) to detect the fusion protein of 
(55KDa).   50 puromycin resistant clones were selected for each construct (fusion protein 
or empty vector) and cell line of which 10 EGFP positive clones were tested further by 
Western blot.   Figure 4.9 c is a representative sample of highly expressing WT BCL2 
(F4) and Null Bcl2 clones (7B), negative empty vector controls (WT D3 and Null E1) 
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Figure 4.9 BCl2 over-expression. (a) A schematic 
showing the PCAGsip vector containing the 1484 bp 
cDNA EGFP-FLAG-BCL2 fragment generated by 
PCR.  Location of the CAG promoter, selectable 
marker (puromycin), vector backbone and 
sequencing primers are also shown. (b) Over-
expressing clones were selected by a positive shift in 
the FL1 channel (GFP) with Flow Cytometry analysis. 
WT E14 and NNC1 (black histogram) cells do not 
express the fusion protein whereas WT BCL2 and 
null BCL2 (pink histogram) constitutively express 
the fusion protein and fluoresce.  (c) A Western Blot 
showing protein lysates (LIF+) from WT E14 and 
NNC1 cells electroporated with an empty vector 
containing only the vector back-bone and the BCL2 
fusion protein vector .  Protein lysates were tested for 
EGFP, BCL2 and Flag.  50µg of protein were added 
to each well and GAPDH was used as a loading 
control.  CAG = CAG Promoter; IRES = Internal 
Ribosomal Entry Site; Puro = Puromycin; EGFP = 
Enhanced Green Fluorescent Protein. 
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4.4.7 BCL2 over-expression in ES cells 
The pro-survival protein BCL2 was over-expressed in self renewing and differentiating 
WT E14 and KIT Null cells to observe its effect on ES cell survival. Cells were tested for 
nuclear fragmentation and condensation by DAPI stain, caspase activation by FLICA and 
membrane PS exposure by Annexin V FITC. Under self-renewing conditions, over-
expression of BCL2 significantly reduced nuclear fragmentation and condensation in 
both WT E14 and KIT Null cells (p=0.02 and p=0.01 respectively; figure 4.10 a).  On the 
removal of LIF and the onset of differentiation (day 3, LIF-) BCL2 over-expression 
significantly lowered the percentage of DAPI positive cells in KIT Null cells (P<0.01) 
when compared with their parental equivalent (NNC1) and have a cell death profile 
similar to and non significantly different from WT E14 cells and WT E14 cells over-
expressing BCL2 (figure 4.10 a).  BCL2 over expression in WT E14 did not significantly 
reduce the percentage of DAPI positive cells when compared with the parental line 
regardless of growth condition. 
 
In the presence of LIF, the percentage of caspase activation was minimal in both KIT 
Null and WT E14 cells which may account for the slight and non-significant reduction of 
caspase activation with BCL2 over-expression (Figure 4.10 b).  However, upon 
differentiation, BCL2 over-expression significantly reduced caspase activation in both 
WT (approximately 52% reduction, P<0.01) and KIT null cells (approximately 56% 
reduction, p<0.01) indicating that BCL2 plays a role in the survival of differentiating ES 
cells by inhibiting cell death in cells entering the apoptotic crisis.  Duval et al report that 
this apoptotic crisis is initiated two days after LIF withdrawal and apoptotic signals 
produced at this time may be required to trigger the differentiation process.  
Concurrently, some of these cells may commit to irreversible apoptosis if apoptotic 
signals exceeded a survival threshold (Duval et al.  2000).   
. 
 
As the assays described above monitor cell survival until day 3 of LIF withdrawal 
reflecting only the initial stages of differentiation, clonal assays were established to 
provide a quantitative analysis of cell survival resulting from BCL2 over-expression in 
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late stage differentiation (Figure 4.10 c). In the presence of LIF, over-expression of BCL2 
has no effect on the ability of WT E14 or KIT Null cells to self-renew.  Conversely, in 
the absence of LIF, BCL2 over-expression in WT E14 cells resulted in a significant 
increase in the number of differentiated colonies (approximately 28%) when compared 
with cell and empty vector controls (p<0.01). Duval et al (2004) reported a similar 
increase in survival of differentiating cells (approximately 30%) in ES cells over-
expressing BCL2 compared to control cells. However, there was no cell survival when 
BCL2 was over-expressed in differentiating KIT Null cells (Figure 4.10 d). Therefore, 
BCL2 over-expression prolongs the survival of KIT Null cells during the initial stages of 
differentiation but does not prevent the KIT null phenotype of death upon differentiation 
in later differentiation events.  We can conclude that there is an absolute requirement for 
KIT during the later stages of ES cells differentiation and KIT mediated survival does not 















































Figure 4.10 BCL2 over-expression and effect on cell survival. (a) Apoptosis detection by DAPI staining 
of WT E14 cells,  NNC1 cells, WT BCL2 and Null BCL2 cells grown in the presence of LIF and absence of 
LIF for 3 days.  Apoptotic cells were expressed as a percentage. (n=3. Error bars represent SEM.  Analysed 
using a student’s t-test(b) FLICA staining of control and BCL2 over-expressing WT and KIT Null cells in the  
presence of LIF (LIF +) of after 3 days after LIF withdrawal (LIF-). (c) WT and (d) KIT Null clonal assays of 
control and BCL2 over-expressing clones under self renewing and differentiating conditions. Significant 
differences between each condition are depicted by the asterisk and by pink bars (p<0.05). Refer to text for 
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4.4.9 The effect of BCL2 over-expression on the KIT Null Annexin V positive 
phenotype.  
 
As BCL2 has been associated with PS exposure inhibition (Uthaisang et al. 2003) we 
wanted to observe the effect of BCL2 over-expression on constituently annexin positive 
KIT Null cells (Figure 4.11).  In the presence of LIF, BCL2 over-expression did not 
prevent the KIT Null Annexin V positive phenotype as KIT Null cells over expressing 
BCL2 displayed significantly  greater Annexin V staining when compared with control 
WT E14 cells assayed under the same growth conditions (p<0.01). Upon differentiation, 
KIT Null cells (NNC1) were approximately 90% Annexin V positive, which significantly 
reduced to 60% positive with BCL2 over-expression (p<0.01). However, this reduction in 
Annexin V staining was not sufficient to be within limits of the WT E14 control cells 
grown under the same conditions (P<0.01).  
 
In comparison, BCL2 over-expression significantly reduced the proportion of apoptosing 
WT E14 cells grown under both self renewing (p<0.01) and differentiation 
(approximately 31% reduction<0.01) conditions.  This result is similar to that reported by 
Duval et al (2004) indicating efficacy of the BCL2 vector.  
4.4.10 Apoptotic factors from micro array  
To investigate the role of apoptotic factors further, a simple search was carried out on the 
differentially expressed genes using the SCF/KIT database to identify pro and apoptotic 
factors (Appendix 14). The identified apoptotic genes only contributed to 3.6% of the 
total differentially expressed genes and contained both pro and anti apoptotic factors of 
which only one BCL2 family member was down regulated. This was Bclaf1 a 
transcriptional repressor that interacts with several members of the BCL-2 family. Over-
expression of this protein induces apoptosis, and its down regulation at the protein level 
is associated with binding to pro-survival proteins such as BCL2 or BCL-XL (Kasof 
1999). Bclaf1 gene expression was down regulated during KIT Null differentiation and 
























Figure 4.11 BCL2 over-expression and effect on KIT Null Annexin V positive 
phenotype. Annexin V staining of control and BCL2 over-expressing WT and KIT 
Null cells in the  presence of LIF (LIF +) of after 3 days after LIF withdrawal (LIF-) 
Significant differences between each condition are depicted by the asterisk and by 
pink bars (p<0.05). Refer to text for exact p-values. (n=3. Error bars represent SEM.  
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4.5.1 Explaining the Annexin V positive phenotype 
 
The Annexin V positive phenotype was observed in all independently derived KIT Null 
clones where the effect of non-specific binding was eliminated with decreasing 
concentrations of Annexin V-FITC and specificity was confirmed with a pre-adsorption 
step with recombinant Annexin V. Determining whether this effect was caused by 
ablation of KIT signalling or due to a physical loss of the receptor causing membrane 
perturbation was only partially resolved with pre-treatment of WT E14 cells (+LIF) with 
ACK2.  Here, a block in KIT signalling did not recapitulate the KIT Null Annexin V 
positive phenotype and alone, may not be involved in the maintenance of membrane 
asymmetry. 
 
In mammalian cells, membrane composition is not uniform along the two leaflets of the 
plasma membrane where the distribution of phospholipids differs between the inner and 
outer layers.  Choline containing lipids such as phosphatidylcholine
 
(PC) and 
sphingomyelin (SM), are located  primarily on the outer leaflet whereas amine-containing
 
glycerophospholipids, phosphatidylethanolamine (PE) and phosphatidylserine
 
(PS) are 
distributed primarily on the  inner leaflet The inner leaflet also contains minor 
phospholipids such as phosphatidic acid (PA), phosphatidylinositol
 
(PI), 
phosphatidylinositol-4-monophosphate (PIP), and phosphatidylinositol-4,5-bisphosphate
 
(PIP2) (Hasegawa et al. 2006; Daleke et al. 2003).  Phospholipid asymmetry is 
maintained by ATP dependent transporters called flippase and floppase as well as the 
ATP independent transporter, Scramblase. Flippase is highly selective for PS and 
functions to maintain this phospholipid to the inner cell surface. Floppase keeps 
phospholipids to the outer leaflet and Scramblase randomly distributes newly synthesised 
lipids throughout the membrane 
 
Phosphatidylserine (PS) transfer to the outer leaflet of the plasma membrane is associated 
with early apoptosis onset and exposure acts as a phagocytotic trigger to circulating 
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macrophages in order to eliminate compromised material (Botto et al, 2004;  Fadok et al.  
1998).   Although KIT Null cells express PS on their outer membrane leaflet, the theory 
of apoptosis predisposition can be eliminated as they have the ability to self renew, 
express gene markers associated with self renewal and do not display the morphological 
features associated with apoptosis under self renewing conditions.  
 
Exposure of PS to the outer leaflet in viable cells is not exclusive to KIT Null cells and 
has been observed in activated platelets during cell-cell interactions enabling the process 







T cells and during murine, embryonic myotube 
formation. Viable, PS exposing cells are thought to evade the phagogytotic process as 
macrophage chemotactic factors are not excreted concurrently alongside PS exposure 
(Van Den Eijnde et al. 2001). PS is also exposed in viable B-cells lacking the protein 
tyrosine phosphatase (PTP) called CD45. CD45 is located on all hematopoietic cells 
except erythrocytes and platelets and functions to regulate T and B cell signal 
transduction via SRC kinase (Kung et al. 2000).  PS exposure on CD45 deficient B-cells 
was explained by deregulation of survival pathways due to a physical loss of CD45 as 
well as membrane distortion caused by decreased lipid packing (Elliott et al, 2006).   
 
One membrane component that relies on dense lipid packing for correct function is the 
lipid raft. This domain is rich in densely packed cholesterol, sphingolipids and protein 
receptors and is also associated with PS surface exposure on both viable and apoptotic 
cells (Ishii et al. 2005; Dillon et al, 2000; Pike. 2003). Lipid rafts are enriched with 
signalling proteins and act as a platform to unite and promote these receptor-protein 
interactions (Calder et al. 2007). KIT and KIT associated signalling has been linked with 
lipid raft interaction and Jahn et al (2004) described how KIT recruitment to lipid rafts 
was required for efficient activation
 
of the PI3-K/Akt pathway in order to mediate 
survival and proliferation. As previously stated, B-cells deficient in the transmembrane 
membrane protein CD45 are PS positive yet viable due to an altered membrane structure 
and reduced lipid packing.   KIT Null cells are also PS positive yet viable.  Could this 
phenomenon have arisen in the KIT Null cells due to a physical loss of the 
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transmembrane KIT protein resulting in lipid raft perturbation and PS exposure? Perhaps 
KIT signalling plays a more fundamental role and is involved in the expression of the 
Flippase, Floppase Scramblase genes required to maintain membrane asymmetry. 
Upon investigation of the microarray data for genes responsible for membrane 
asymmetry maintenance (Scramblase, flippase and floppase), only floppase (Abca3) was 
up regulated in the absence of LIF. Although floppase is responsible for the 
externalisation of PI to the outer leaflet of the plasma membrane it was not highly 
expressed under growth conditions for pluripotency. If this gene was responsible for the 
Annexin V positive phenotype the expectation would be its significantly high expression 
under all growth conditions. However, it should be noted that in the presence of LIF, 
floppase has a fold change of 1.49 and p value of 0.06 which may merit further 
investigation of this gene (Q-RT-PCR) and resulting protein expression (Western blot) in 
explanation of the Annexin V positive phenotype.  
BCL2 over-expression and prolonged survival did not prevent the KIT Null Annexin V 
positive phenotype (+LIF). Again, the Annexin V positive phenotype of the KIT Null 
cells may not be indicative of cells primed for apoptosis but a phenotype occurring 
independently from cell death potentially via membrane perturbation. As yet, the reason 
for KIT Null PS exposure is unknown but determination of function may be resolved by 
conducting a phagocytosis assay.  KIT Null cells may only survive in culture in vitro as 
there is no means for their removal and destruction. If the function of PS exposure on 
KIT Null cells was to flag this defective cell population for macrophage clearance, the 
engulfment of stained KIT Null cells cultured alongside macrophages could be observed 
and quantitatively measured via Flow Cytometry.   
 
4.5.2 KIT Signalling and Cell Survival. 
 
The SCF-KIT signalling pathway has been implicated with survival in many stem and 
progenitor types and specific survival pathways appear to be cell type and developmental 
stage dependent and include PI3K activation in early haematopoietic progenitors 
(Wandzioch et al. 2004), PKB activation and inactivation of FoxO3a (Engstrom et al. 
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2003) and by activation of SRC Kinase in T and B cells independently from PI3K 
(Agosti et al.  2004). PGC survival is via activation of SRC and AKT independently from 
PI3K (Miguel et al. 2002; Mclaren. 2003) whereas mast cell survival is through PIK/SRC 
kinase activation of RAC1 and JNK (Timokhina et al. 1998).  JNK activation via KIT has 
also been implicated in cell cycle arrest and survival in melanoma cells (Alexaki et al. 
2008).  The specific role of KIT mediated JNK activation and its role in ES cell 
differentiation will be discussed in Chapter 5. 
 
Previous investigations have indicated that the specific action of KIT mediated survival is 
through up-regulation of the pro-survival protein BCL2 (Bashamboo et al. 2006; Carson 
et al. 1994; Zeuner et al. 2003).  In this present study, BCL2 over-expression delayed the 
effects apoptosis in differentiating cells but did not prevent cell death caused by KIT 
receptor ablation.  This delayed apoptosis yet failure to enhance cell survival was also 
demonstrated with P38 and Caspase activity inhibition.  Functionality of the BCL2 over-
expressing vector, ZVAD and PD169316 inhibitors was confirmed via rescue of 
approximately 30% of differentiating WT E14 in accordance with the result described by 
Duval et al (2004; 2006), FACS analysis with Annexin V-FITC and FLICA reagents.  
 
The detection of early apoptotic markers could only be extended until day three after 
which time, all parental KIT Null cells perished and could not be compared with BCL2 
P38 or Caspase inhibited cells.  To give a quantitative measure of the later stages of 
apoptosis, clonal assays were conducted over a 5 day period where day 5 was the earliest 
time point at which distinct colonies could be observed in WT E14 control wells.  
However, the wells containing the KIT Null clones did not form colonies and all cells had 
perished by day 5. This was also the case for KIT Null clones over-expressing BCL2 or 
treated with inhibitors. Both treated and control KIT Null cells had the ability to adhere to 
the wells and began to flatten but were unable to sustain the later stages of differentiation 
upon LIF withdrawal. Although it may be surmised that a block in apoptosis should allow 
the cells to survive to some capacity in culture, the lack of an appropriate differentiation 
signal may result in cell death via caspase independent cell death (Kroemer el al. 2005) or 
secondary necrosis (Krysko et al. 2008)  
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Duval et al (2000; 2004) claimed that the signals required for differentiation were the 
same as those required for cell death.  Therefore, cell survival upon differentiation 
depended on maintaining these death signals within a defined threshold. However, the 
data from this present study indicates that two signals may be required for differentiation 
progression; one for apoptosis inhibition and the other for differentiation. To test this 
hypothesis, KIT Null cells inhibited with ZVAD, PD169316 or BCL2 over-expressing 
clones could be taken through a 3D aggregation stage via embryoid body formation to 
observe if a survival signal (or a combination of survival signals using multiple 
inhibitors) with a differentiation signal could enhance and sustain survival upon 




By knocking out the Kit gene in ES cells, we recapitulated the KIT Null death upon 
differentiation and constituently Annexin V positive KIT Null phenotype reported by 
Bashamboo et al 2006. Further to this, apoptosis was confirmed as the mechanism of cell 
death by detection of chromatin condensation, nuclear fragmentation and caspase 
activation.  Although we were able to delay the effects of programmed cell death by 
inhibition of the P38 pathway, caspase inactivation and the over-expression of BCL2, this 































































JNK1, JNK2 and JNK3 along with their subsequent downstream effectors have been 
shown to promote proliferation and survival in several cell types including ES cells (Xu 
et al. 2010) erythroid cells (Jacobs et al. 2004), cells of the liver during regeneration 
(Schwabe et al.  2003) and Mouse Embryonic Fibroblasts (Tournier et al. 2000). 
Specifically, c-Jun, the major downstream effector of the JNK pathway has been 
associated with proliferation (Angel et al. 1991) and cells lacking c-jun or non-
phophorylatable c-jun mutants, displayed defects in both proliferation and embryonic 
development (Behrens et al. 1999; Foltz et al. 1997; Hong et al. 2003; Timokhina et al. 
1998).  
 
Previous reports have shown that JNK is activated by SCF /KIT signaling to promote the 
proliferation and survival of haematopoietic cells (Foltz et al. 1997) and bone marrow 
derived mast cells (BMMC) (Timokhina et al. 1998).  By expressing a mutated KIT 
receptor which contained point mutations at the major phosphorylation sites in KIT 
(tyrosines 567, 569, 702, 719, 728, 745, and 934) in 32D cells (cells that do not normally 
express KIT), and then adding back specific binding sites, Hong et al (2003) showed that 
KIT dependent JNK activation and subsequent cell survival was via SRC binding, rather 
than PI3K binding to the specific tyrosine residues 567 and 569 on the mutant KIT 
receptor. (Hong et al. 2003).  
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To determine whether there is a link between KIT signalling, JNK activation and ES cell 
survival upon differentiation we inhibited JNK in WT E14 cells using the chemical 
inhibitor SP600125.  This JNK specific, cell permeable inhibitor is ATP competitive with 
a 300 fold greater affinity for JNK 1, 2 and 3 over other MAPKs such as P38 and ERK 
(Bennett et al. 2001). The effects and associated phenotype of JNK inhibition in 
differentiating ES cells were correlated with the KIT Null phenotype to determine if the 




5.3 EXPERIMENTAL STRATEGY 
 
5.3.1 Determine the effect of JNK inhibition on ES cell self renewal and differentiation, 
and survival using the chemical inhibitor SP600125. 
 
5.3.2 Analyse the downstream effect of KIT mediated JNK activation via detection of 





5.4.1 JNK inhibitor SP600125 dose-dependency assay 
 
As JNK has been associated with both anti- and pro apoptotic functions dependent on cell 
type and stage of differentiation (Nishina et al. 2003; Wada et al. 2004), we tested the 
effect of JNK inhibition on ES cells using the JNK inhibitor, SP600125.  Here, WT E14 
cells were grown in the presence of SP600125 from 0μ-20μM under self-renewal (+LIF) 
and differentiation (-LIF) conditions to ascertain the optimal inhibitor concentration for 
use in subsequent assays.  The concentration at which the inhibitor caused minimal 
adverse effects to the cells under self-renewal conditions was selected. The initial dose 
dependency analysis involved a 2D monolayer clonal assay where the inhibitor was 
added directly to the cells on assay (Figure 5.1a). Under self-renewing conditions (+ 
LIF), there was a trend for stem cell colonies to reduce in number as inhibitor 
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concentration increased but this reduction became significant when the inhibitor 
concentration increased beyond 15μM (p<0.01). At this stage it was difficult to 
distinguish whether the significant reduction of stem cell colonies was due to inhibitor 
toxicity or a phenotype specific to JNK inhibition. Using the same inhibitor 
concentrations under differentiation conditions (-LIF), there was a trend for the number 
of differentiated colonies to decrease with inhibitor inclusion and this decrease became 
significant at 5μM (p<0.01). The unaffected self renewal potential of JNK-inhibited WT 
E14 cells; in conjunction with the death phenotype upon differentiation was of particular 
interest as it reflected the reported KIT Null phenotype under the same growth 
conditions.  To investigate this speculative relationship further, the SP600125 inhibitor 
was then used at the non-toxic concentration of 5μM in subsequent assays. There was no 
effect on self-renewal or differentiation when the DMSO (diluent control) was added to 


















































5.4.2 JNK activation and cell survival. 
Figure 5.1 Clonal and dose-dependency assay to assess the effect of the JNK inhibitor SP600125 
on WT E14 cells.  WT E14 cells were grown in the presence of (a) SP600125 from 0-20μM or (b) a 
diluent control (DMSO) 0-20µL (0-0.2%) in the presence (LIF+) or absence (LIF-) of LIF.  SP600125 or 
DMSO was added directly to the c lls on ass y. Significant differences (P<0.01) are represented by the 
pink bar and asterisk.DMSO will be used at a concentration of 0.1% insubsequent assays. ). (n=3. Error 
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5.4.2.1 Blocking c-jun phosphorylation with SP600125  
 
To determine inhibitor efficacy, protein lysates from untreated and SP600125 (5μM) 
treated WT E14 cells were tested by Western Blot for JNK and c-jun, a transcription 
factor phosphorylated by JNK. JNK phosphorylates c-jun on serine-63 and serine-73 to 
cause an increase in transcriptional activity of IFN-γ, IL-2, TNF-α and VEGF 
(Finkenzeller et al. 1995; Foletta et al. 1998; Jainet al. 1992; Pulverer et al. 1991) (Figure 
5.2a). Although it is customary to test several down stream targets of a particular pathway 
when determining the effect of an inhibitor e.g. JNK/p-JNK/c-jun/p-c-jun, this was a 
preliminary investigation and was based on the work by Bennett et al (2001) who 
originally optimised the effect of SP600125 in Jurkat T-cells using p-c-jun. In the 
presence of LIF and the absence of SP600125, both JNK and phosphorylated c-jun were 
detected. When the cells were directed to differentiate on LIF withdrawal, there was a 
slight reduction in detected phosphorylated c-jun whereas JNK expression remained 
constant. On addition of the SP600125 inhibitor, the intensity of the phosphorylated c-jun 
band is visibly diminished compared with LIF-/inhibitor- control indicating efficacy of 
the inhibitor at the protein level during differentiation onset.  However, total jun levels 
would have to be compared with p-c-jun levels before  conclusions can be drawn on 
phosphorylation differences. 
 
5.4.2.2 KIT signaling and down stream protein expression of c-jun   
 
To assess whether c-jun was phosphorylated upon activation of the SCF/KIT pathway, an 
experiment was devised which compared p-c-jun expression in untreated WT E14 cells, 
isotype control antibody treated cells and WT E14 cells stimulated with SCF or blocked 
with ACK2. Untreated cells were grown in the presence of LIF and serum and GAPDH 
was used a loading control (Figure 5.2). A comprehensive description of this experiment 
is described in the materials and methods section. 
 
In the absence of LIF, serum and SCF (Figure 5.2b), levels of phosphorylated c-jun are 
reduced when KIT is blocked with ACK2. As ACK2 specifically blocks KIT signaling 
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(Nishikawa et al. 1991) and causes cells to apoptose upon differentiation with a down 
regulation of p-c-Jun and because addition of the JNK inhibitor at 5μM to differentiating 
ES cells recapitulates the KIT null phenotype, these data may be consistent with the 
hypothesis that KIT signaling mediates the survival of differentiating ES cells by 
activating the JNK pathway.   
 
Phosphorylated c-jun was present in untreated, undifferentiated WT E14 cells which, as 
stated previously, may associate c-jun activation with ES cell self renewal. c-jun 
phosphorylation was also evident in serum- and LIF-starved cells stimulated with SCF, 
regardless of ACK2 inclusion. Here, ACK2 does not appear to have blocking effect on 
WT E14 cells when they are stimulated with additional SCF suggesting that either 
endogenous SCF produced by the ES cells (Palmqvist et al, 2005) or exogenous SCF, at a 
concentration of 10µg /ml, overrides the blocking effect of ACK2. Previously, we have 
shown that ES cells require at least two passages in ACK2 in order to cause a significant 
apoptotic effect in differentiating WT E14 ES cells.  It may be that these cells require a 
longer incubation time with ACK2 or an additional passage with the antibody prior to 
assay in order to contend with a SCF challenge and to observe an ACK2 dependent 
inhibition effect at the protein level.  
 
 
5.4.2.3 SP600125 treated WTE14 cells die by apoptosis upon differentiation 
 
To determine the manner in which the WT E14 cells were dying in response to SP600125 
treatment, WT E14 cells were tested by Flow Cytometry for Annexin V (Figure 5.2c) and 
FLICA (Figure 5.2d expression).  The percentage of Annexin V positive cells was 
significantly greater in differentiating SP600125 treated WT E14 cells than both self-
renewing cells (p=0.01) and untreated differentiating WT E14 cells (p=0.01).  When WT 
E14 cells were tested for activated caspases, again differentiating SP600125 treated cells 
were significantly more FLICA positive than both undifferentiated cells (p<0.01) and 
untreated differentiating cells (p<0.01).    As addition of SP600125 to differentiating WT 
E14 cells enhanced Annexin V positivity as well as caspase activity this associates 
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SP600125 induced death with apoptosis.  Again, this phenotype is consistent with KIT 
Null apoptosis upon differentiation phenotype and the hypothesis of a pro-survival role 
for JNK activation in differentiating ES cells.    
 
5.4.2.4 The effect of JNK inhibition on KIT Null cells.  
 
It was hypothesised that a block in JNK activation would increase the level of apoptosis 
in differentiating KIT Null cells if JNK activation was working independently from KIT 
signalling. To test this hypothesis NNC1 cells were primarily tested by clonal assay to 
observe the effect of JNK inhibition during self renewal and colony formation (Figure 
5.3a). In the presence of LIF there was no significant difference in the ability of the cells 
to form stem cell colonies and in the absence of LIF no stem, mixed or differentiated 
colonies were detected.  As expected, JNK inhibition did not appear to affect the self 
renewal capacity or differentiation capacity of the KIT Null cells.   
 
To test whether JNK inhibition increased the level of apoptosis in differentiating KIT 
Null cells, parallel testing of KIT null cells in their self renewing state were tested 
alongside differentiating (day3, LIF-) KIT Null cells and KIT Null cells allowed to 
differentiate in the presence of SP600125  (Day3, LIF-, SP600125+). As KIT Null cells 
are constitutively Annexin V positive, apoptosis was identified by activated caspase 
detection with the FLICA reagent (Figure 5.3b).  Although the percentage of FLICA 
positive cells significantly increased in  differentiating KIT Null cells in comparison to 
cells grown under self renewing conditions (P<0.01), there was no significant increase of 
FLICA positive cells on addition of SP600125 on comparison to untreated, differentiating 
cells. Therefore, the hypothesis that there is no association between KIT signaling and 
JNK activation can be rejected as no additional caspase activation was observed when the 
KIT null cells were directed to differentiate in the presence of the inhibitor.  Again, this 
correlates with the data presented from protein analysis and clonal assay from JNK 



































Figure 5.2 Testing the functionality of the of the SP600125 inhibitor in WT cells. (a) Protein lysates isolated from WT E14 cells 
grown in the presence (+) or after 3 days absence (-) of LIF and the presence or absence of the inhibitor SP600125 (5μM). Proteins 
were tested with anti-GAPDH (40), anti-JNK (46kD) and anti phosphorylated -c-Jun (p-c-jun, 45kD). (b) WT E14 cells grown in the 
presence or 3 days absence of LIF, Serum, SCF, ACK2 or an isotype control. Resulting protein lysates were tested for p-c-jun and 
GAPDH. (c) Annexin V-FITC staining of WT E14 cells +/- LIF and +/- SP600125. (d)  FLICA staining of WT E14 cells +/- LIF and +/- 
SP600126. Significant differences are represented by the pink bars and asterisks where p<0.05. Refer to text for exact p-values. 
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Figure 5.3 Testing the role of SP600125 inhibitor on KIT Null cells. (a) (c) KIT Null cells (NNC1) 
were tested by clonal assay in the presence and absence of LIF and the presence and absence of 
SP600125. DMSO was used as a diluent control. (b) FLICA of KIT Null (NNC1) cells +/- LIF and +/- 
SP600126. Cells were allowed to differentiate for 3 days in the absence of LIF. Significant 
differences (p<0.01) are represented by the pink bars and asterisks. ). Refer to text (n=3. Error bars 
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5.4.2.5 Prolonged effect of JNK inhibition 
 
As prolonged exposure of WTE14 cells to ACK2 revealed a role for KIT signalling 
during the self renewal process, we wanted to investigate the effect of prolonged JNK 
inhibition on ES cells.  To accomplish this, WT E14 cells were grown in the presence and 
absence of LIF and the JNK inhibitor, then analysed by clonal assay over serial passage 
(Figure 5.4). Initially, SP600125 was added to the cells directly on assay (Figure 5.4 P0) 
and under self renewing conditions there was no significant difference in the ability of 
SP600125 treated cells to form stem cell colonies when compared with diluent control 
and untreated control cells. In the absence of LIF and the onset of differentiation, 
SP600125 treated cells form significantly fewer differentiated colonies (P<0.01) when 
compared with controls.  
 
When the cells were passaged once (2 days) in the inhibitor (Figure 5.4 P1) there was no 
effect on stem cell colony formation.  On the removal of LIF, SP600125 treatment 
resulted in a significant reduction (p<0.01) the number of surviving differentiated 
colonies.  As SP600125 treated cells were able to self renew in the presence of LIF, the 
potential effect of inhibitor toxicity was eliminated.  To test if SP600125 induced death 
was reversible, SP600125 was removed from inhibitor-treated cells on assay and the 
ability of the cells to survive upon differentiation was recorded.  After removal of the 
inhibitor on assay, cell death was prevented and cells were able to survive upon 
differentiation similarly to and non-significantly different from control cells. 
 
When WT E14 cells were passaged twice (4 days) in the presence of the  inhibitor, again 
there was no effect on self-renewal in the presence of LIF but the number of 
differentiated colonies was significantly lower (p<0.01) than controls when LIF was 
removed. However, unlike the observation made from P1, exclusion of SP600125 from 
inhibitor treated cells on assay did not significantly prevent cell death (p<0.01).  Here, 
SP600125 treated cells required one clear passage (2 days without inhibitor) prior to 
clonal assay inclusion before the number of differentiated colonies was comparable to 
control cells (Figure 5.4 P2).  
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When the cells were passaged twenty times in the inhibitor (40 days), results comparable 
to P2 were obtained (Figure 5.4 P20).  Self renewal was unaffected, the number of 
differentiated cells was significantly reduced (p<0.01) and SP600125 treated cells 
required one passage in the absence of the inhibitor before differentiation potential was 
restored to the cells.  These data implies that prolonged exposure to SP600125 in 
differentiating ES cells causes a cell death phenotype similar to that of differentiating 
KIT Null cells, which is fully reversible and does not affect self-renewal.  Therefore, a 
block in JNK signaling does not play a role in the self-renewal of ES cells but may 


































































Figure 5.4 Serial passage of SP600125 (5µM) in WT E14 cells.  WT E14 cells were grown in +/- LIF and +/- DMSO 
(diluent control) and placed into clonal assays.  SP600125 was added on assay (P0), after passage 1 (P1), passage 2 
(P2) or passage 20 (P20).  To prevent cell death caused by SP600125 inclusion, the inhibitor was removed from cells 
on assay (Inhibitor removed on assay; blue bar) or the cells were given one clear passage without the inhibitor (P1 
without inhibitor; red bar).Significant differences are represented by the pink bar and asterisk where p<0.01 in all cases. 
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5.5.1 JNK and self renewal  
 
Although phosphorylated c-jun was evident under self renewal conditions and also 
reduced on LIF withdrawal, a block in JNK did not negatively affect the ability of WT 
E14 cells or KIT null cells to proliferate when grown under self renewing conditions. 
However, further experimentation comparing total c-jun with p-c-jun must be carried out 
in order to confirm this result. Even so, this preliminary result agrees with a recent study 












) did not display a 
phenotype that negatively affected ES cells self renewal.  Interestingly, their study 
reported that a deficiency in JNK2 alone caused an increase in ES cell proliferation as 
JNK2 
-/-
 mutants proliferated more rapidly than wild type control, JNK1 
-/-
 and the 
JNK1/2 double knock out cells.  In regard to rapid proliferation, we did not observe an 
increase of stem cell colony number with SP600125 treatment.   
 
Increasing inhibitor concentrations during the dose dependency assay produced fewer 
stem cell colonies than controls. This reduction may be attributed to SP600125 toxicity at 
increased inhibitor concentrations (Bennett et al. 2001) rather than a direct effect of JNK 
inhibition on ES cell self renewal. Toxicity rather than proliferation inhibition is also 
supported by the fact that prolonged inhibitor exposure had no significant effect on the 
development of stem cell colonies or the ability of the cells to self renew during serial 
passage.   
 
5.5.2 JNK, differentiation and apoptosis 
 
Using the JNK inhibitor SP600125, we have shown an absolute requirement for JNK 
activity during the onset of differentiation in WT E14 ES cells. A similar result was 
reported by Xu (2010) who employed JNK knock out ES cells to demonstrate the 
requirement of JNK during EB formation and differentiation where genes involved in 
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mesoderm formation (Brachyury,), endoderm development  (Sox17 and Hnf1,)  and 
ectoderm differentiation (Wnt1 and Pax2) were down-regulated. A fundamental role for 
JNK activation has also been reported for successful T-cell (Dong et al. 1998) and 
erythroid differentiation (Hietakangas et al. 2001). 
 
The detection of elevated PS exposure (Annexin V positive) and activated caspase 
(FLICA positive) levels confirmed that apoptosis was the means by which WT E14 cells 
perished upon differentiation onset when JNK activity was inhibited. Taking advantage 
of the reversible action of SP600125 we could also determine that a block in JNK during 
self renewal followed by a period of inhibitor withdrawal did not permanently affect the 
potential of the cells to differentiate in subsequent assays indicating that the block in JNK 
becomes important upon differentiation onset rather than a manifestation of inhibitor 
toxicity. However, WT E14 cells with extensive exposure to the SP600125 required at 
least one passage free of the inhibitor before differentiation potential was restored to 
control levels. This reversibility and also the delay in reversibility may be explained by 
the chemical composition of the inhibitor. SP600125 binds to the ATP binding pocket of 
JNK without permanently altering the conformation of the JNK protein and is therefore 
fully reversible (Bennett et al. 2001). SP600125 comprises of 3 aromatic, one pyrazole 
and three aromatic rings and as such, was assigned a low disassociation constant (ki = 
190nm) which implies a strong bond between the inhibitor and the substrate.  Therefore, 
it is likely that inhibitor and substrate may take several days to dissociate and become 
fully metabolized from the cells (Bennett et al 2001; Kar, 2005).   
 
5.5.3 Drawing parallels between the KIT Null model and JNK inhibition 
 
The KIT Null ES cell model and the WT E14/ACK2 inhibition model (Chapter 3) 
demonstrate an absolute requirement for KIT mediated survival during differentiation 
onset.  Using WT E14 cells inhibited with SP600125 we have also demonstrated an 
absolute requirement for JNK during apoptosis onset. As KIT has been linked to JNK 
activation and cell survival in other cell systems (Foltz et al. 1997; Hong et al. 2003; 
Timokhina et al. 1998) we wanted to investigate if KIT mediated ES cell survival acted 
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through activation of the JNK pathway.  Although the results presented only give a 
correlative association of KIT with JNK activation for example, a reduction of 
phosphorylated c-jun in the presence of the KIT inhibitor ACK2 when compared to 
controls; the similarities in phenotype of KIT null cells and the SP600125 treated WT14 
cells upon differentiation; as well as the non additive effect of SP600125 on apoptosis 
upon KIT Null differentiation; this study has provided preliminary evidence for a 
potential KIT mediated survival pathway that could be investigated further.   
Unfortunately time did not permit me to carry out a full analysis of expression of 
signalling molecules of the JNK pathway, the levels of both total and phosphorylated 
JNK and c-jun proteins (e.g. JNK/p-JNK/c-jun/p-c-jun), need to be investigated in 
WTE14, SP600125 treated WTE14 cells and KIT null cells under both conditions for self 
renewal and differentiation.  This would clarify the role of KIT signalling with JNK 
activation and survival. 
  
When sorting the micro array data for MAPK associated genes, it became evident that 
regulators of the JNK pathway were most predominant (Appendix 15). Only one gene, 
P2rx7, associated with ERK activation, was down regulated in the absence of LIF. Many 
genes involved with JNK activation were down regulated in KIT Null cells, even in the 
presence of substrates that usually cause induction of this pathway such as Adm and 
Gadd45b. Both Adm and Gadd45b were highly expressed regardless of LIF inclusion. In 
the absence of LIF, the gene Als2cr2 was highly expressed and functions to inhibit 
apoptosis via the JNK signalling pathway.  
Ask1 and Tak1 are upstream positive activators of the JNK pathway that interact with the 
scaffold protein Sh3rf1. These MAPKKK have been linked to KIT signalling pathways 
via PI3K, RAC and SRC phosphorylation. In the absence of LIF and the onset of 
differentiation these upstream regulators significantly reduce in expression level (p<0.05) 
in parallel with an up-regulation of factors that are usually inhibited (Nupr1) or 
negatively regulated (Nup62 and Efna1) by the JNK pathway. Genes that are always 
negatively regulated regardless of self renewal or differentiation status include (Ndst1 
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and Fgd4). No striking differences were observed when cells were grown under 
conditions for pluripotency (LIF+).  
As there is a potential association between KIT signalling, JNK activation upon 
differentiation and cell survival (Chapter 5) and previous research has shown that JNK 
expression was not required for ES cell self renewal but became an important factor upon 
LIF withdrawal (Xu 2010), the microarray analysis presented may provide additional 
support for the theory that KIT mediated survival is via the JNK pathway.  
Confirmation of expression levels of the key regulating genes involved in this pathway 
with Q-RT-PCR in conjunction with Western blot analysis and perhaps gene expression 
knock down using siRNA techniques in WTE14 cells to investigate JNK up/down stream 
effectors would also provide evidence for the role of JNK during KIT mediated survival.  
 
Stimulants such as mustard oil or gonadotropin elevate the transcription and 
phosphorylation activity of c-jun in neurons (Jin woo 2008 and evi 1998) by driving 
upstream effectors of JNK.  Over-expression of upstream effectors such as MLK3, a 
direct activator of MKK4, has also proven successful in JNK/c-jun activation of murine 
fibroblastic NIH 3T3 cells and human embryonic kidney (HEK) 293 cells (Hartcamp et 
al. 1999). Activation of JNK phosphorylation events in the KIT Null cell line using these 
stimulators alongside Western blot analysis to verify JNK activation at the molecular 
level and effect of the stimulation at the biological level using clonal assays   would be a 
simple experiment to observe a restoration of differentiation in the KIT null cells.  
 
5.5.4 Conclusion  
 
Both pro-and anti-apoptotic roles have been assigned to JNK activation in various cell 
lineages and this study associates JNK signaling with ES cell survival upon 
differentiation. The correlation of the KIT Null phenotype with the SP600125 inhibited 
WT E14 phenotype upon differentiation as well as the preliminary result from microarray 






































Regenerative medicine encompasses the establishment of functional tissues or cells in 
vitro in order to alleviate the problems of damaged or diseased tissues and organs in vivo.  
This field involves a biomedical approach to clinical therapy such as organ and tissue 
engineering as well as progenitor and stem cell technology (Mason et al. 2008).  ES cells 
have provided an exciting avenue for regenerative medicine due to their ability to self 
renew, proliferate and differentiate into cells of the three germ layers including germ cells 
(Evans et al. 1981; Martin, 1981).  
 
The self renewal ability and genetic status of the founding ES cell population is of 
particular importance in the development of novel cellular therapies to ensure a 
continuous supply of cells that can be differentiated reliably and safely into specified 
lineages using defined protocols with defined growth factor and cytokine cocktails. To 
avoid the potential risk of zoonotic pathogen transmission from animal derived products 
and the addition of undetermined growth constituents to the culture media, ES cells must 
be grown feeder layer free without the inclusion of animal serum. As the molecular 
mechanisms controlling ES cell differentiation is still poorly understood it is difficult to 
supplement serum and feeder free systems with the correct balance of growth factors for 
optimal self renewal, pluripotency, proliferation, differentiation and lineage specific 
survival. 
 
The SCF-KIT pathway has been correlated to pluripotency in ES cells (Palmqvist et
 
al. 
2005; Lu et al 2007) and implicated in the survival of many stem and progenitor lineages. 
Specifically, the research by Bashamboo et al (2006) associated the KIT receptor with a 
key role in murine ES cell survival upon differentiation and was the founding paper on 
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which this study was based.  This project aimed to further investigate the findings by 
Bashamboo et al by defining the role of the SCF/KIT signalling pathway during ES cell 




6.1.1 Self renewal and differentiation 
 
Using gene targeting techniques, we generated a murine ES cell model that could directly 
compare the effect of a KIT Null mutation with their wild type counterparts at both the 
cellular and molecular level under conditions for both self renewal and differentiation.  
Following from this, we were able to compare our findings with the work by Bashamboo 
and other related publications. Although there was some debate over the role of KIT 
during ES cell maintenance (Lu et al. 2007; Bashamboo et al. 2006) we support the 
theory that KIT signalling is required for the proliferation of self renewing ES cells rather 
than the process of self renewal itself. We can substantiate this claim as the gene markers 
for pluripotency (Oct4 and Nanog) had similar expression levels in both KIT Null and 
wild type cells and when each cell type was placed into clonal assay, they produced 
comparable stem cell colony numbers yet, colony size, growth rates and cell number after 
passage were significantly lower in KIT null cells than wild type cells.  Additionally, this 
phenotype of small colony size was recapitulated in ACK2 treated wild type cells when 
placed into a clonal assay.  However, prolonged exposure of ACK2 to wild type cells 
caused a reduction in stem cell colonies on clonal assay indicating a non-essential, 
auxiliary role for KIT during ES cell self renewal.   
 
Enriching a population of ES cells based on KIT expression not only resulted in a 
positive effect on self renewal (this study; Lu et al. 2007) but enhanced differentiation in 
clonal assay (this study and Lu et al. 2007) and EB formation (Lu et al. 2007). 
Conversely, a block in KIT signalling caused by gene targeting or neutralising antibody 
demonstrated a key requirement for KIT upon monolayer differentiation with the severest 
phenotype being KIT ablation where all differentiating cells perished by apoptosis.  
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When cultured as embryoid bodies, KIT Null cells produced smaller bods then limited 
differentiation upon cardiomyocyte differentiation.  This limited differentiation may be 
due to receptor cross talk where a similar receptor with converging pathways could signal 
in place of KIT.  One potential candidate was the Platelet Derived Growth Factor b 
(PDGFb) receptor.  This receptor is of the same receptor family as KIT and was up 
regulated at all times upon microarray analysis.  A compensatory receptor such as 
PDGFb may also account for the comparable level of self renewal potential that was 
observed in both the KIT null cells and the wild type control when compared with the 
reduced stem cell colony numbers in the ACK2 treated cells.  
 
 
KIT signalling appears to have a profound effect on the ability of undifferentiated ES 
cells to proliferate in culture and perhaps a minor role in the process of self renewal itself. 
However it is likely that another receptor may compensate for KIT under conditions for 
self renewal and differentiation.  Even so, it may be beneficial to add SCF as a 
supplement to undifferentiated cells in the absence of serum to promote proliferation. At 
this stage, the consequences of compensatory mechanism activation are not defined.  
Would activation of the PDGFb in place of KIT result in an alteration of the 





Bashamboo et al were the first to associate KIT signalling with BCL2 mediated survival 
of differentiating ES cells.  They also defined apoptosis as the mechanism of cell death 
caused by KIT ablation.  We confirmed this cell death mechanism by detection of 
caspase activation (FLICA), chromatin condensation and DNA fragmentation (DAPI) in 
differentiating KIT Null cells as well as recapitulating apoptosis detection in 
differentiating ACK2 treated wild type cells.  However, blocking apoptosis in KIT Null 
cells by over-expressing the pro-survival protein BCL2 and inhibiting caspase activation 
(ZVAD) and P38 activation prolonged survival but did not support the cells through the 
apoptotic crisis initiated by the differentiation process.  Although microarray data 
identified several genes associated with both positive and negative regulation of 
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apoptosis, genes with the highest differential expression in KIT Null cells encoded 
stimulators of signalling pathways leading to differentiation (Adrenomedullin and 
Gadd45b) rather than anti-apoptotic proteins or members of the Bcl2 family. This 
indication from microarray analysis, along with the inability to progress differentiation by 
inhibition of apoptosis, raises the hypothesis that KIT signalling provides a pro-
differentiation signal rather than an anti-apoptotic signal upon LIF withdrawal and may 
imply that the relationship between KIT and BCL2 may be a consequence of two 
independent processes occurring at the same time. Although the processes stimulated by 
KIT signalling and BCL2 activation may work in conjunction to drive optimal survival in 
differentiating cells, one may not depend exclusively on the other.   
 
 
KIT Null cells grown under conditions for pluripotency are viable and have the ability to 
self renew, yet display an Annexin V positive phenotype that could not be explained by 
non-specific staining. This phenotype was consistent across four independently derived 
KIT Null clones and as caspase activation, chromatin condensation or DNA 
fragmentation was not observed in these self renewing cells, it appeared to be a 
phenomenon occurring independently from apoptosis.  As self renewing, ACK2-treated 
wild type cells did not recapitulate this phenotype it may be hypothesised that the 
Annexin V positive phenotype of the Null cells is due to a physical loss of the receptor 
causing membrane perturbation rather than a block in KIT signalling.  One potential 
explanation may be disrupted lipid packing at lipid raft sites resulting in surface PS 
exposure. Microarray data has indicated that the gene responsible for externalisation of 
phospholipids to the outer membrane Abc3r (floppase) has elevated expression (both 
LIF+/LIF-) in two independent KIT null cell lines  when compared with controls and may 
be a potential candidate to explain the KIT Null Annexin V positive phenotype. 
However, it is unclear if this phenotype that we have observed in our experimental model 
has any relevance in vivo.  Does this phenotype arise in vivo and is it a mechanism to rid 






6.1.3 Cell sorting 
 
Sorting WT E14 cells based on KIT expression resulted in a population of KIT negative 
cells that became KIT positive over serial passage under self renewing conditions.  Even 
though KIT was not restored to control limits, this identified the fluctuation of Kit 
expression during self renewal.   A similar observation of KIT restoration was observed 
by Lu et al upon serial passage of KIT neg grown under conditions for self renewal.   
 
Upon differentiation, we demonstrated that KIT ablation was not equivalent to a 
population of KIT negative cells as KIT negative cells displayed a phenotype skewed 
towards differentiation, even in the presence of LIF, whereas the KIT Null cells did not 
survive upon differentiation.  Similar phenotypes of fluctuating expression during self 
renewal and skewed differentiation have been observed when sorting wild type 
populations for Nanog and Hex. 
 
To monitor the expression of Nanog in undifferentiated and differentiating ES cells, 
Chambers et al generated an ES cell line with GFP targeted to Nanog.  They found that 
under conditions for self renewal GFP
-
, and therefore Nanog negative, cells became GFP
+
 
and remained positive even after serial passage. When GFP
-
 cells were placed into clonal 
assay and initiated to differentiate, they produced fewer differentiated colonies with a 
lower rate of proliferation. Therefore, down regulation of Nanog predisposed ES cells to 
differentiate but does not mark their commitment to differentiate upon re-expression of 
Nanog (Chambers, 2007) 
 
In another study, Canham
 
et al (2010) used an enhanced yellow fluorescent protein 
(Venus) to monitor the expression of the early endodermal marker Hex in 
undifferentiated ES cells. Sorting ES cells by Venus (V) expression and the expression of 





) as well as a population of (V-S+) cells. Under self renewing conditions, 
these populations exist in equilibrium where each cell type can switch to their 










 cells developed into 
epiblast (Canham, 2010).  This presents the possibility that wild type ES cells could be 




Signals relayed by JNK through c-Jun regulate a range of cellular process including cell 
proliferation, tumourigenesis, apoptosis and embryonic development (Dunn et al. 2002; 
Timokhina et al. 1998; Wiltshire et al. 2002).  JNK has also been associated with KIT 
related cancers such as mastocytosis and small cell lung carcinomas (SCLC) (Shinoda et 
al. 2005). In particular, JNK 1 and 2 cause a cellular proliferative effect when stimulated 
by the constituently active D816V c-kit mutant  during mastocytosis progression 
(Timokhina et al. 1998; Wang et al. 2006) whereas JNK provides an anti-apoptotic effect 
that  enhances multi drug resistance during the chemotherapy  treatment of small cell 
lung carcinomas (SCLC) (Shinoda et al. 2005).  As both of these cancers are associated 
with defects in KIT signalling, the JNK pathway may be an important target in the 
treatment of KIT mediated disease.   
 
To observe the effect of JNK activation on the self renewal, proliferation and 
differentiation capacity of ES cells and find evidence of an association with KIT 
signalling and JNK activation, JNK was blocked in ES cells using the JNK inhibitor 
SP600125 and the resulting phenotypes were correlated with our KIT Null/WTE14 
model.  From this analysis, there were several parallels drawn between the KIT null 
phenotype and the phenotype of JNK inhibited ES cells.  Similarly to KIT ablation, 
SP600125 inhibition revealed a non-essential role for JNK during ES cell self renewal 
but an essential role during differentiation onset.  Upon differentiation, the mechanism of 
cell death was confirmed as apoptosis via detection of PS exposure and activated 
caspases. Further to this, ACK2 blocked ES cells displayed a down regulation of c-jun 
expression at the protein level similarly to SP600125 treated cells in the absence of LIF.   
Therefore, the hypothesis that „KIT signaling mediates the survival of differentiating ES 
cells by activating the JNK pathway‟ was formulated.  To add support to this claim, JNK 
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inhibition did not increase the proportion of apoptotic cells during KIT Null 
differentiation. An increase in cell death would have been observed with inhibitor 
inclusion if JNK were acting independently from KIT. At the molecular level, analysis of 
micro array data also highlighted that major upstream regulators of the JNK pathway, 
such as Ask1 and Tak1, were down regulated in differentiating KIT Null cells reinforcing 
the theory that this signalling pathway could be involved in KIT mediated survival.  
 
Finding a pathway downstream of the KIT receptor that is specifically responsible for the 
aberrant growth of a particular cell linage is particularly important in development of new 
pharmacological therapies.  In particular, mastocytosis arises from the Kit mutation Asp 
816 Val, an activating mutation that is resistant to Imatinib mesylate STI571.   Blocking 
the JNK/c-Jun pathway would provide selective approach disease suppression and avoid 




6.1.5 Genetic stability and methylation 
 
 
Although ES cells have the ability to remain pluripotent and can self renew for prolonged 
periods in culture, extensive passages of both murine and human ES cell lines have the 
potential to accumulate karyotypic abnormalities and changes in methylation patterns.   
(Liu et al. 1997; Longo et al. 1997; Draper et al. 2004; Inzunza et al. 2004) The rate of 
genetic abnormality accumulation and can be enhanced with clonal selection or alteration 
of culture method.  Weaning human ES cells from feeder layers resulted in trisomy of 
chromosome 17 or 12 (Draper et al. 2004; Inzunza et al. 2004) and changes in growth 
media altered the methylation patterns of the maternally expressed H19 gene.  Here, a 
loss of methylation on the paternal allele was observed in embryos cultured in Whittens‟s 
medium but not KSOM medium supplemented with amino acids indicating that culture 
conditions can selectively affect imprinted gene expression (Doherty et al. 2000). These 
problems will have to be addressed during the development of human ES cell based 
transplantation and cellular therapies to ensure product safety.  
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In our model, karyotypic analysis of KIT Null cells demonstrated an increase in 
chromosome number after serial passage.  Although the data presented by this study was 
unable to elucidate the means by which this process occurred.  Further investigation will 
clarify whether karyotipic instability arose from adverse growth conditions during 
selection or via a direct effect of KIT ablation. If KIT is involved in the maintenance of 
genetic stability, this would have implications on the addition of SCF to ES cell culture 
media during their routine culture. 
DNA methylation involves the modification of gene expression through interaction with 
DNA methyltransferase (DNMT). In mammals there are three active DNMTs (1, 3a and 
3b) which covalently binds a methyl group to DNA at CpG islands in regulatory regions 
or promoter regions of DNA. As a result binding sites for transcription factors are 
blocked and consequently repress gene expression. DNMT1 is a maintenance 
methyltransferase, which preferentially recognizes hemimethylated DNA and methylates 
newly synthesized DNA whereas DNMT3a and 3b are de novo methyltransferases which 
create new methylation patterns on non-methylated DNA (Bestor, 2000). DNA 
methylation is an epigenetic regulator of parent-specific genomic imprinting (Reik,  
2001). Imprinting relies on both maternal and paternal methylation patterning and plays a 
significant role in regulating embryonic development, placental function and behavioral 
processes (McGrath,2005; Lefebvre 1997). In vivo, parental methylation patterns are 
erased during embryogenesis and re-established during gametogenesis. The fertilized 
embryo is also initially methylated on both imprinted and non imprinted genes from male 
and female origin and then de-methylates prior to implantation with the exception of 
imprinted genes which remain methylated. Re-methylation of the blastocyst ICM occurs 
by de novo DNMT 3a/3b (McLaren et al. 1999). In vitro, ES cells are derived from ICM 
cells harvested during the initial stages of re-methylation and ES cells quickly become 
methylated upon cell line establishment. Therefore, these cells may not reflect a cell 
population that exists in vivo (Latham et al. 2007). Although ES cell with Dnmt1−/− and 
Dnmt [3a−/−,3b−/−] mutations are hypomethylated, they are able to self renew 
successfully but are unable to terminally differentiate into specific lineages on the 
removal of LIF (Jackson et al.  2004)  
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Microarray analysis presented another theory of cell survival by means of KIT regulated 
methylation patterns. The gene that displayed the greatest fold change (-22.89 Appendix 
4) and was down regulated in both the presence and absence of LIF was the mesoderm 
specific transcript gene Mest (Peg1) which encodes an endoplasmic reticulum expressed 
protein. Mest is an imprinted gene expressed only from the paternal allele and due to its 
unmethylated state is expressed during all stages of male germ cell development (swales 
2005). The female allele becomes highly methylated upon oocyte maturation by de novo 
DNMT 3a/3b (Lucifero et al. 2004) and remains silent. In the embryo, the Mest gene is 
exclusively expressed in embryonic and extra-embryonic mesoderm in early post 
implantation embryos (Sado et al. 1993), Upon differentiation and lineage specification 
Mest expression is reduced. However, complete loss of Mest during the early stages of 
development causes embryonic lethality and Mest deficiency or inappropriate expression 
causes growth retardation of embryonic structures and behavioral defects in the adult 
(Kanwar et al. 2002; Lefebvre et al. 1997).  
The data presented from this array data shows that Mest expression is reduced at all times 
in the KIT null cells with a concurrent 2 fold increase of DNMT3a. As de novo 
methylation is responsible for Mest methylation and therefore silencing in vivo, it is 
possible that KIT Null cells are hypermethylated. Further to this the other paternally 
expressed genes Peg3 ,Snrpn , Znf127, Ndn, and Impact genes as well as maternally 
expressed Igf2r and p57KIP2 genes were investigated but returned no differential 
expression. This may link KIT signalling specifically to Mest expression via DNMT3a. 
Further experimentation confirming the expression levels of Mest and DNMT3a in KIT 
Null cells as well as establishing the methylation status of the KIT Null cells would be 












6.2.1 The generation of an inducible vector 
 
 
The generation of a KIT Null ES cell line has been invaluable in demonstrating the 
importance of KIT signalling during ES cell differentiation in vitro.  However, this is „an 
all or nothing‟ model and can not be employed to investigate the effect of KIT activation 
or exclusion at specific time points during lineage specification.  To account for this, 
Bashamboo et al generated a pharmacologically inducible KIT Null cell line (FKB/KIT) 
which comprised of two FK506-binding domains (FKBP12) fused
 
to KIT- intracellular 
kinase signalling domains (Jin et al. 1998). Stimulation of the FK506 binding domains by 
the drug AP20187 caused dimerisation and auto-phosphorylation of the intracellular 
kinase domains of KIT and activation of signal transduction that was comparable to the 
wild type receptor.  This system allowed the reversible and specific activation of KIT at 
desired periods during cellular differentiation.  Bashamboo et al (2006) generated the 
inducible cell line by knocking the FKB/KIT gene into a heterozygous Kit
W-lacZ/+ 
clone 
resulting in the Kit
W-lacZ/W-FKB 
cell line. Although Kit
W-lacZ/W-FKB
 partially rescued the KIT 
Null phenotype with the administration of AP20187, this cell line did not grow well after 
extensive culture possibly due to the accumulation of chromosomal abnormalities as 
previously discussed.  Unfortunately, this cell line was lost due to poor cell growth before 
karyotypic analysis could commence to test this hypothesis.     
 
As the vector used to generate the inducible line had a low targeting efficiency of only 
1% it would be of use to re-design the targeting vector using a Kit containing bacterial 
artificial chromosome (BAC) in conjunction with recombineering techniques (Copelamd 
et al. 2001) to lengthen the targeting arms and increase vector efficiency.  Designing the 
vector with a neomycin cassette flanked by two loxP sites in frame with the inducible 
gene would allow targeting directly into wild type cells without the requirement of the 
heterozygous line. After clonal selection and targeting confirmation using Southern blot, 
the neomycin cassette could be removed using cre-recombinase. Following this, the 
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newly derived KIT 
+/FKB
 cell line could be retargeted with the same vector to produce a 
fully inducible cell line avoiding the requirement for high G418 exposure or extensive 
passage in the absence of functional KIT signalling.  
 
Chapter 3 gave a crude indication that KIT was expressed at varying levels throughout 
differentiation in vitro.  Interestingly, this in vitro model mimics the waves of Kit 
expression observed during developmental processes such as melanogenesis, 
gametogenesis and haematopoiesis in vivo. An inducible cell line would allow the 
specific analysis of the effects of Kit expression during lineage specification and in 
conjunction with Q-RT-PCR give a quantitative measure of lineage specific genes that 
are up or down regulated upon Kit induction or elimination. Protein analysis carried out 
on cell lysates isolated during the different differentiation strategies would confirm the 
results from Q-RT-PCR as well as identify distinct KIT mediated signalling pathways 
that are active during lineage specification.  Again WT and KIT Null cells could serve as 
positive and negative controls for these processes.  
 
 
6.2.3 Receptor compensation 
Low level differentiation was observed in KIT Null cells when directed to differentiate 
via embryoid body formation.  This was in contrast to the monolayer system in which all 
cells died by apoptosis upon differentiation. Early microarray analysis has indicated that 
the Pdgfb was elevated in both the presence and absence of LIF in two independent KIT 
Null cell lines. As this receptor is of the same receptor family as KIT it would be of 
interest to establish if this receptor could aid differentiation in the absence of KIT 
signalling by engaging in convergent signalling pathways.  No differential expression 
was shown for in vivo compensatory receptors such as the Epo, IL-3 , Tpo or flt-3 
associated with erythroid rescue or hepatic stem cell activation in W/W
v
 mutant cells 
(Antonchuk et al. 2004; Goldwasser et al. 1990; Omori et al. 1997) or colony-stimulating 
factor-1 (CSF-1)/c-fms in murine peri-implantation blastocysts (Arceci et al. 1992) or c-
fms during mast cell survival (Dubreuil et al. 1991).  
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 Q-RT-PCR analysis of KIT Null cells would allow the confirmation of elevated Pdgfb 
expression and subsequent Western blot of cell lysates or Flow Cytometry analysis of 
intact cells would confirm elevated expression at the protein level in comparison to wild 
type cell controls. To determine if a switch in receptor signalling from KIT to PDGFb 
causes an alteration in lineage specification, Q-RT-PCR could be employed to identify 
genes that are on / off during at several stages of EB formation or cardiomyocyte assay 




6.2.4 Cell populations  
 
The observation that undifferentiated ES cells could be segregated into categories based 
on KIT expression and that these sorted cells remained in their specific categories over 
serial passage was used to formulate the hypothesis that „specific undifferentiated cellular 
compartments may represent specific progenitor lineages‟.   
 
During her PhD study Gillian Cowan carried out provisional Q-RT-PCR analysis of 
WTE14 cells sorted on the basis of KIT 
hi
 and KIT 
neg
 expression (Gillian Cowan, PhD 
thesis 2009).  This study indicated that a KIT 
Hi
 population positively correlated with 
early germ cell gene markers such as Blimp1, Fragilis and Stella. It would be of 
importance to pursue this hypothesis to investigate the possibility that an undifferentiated 
population of ES cells could be sorted on the basis of KIT expression in order to enrich 
for an early germ cell progenitor. 
 
6.2.5 Membrane asymmetry 
 
The constituently Annexin V positive phenotype of the KIT null cells may be explained 
by the up-regulation of the gene floppase (Abc3r) as indicated by early micro array 
analysis.  Confirmation of Abc3r up-regulation by Q-RT-PCR and protein analysis would 
provide support for the mechanism. However, it is not certain whether this PS exposure 
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phenotype has function.  As PS exposure is associated with apoptosis onset and 
phagocytotic engulfment, it would be of interest to observe the uptake of KIT Null cells 
upon co-culture with macrophages and compare this engulfment, if any, with Annexin V 
low wild type ES cells.  Engulfment could be observed and quantified via dual staining of 








One pathway that has linked KIT signalling with the positive regulation of 
tumourigenesis is the JNK pathway (Vivanco et al. 2007; Sancho et al. 2009).  Although 
the results presented by this study only demonstrate a correlative association of KIT with 
JNK activation, a comprehensive screen of JNK downstream signalling molecules e.g. 
JNK/p-JNK/c-jun/p-c-jun, in WTE14, SP600125 treated WTE14 cells and KIT null cells 
under both conditions for self renewal and differentiation would clarify this association 
and relate KIT signalling with JNK activation and ES cell survival. 
Already micro array analysis indicates that genes encoding proteins that mediate JNK 
activation are down regulated upon differentiation onset in two independent KIT Null 
clones.  Confirmation of this result with Q-RT-PCR in conjunction with Western blot 
analysis and functional assays would provide evidence for the role of JNK during KIT 
mediated survival of differentiating ES cells.  
 
 
6.2.7 Gene regulation  
 
To determine the role of KIT in the maintenance of chromosome stability, wild type ES 
cells may be grown in the presence of the KIT neutralising antibody ACK2 for prolonged 
passage then analysed karyotypically.  Concurrent passage of untreated wild type ES 
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cells could serve as a control.  In the event of generating an inducible cell line, a similar 
experimental procedure could commence but with the addition or absence of the 
stimulating drug, AP20187.  
 
Epigenetic changes brought about by changes in DNA methylation patterns is an 
intriguing line of investigation for KIT mediated signalling pathways. Many cancers 
show aberrant methylation patterns, and methylation is central to many other important 
processes, such as embryonic development and cell cycle regulation. 
The data presented from this array data implies that Mest expression is reduced at all 
times in the KIT null cells with a concurrent 2 fold increase of DNMT3a.  As de novo 
methylation is responsible for Mest methylation and therefore silencing in vivo, it is 
possible that KIT Null cells are hypermethylated. Again, confirmation of the down 
regulation of Mest and up-regulation of DNMT3a using Q-RT-PCR as well as protein 
analysis could confirm the microarray findings as well as provide support for the 




6.2.8 Final thought 
 
This study has presented a plethora of intriguing phenotypes which have inspired the 
formulation of novel hypotheses for further exploration. Investigation of the KIT receptor 
using our knock out model has allowed the association of KIT signalling with 
proliferation as well as survival upon differentiation via a pro differentiation signal rather 
than an anti-apoptotic signal.  We have also identified the JNK pathway as a potential 
target of KIT mediated survival in addition to a hypothetical link with DNA methylation, 
gene expression regulation, membrane asymmetry regulation and chromosome stability. 
Kit is a gene responsible for many pleotrophic effects in vivo as reflected by its varied 
phenotypes in vitro and thus, should be considered during ES cell maintenance, 
differentiation, lineage specification and during the derivation of cellular or 
























































Appendix 1 - pCR8/GW/TOPO bcl2 
 
































































Complete Gene Listings – Micro Array Data 
 







Mest 17294 -22.89 8.46691E-06 
Kit 16590 -11.27 0.000131969 
Tox3 244579 -5.38 0.000510852 
Hmga2 15364 -4.48 0.00244546 
Lefty1 13590 -4.39 0.0466286 
2610528J11Rik 66451 -3.83 0.00460529 
Car2 12349 -3.55 0.0105087 
Ube1y1 22202 -3.46 0.00391346 
Uty 22290 -3.15 0.00172268 
Ddx3y 26900 -3.08 0.000606614 
Bmi1 12151 -3.05 0.00020175 
Ddx3y 26900 -3.04 0.000568738 
Lefty1 13590 -2.87 0.000559163 
Aff3 16764 -2.82 0.00298331 
Mat2a 232087 -2.74 0.0405987 
Plac8 231507 -2.63 0.00274024 
Eif2s3y 26908 -2.61 0.00456108 
Alox5ap 11690 -2.54 0.000816223 
Uty 22290 -2.53 0.00608592 
Pof1b 69693 -2.52 0.0128626 
Fgd4 224014 -2.5 0.0351006 
Pcolce2 76477 -2.49 0.00034343 
EG667823 667823 -2.42 0.0251314 
Rpl30 19946 -2.4 0.018457 
Gpr177 68151 -2.39 0.0120792 
4930526L06Rik 75138 -2.33 0.00268558 
2610528J11Rik 66451 -2.33 0.00414445 
Plac8 231507 -2.32 0.00169168 
4930526L06Rik 75138 -2.27 0.0358052 
Odz4 23966 -2.24 0.0353817 
Eif2s3y 26908 -2.21 0.00182436 
Rgnef 110596 -2.17 0.00329201 
Car2 12349 -2.15 0.00188042 
2700023E23Rik 70036 -2.15 0.015266 
Stx3 20908 -2.14 0.00115826 
Kcnk1 16525 -2.14 0.0161313 
Rgnef 110596 -2.11 0.00868319 
EG667823 667823 -2.1 0.00214902 
Gpr177 68151 -2.1 0.000497039 
Galnt7 108150 -2.01 0.0481532 
Tox3 244579 -2 0.00278207 
Efs 13644 -2 0.00632446 


























































Hmgb1 15289 -1.94 0.0142479 
2700023E23Rik 70036 -1.93 0.00739123 
Stx3 20908 -1.93 0.0266332 
Zfy2 22768 -1.92 0.00139377 
Fgd4 224014 -1.92 0.00795374 
Tmem144 70652 -1.9 0.0295257 
Sfrs12 218543 -1.9 0.015665 
Mtdh 67154 -1.89 0.0150715 
Zfy2 22768 -1.88 0.0133547 
Chmp4c 66371 -1.87 0.00199394 
Bmi1 12151 -1.86 0.0231236 
Marveld1 277010 -1.86 0.0159641 
Galnt7 108150 -1.84 0.0214465 
Chmp4c 66371 -1.82 0.0188394 
Pcolce2 76477 -1.8 0.0182913 
Rpl30 19946 -1.79 0.00196609 
Pttg1 30939 -1.79 0.00385103 
5730601F06Rik 77519 -1.77 0.0260964 
Odz4 23966 -1.76 0.0131493 
Mat2a 232087 -1.76 0.0121224 
Sfrs12 218543 -1.74 0.0363009 
Aff3 16764 -1.73 0.0304486 
Xpo1 103573 -1.73 0.00391355 
Marveld1 277010 -1.73 0.0150785 
Alox5ap 11690 -1.72 0.0068364 
Pof1b 69693 -1.72 0.0230529 
Uspl1 231915 -1.71 0.0025972 
Kcnk1 16525 -1.67 0.00922084 
Pttg1 30939 -1.65 0.0340946 
Hmgb1 15289 -1.63 0.00100996 
Ndst1 15531 -1.62 0.00872428 
Itgb5 16419 -1.58 0.00670989 
Mtdh 67154 -1.58 0.00133284 
5730601F06Rik 77519 -1.57 0.0138925 
Xpo1 103573 -1.56 0.00355708 
Itgb5 16419 -1.55 0.0190201 
Efs 13644 -1.53 0.0242852 





Complete Gene Listings – Micro Array Data 
 




ID fold change p-value 
Serpinb6c 97848 -3.13 2.56E-05 
Lefty2 320202 -2.93 0.002403 
Dppa3 73708 -2.81 0.008322 
Aoah 27052 -2.7 0.00052 
Enah 13800 -2.5 7.38E-05 
Cphx 105594 -2.5 0.01397 
Vwf 22371 -2.49 0.018866 
672498 672498 -2.47 0.00266 
EG668339 668339 -2.38 0.001481 
Apobec2 11811 -2.27 0.002513 
Slc23a1 20522 -2.27 0.033908 
Calml4 75600 -2.27 0.004967 
Notum 77583 -2.24 0.006423 
Lpar4 78134 -2.23 0.010817 
Trim2 80890 -2.23 0.000516 
Gpa33 59290 -2.18 0.001787 
Magohb 66441 -2.14 0.000896 
Rbm35a 207920 -2.14 0.003232 
Patl2 67578 -2.12 0.013564 
Tacstd1 17075 -2.08 0.00095 
2210409E12Rik 72381 -2.01 0.008096 
Si 20431 -2 0.016195 
Dpys 64705 -2 0.011006 
C430002E04Rik 78706 -1.99 0.003142 
Obox6 252830 -1.99 0.000785 
AW061290 381110 -1.98 0.013781 
Pga5 58803 -1.96 0.004373 
Hesx1 15209 -1.95 0.000381 
Pou4f2 18997 -1.94 0.003401 
Aldh3a1 11670 -1.93 0.009362 
Nat2 17961 -1.93 0.011506 
1190005I06Rik 68918 -1.92 0.001761 
D1Pas1 110957 -1.91 0.003641 
Tmem64 100201 -1.9 0.000188 
Msc 17681 -1.88 0.007444 
Slc40a1 53945 -1.88 0.0051 
3021401C12Rik 70678 -1.87 0.003689 
Pdzd4 245469 -1.85 0.000148 
Zscan5b 170734 -1.84 0.007297 
Slfn9 237886 -1.84 0.001019 
Brd4 57261 -1.82 0.001107 
OTTMUSG00000002042 432591 -1.82 0.039722 
 187 
Mypn 68802 -1.81 0.013675 
Calcoco2 76815 -1.81 0.004712 
BC049349 234413 -1.81 0.008461 
Ldhc 16833 -1.8 0.000289 
Lad1 16763 -1.79 0.023699 
Epha4 13838 -1.77 0.004836 
Spp1 20750 -1.76 0.00255 
Pramel7 347712 -1.76 0.037836 
Terf1 21749 -1.75 0.004492 
Ier2 15936 -1.73 0.001907 
Dpp4 13482 -1.72 0.001814 
Tmem40 94346 -1.72 5.07E-05 
1500011B03Rik 66236 -1.71 0.011704 
Duxbl 278672 -1.71 0.022354 
Efhd1 98363 -1.69 0.010199 
Ppap2b 67916 -1.67 0.005386 
Kcmf1 74287 -1.67 0.002227 
Scarb2 12492 -1.66 0.00583 
Tsx 22127 -1.65 0.023659 
B3galtl 381694 -1.64 0.000956 
Ddr2 18214 -1.63 0.038155 
Xlr3a 22445 -1.63 0.038874 
EG626058 626058 -1.62 0.006667 
Tfpi 21788 -1.6 0.01845 
Dmrtc1c 71083 -1.59 0.016547 
Aurkc 20871 -1.58 0.001552 
Chic1 12212 -1.56 0.008671 
Rex2 19715 -1.56 0.010866 
Lpar1 14745 -1.55 8.96E-06 
Rpl39l 68172 -1.55 0.000145 
Acss1 68738 -1.55 0.024295 
Rhox13 73614 -1.55 0.015154 
Birc3 11796 -1.51 0.007559 






















Complete Gene Listings – Micro Array Data 
 







1300003B13Rik 74149 -4.63 0.004526 
Hs6st2 50786 -4.37 0.008932 
1110012J17Rik 68617 -3.9 0.021317 
Has2 15117 -3.67 0.002887 
Pftk1 18647 -3.49 0.009212 
Irs1 16367 -3.37 0.006214 
Dscaml1 114873 -3.31 0.002029 
Grhl2 252973 -3.26 0.021473 
B230206F22Rik 78878 -3.22 0.006588 
Slc16a2 20502 -3.21 0.020233 
Mcoln3 171166 -3.21 0.00145 
Pphln1 223828 -3.08 0.000916 
2700008G24Rik 72545 -3.01 0.001721 
Cdh9 12565 -2.99 0.010782 
Prkcbp1 228880 -2.96 2.96E-05 
P2ry5 67168 -2.91 0.02685 
2610008E11Rik 72128 -2.83 0.006625 
Ptpn13 19249 -2.79 0.019421 
Hivep2 15273 -2.77 2.54E-05 
Marveld3 73608 -2.77 0.002929 
Lrp2 14725 -2.75 0.020445 
Peli2 93834 -2.75 0.009335 
Dnase2a 13423 -2.74 0.04551 
Arl4c 320982 -2.74 0.001502 
Cacna1b 12287 -2.69 0.00137 
Id1 15901 -2.65 0.006057 
Car4 12351 -2.64 0.001113 
Dab2 13132 -2.64 0.014852 
Setd1b 208043 -2.63 0.033169 
Fat1 14107 -2.62 0.025426 
Gfra1 14585 -2.61 0.003505 
Zfp467 68910 -2.57 0.029875 
Irs4 16370 -2.56 0.006105 
Pou3f1 18991 -2.56 0.042136 
Wnt8a 20890 -2.55 0.002471 
Thbs1 21825 -2.55 0.001591 
2610019E17Rik 75614 -2.55 0.046492 
Prss8 76560 -2.53 0.002669 
Cpeb1 12877 -2.51 0.003853 
Rbm39 170791 -2.51 0.016205 
Wt1 22431 -2.48 0.008853 
Myl9 98932 -2.48 0.017298 
Cdh2 12558 -2.46 0.003841 
 189 
Wbscr27 79565 -2.44 0.001457 
Klhl23 277396 -2.44 0.024422 
Cobll1 319876 -2.44 0.010882 
Slc6a15 103098 -2.43 0.034368 
Centd1 212285 -2.43 0.019124 
2410014A08Rik 109154 -2.42 0.043674 
Hdgfrp3 29877 -2.41 0.001173 
Rbm35b 77411 -2.4 0.002412 
Ripk1 19766 -2.38 0.027257 
Ms4a4d 66607 -2.37 0.004601 
Plch1 269437 -2.34 0.018138 
Cachd1 320508 -2.34 0.024622 
Fbxo32 67731 -2.33 0.007874 
Pdf 68023 -2.33 0.033294 
Chd7 320790 -2.33 0.001028 
Zfp758 224598 -2.32 0.042235 
Irs2 384783 -2.3 0.004224 
Cited2 17684 -2.29 0.03814 
Plxdc2 67448 -2.29 0.0059 
6430527G18Rik 238330 -2.29 0.010347 
Marveld2 218518 -2.28 0.005277 
Sema3c 20348 -2.27 0.000154 
Smarca1 93761 -2.27 0.00228 
Lrrn4 320974 -2.27 0.002532 
Plcxd1 403178 -2.27 0.012106 
Rbm3 19652 -2.25 0.000213 
Riok2 67045 -2.24 0.034541 
Lrfn4 225875 -2.24 0.001177 
2210010L05Rik 98682 -2.23 0.002364 
1810032O08Rik 66293 -2.22 0.003471 
Katnal2 71206 -2.22 0.011697 
Slc12a2 20496 -2.21 0.041235 
AA409316 105732 -2.21 0.025703 
Amotl2 56332 -2.2 0.005538 
Kctd12b 207474 -2.19 0.003363 
Gramd1c 207798 -2.18 0.007781 
Inadl 12695 -2.17 0.005962 
Kctd15 233107 -2.17 0.031149 
Kif1a 16560 -2.16 0.011096 
Kdelc2 68304 -2.16 0.011168 
Atf7ip2 75329 -2.16 0.035758 
A730035I17Rik 77630 -2.16 0.02576 
Ccno 218630 -2.16 0.006081 
C530008M17Rik 320827 -2.16 0.046789 
Zfhx3 11906 -2.15 0.016242 
Zbtb2 381990 -2.15 0.034374 
Fign 60344 -2.13 0.002315 
Erap1 80898 -2.13 0.029607 
2310045A20Rik 231238 -2.13 0.015188 
Gabra4 14397 -2.12 0.000154 
 190 
Cyr61 16007 -2.12 0.042656 
Rnpc3 67225 -2.12 0.033816 
Zfp423 94187 -2.12 0.016947 
Socs2 216233 -2.12 0.01527 
Foxa1 15375 -2.11 0.016496 
Stk11 20869 -2.11 0.042437 
Malat1 72289 -2.11 0.015565 
Josd3 75316 -2.1 0.040201 
Met 17295 -2.09 0.013785 
Itsn2 20403 -2.09 0.026876 
AI314180 230249 -2.08 0.049732 
Nr3c1 14815 -2.07 0.003118 
Psmb8 16913 -2.06 0.031928 
Rpo1-4 20019 -2.06 0.009543 
Zfp52 22710 -2.06 0.001667 
Trim44 80985 -2.06 0.007409 
P2rx7 18439 -2.05 0.005816 
Atrx 22589 -2.04 0.045986 
Rpl3 27367 -2.03 0.002841 
Rps9 76846 -2.03 0.009922 
Zfp608 269023 -2.03 0.036834 
Mettl2 52686 -2.02 0.000597 
Jmy 57748 -2.02 0.006914 
Eif4g3 230861 -2.02 0.000255 
Gli3 14634 -2.01 0.029701 
Sox3 20675 -2.01 0.030476 
Slc4a4 54403 -2.01 0.005603 
Crebzf 233490 -2.01 0.023509 
Zfp36l2 12193 -2 0.046417 
Map3k5 26408 -2 0.003993 
Dapk1 69635 -2 0.002536 
Pdlim3 53318 -1.99 0.004742 
Lemd3 380664 -1.99 0.037843 
Vamp8 22320 -1.98 0.002052 
Irx5 54352 -1.98 0.007005 
Ubxn2b 68053 -1.97 0.000574 
AI504432 229694 -1.97 0.040809 
Cdc14a 229776 -1.97 0.021854 
Rif1 51869 -1.96 0.008918 
Mrps25 64658 -1.96 0.048512 
1110059G02Rik 68786 -1.96 0.022116 
Tulp4 68842 -1.96 0.027811 
4930426D05Rik 74644 -1.96 0.010737 
Zfp386 56220 -1.95 0.021763 
Afap1l2 226250 -1.95 0.00613 
Ebf1 13591 -1.94 0.038235 
D5Wsu178e 28042 -1.94 0.033293 
Hnrnpa2b1 53379 -1.94 0.001769 
Bclaf1 72567 -1.94 0.046322 
Rbm45 241490 -1.94 0.025121 
 191 
Sall1 58198 -1.93 0.036832 
2310010M24Rik 71897 -1.93 0.007746 
9030204A07Rik 109199 -1.93 0.013572 
Crabp2 12904 -1.92 0.028561 
Crebbp 12914 -1.92 0.014931 
Fndc4 64339 -1.92 0.002796 
5730408K05Rik 67531 -1.92 0.010929 
Larp4 207214 -1.92 0.045947 
Zfp362 230761 -1.92 0.018905 
Pon2 330260 -1.92 0.003686 
Cpsf6 432508 -1.92 0.006211 
Fst 14313 -1.91 0.01336 
Acsl5 433256 -1.91 0.004396 
Rragd 52187 -1.9 0.028614 
Dpp7 83768 -1.9 0.022809 
Thap6 381650 -1.9 0.019976 
Rbmx 19655 -1.89 0.000468 
Zcrb1 67197 -1.89 0.001541 
Pwwp2b 101631 -1.89 0.001716 
Sestd1 228071 -1.89 0.012336 
Bach2 12014 -1.88 0.040329 
Cox7c 12867 -1.88 0.011271 
Mfhas1 52065 -1.88 0.000975 
Mdn1 100019 -1.88 0.042976 
App 11820 -1.87 0.000785 
1200003I07Rik 66869 -1.87 0.045248 
Ttc17 74569 -1.87 0.012215 
Fzd6 14368 -1.86 0.047647 
Slc35b4 58246 -1.86 0.019068 
2610002M06Rik 67028 -1.86 0.002091 
Neto2 74513 -1.86 0.008583 
9430029L20Rik 109249 -1.86 0.03924 
Zfp709 236193 -1.86 0.026503 
Smcr8 237782 -1.86 0.016321 
Rnf217 268291 -1.86 0.000913 
Ank 11732 -1.85 0.035763 
Ctnnd2 18163 -1.85 0.011483 
Atf7ip 54343 -1.85 0.015468 
Prkd1 18760 -1.84 0.009879 
Axud1 215418 -1.84 0.013703 
Ddx51 69663 -1.83 0.024551 
2810403A07Rik 74200 -1.83 0.034454 
Tcf3 21415 -1.82 0.004259 
Naalad2 72560 -1.82 0.009571 
Vgll3 73569 -1.82 0.028932 
Rps15a 267019 -1.82 0.014427 
Wac 225131 -1.81 0.007293 
Lypd6 320343 -1.81 0.00621 
Dtna 13527 -1.8 0.007242 
Ktn1 16709 -1.8 0.02844 
 192 
Nab1 17936 -1.8 0.001827 
Dlg2 23859 -1.8 0.014706 
Phlda3 27280 -1.8 0.001501 
Atxn1l 52335 -1.8 0.0294 
3300001P08Rik 67684 -1.8 0.002263 
Rpl41 67945 -1.8 0.009395 
Stox2 71069 -1.8 0.017063 
Dos 216164 -1.8 0.039114 
Trub2 227682 -1.8 0.00235 
Tmem150 232086 -1.8 0.040777 
D030011O10Rik 320560 -1.8 0.011531 
Csf2ra 12982 -1.79 0.006994 
Mef2a 17258 -1.79 0.026205 
Notch1 18128 -1.79 0.007693 
Matr3 17184 -1.78 0.001189 
Plxnc1 54712 -1.78 0.014776 
1810029B16Rik 66282 -1.78 0.010106 
Rbm12b 72397 -1.78 0.025485 
Csnk1d 104318 -1.78 0.013869 
Ssh1 231637 -1.78 0.011649 
C77370 245555 -1.78 0.01951 
Ctgf 14219 -1.77 0.024081 
Pabpc1 18458 -1.77 0.038973 
2810474O19Rik 67246 -1.77 0.017511 
Tnrc6c 217351 -1.77 0.016622 
Cpne8 66871 -1.76 0.009872 
Cdc2l5 69562 -1.76 0.02757 
Depdc2 109294 -1.76 0.017031 
D8Ertd82e 244418 -1.76 0.005533 
AI747699 381236 -1.76 0.000519 
Rai1 19377 -1.75 0.032389 
Soat1 20652 -1.75 0.016879 
Rpl35 66489 -1.75 0.029639 
Zcchc3 67917 -1.75 0.018492 
Lysmd2 70082 -1.75 0.01475 
1700013H16Rik 75514 -1.75 0.000783 
6820401H01Rik 75743 -1.75 0.007905 
Sertad4 214791 -1.75 0.01064 
Med13 327987 -1.75 0.01668 
Rpl9 20005 -1.74 0.01825 
Map3k7 26409 -1.74 0.037242 
Reep3 28193 -1.74 0.020636 
Zdhhc2 70546 -1.74 0.002655 
Nrip1 268903 -1.74 0.028645 
F830028O17Rik 320071 -1.74 0.007797 
Ldoc1 434784 -1.74 0.00856 
Dab1 13131 -1.73 0.016795 
Dst 13518 -1.73 0.008659 
Epc1 13831 -1.73 0.009848 
Satb1 20230 -1.73 0.021319 
 193 
Nr2c2 22026 -1.73 0.008863 
Zfp644 52397 -1.73 0.017882 
Wars2 70560 -1.73 0.046215 
Cds2 110911 -1.73 0.001189 
Dusp4 319520 -1.73 0.029857 
2810432L12Rik 67063 -1.72 0.022967 
Rps10 67097 -1.72 0.016953 
Akap13 75547 -1.72 0.040414 
Rbm16 106583 -1.72 0.019852 
Ahdc1 230793 -1.72 0.039746 
Suhw4 235469 -1.72 0.006194 
Rbm4 19653 -1.71 0.021568 
Snhg1 83673 -1.71 0.021721 
Tmem5 216395 -1.71 0.00673 
Dsg2 13511 -1.7 0.023819 
Sh3kbp1 58194 -1.7 0.038918 
Sfpq 71514 -1.7 0.00345 
4930432O21Rik 74670 -1.7 0.037117 
Gt(ROSA)26Sor 14910 -1.69 0.00548 
Zfp566 72556 -1.69 0.019449 
Spopl 76857 -1.69 0.02712 
Elf1 13709 -1.68 0.008512 
Epb4.1l3 13823 -1.68 0.020388 
2810002O09Rik 72345 -1.68 0.000362 
Wdr40b 245404 -1.68 0.020668 
Spin2 278240 -1.68 0.010828 
Sos2 20663 -1.67 0.010213 
Wdr4 57773 -1.67 0.031317 
Rpl11 67025 -1.67 0.014557 
ENSMUSG00000073019 331484 -1.67 0.003968 
Pgr 18667 -1.66 0.004369 
Slc20a2 20516 -1.66 0.000442 
Gtf3c6 67371 -1.66 0.012083 
Ipo4 75751 -1.66 0.006757 
Hif1a 15251 -1.65 0.005518 
AU044157 100334 -1.65 0.043483 
Lzts2 226154 -1.65 0.000404 
Lpgat1 226856 -1.65 0.017078 
Phf20l1 239510 -1.65 0.036475 
Setx 269254 -1.65 0.024398 
Auts2 319974 -1.65 0.014278 
Ssbp2 66970 -1.64 0.004692 
Cdc2l6 78334 -1.64 0.018137 
Wdr6 83669 -1.64 0.022616 
Zfp771 244216 -1.64 0.022527 
L1cam 16728 -1.63 0.041958 
Smndc1 76479 -1.63 0.001829 
AW112037 98667 -1.63 0.011406 
D330050I23Rik 399603 -1.63 0.031703 
Pde3b 18576 -1.62 0.00094 
 194 
Rnpepl1 108657 -1.62 0.016373 
AI661453 224833 -1.62 0.035331 
Peo1 226153 -1.62 0.017713 
Id4 15904 -1.61 0.03739 
Prlr 19116 -1.61 0.042153 
Tbk1 56480 -1.61 0.021725 
Wdr12 57750 -1.61 0.035871 
Iws1 73473 -1.61 0.007295 
Gns 75612 -1.61 0.041008 
Cyp7b1 13123 -1.6 0.019112 
Bcl11a 14025 -1.6 0.042175 
Gpatch4 66614 -1.6 0.03109 
2610044O15Rik 72139 -1.6 0.008891 
Bicc1 83675 -1.6 0.03284 
Dcun1d2 102323 -1.6 0.029049 
Ttc13 234875 -1.6 0.040359 
LOC552906 552906 -1.6 0.048088 
Bub3 12237 -1.59 0.018072 
Pbx3 18516 -1.59 0.026522 
Thap2 66816 -1.59 0.015543 
Dph2 67728 -1.59 0.038339 
Wdr81 192652 -1.59 0.014507 
Dse 212898 -1.59 0.029448 
4930513N10Rik 319960 -1.59 0.018207 
Naaladl1 381204 -1.59 0.006749 
BC023969 407828 -1.59 0.000565 
Bicd1 12121 -1.58 0.012318 
1300014I06Rik 66895 -1.58 0.020053 
Yaf2 67057 -1.58 0.043175 
Zfp513 101023 -1.58 0.012258 
Bptf 207165 -1.58 0.021384 
B230354K17Rik 320063 -1.58 0.03487 
Slc20a1 20515 -1.57 0.00052 
Gcs1 57377 -1.57 0.003518 
Sh3rf1 59009 -1.57 0.005608 
2700038G22Rik 67194 -1.57 0.012308 
1110032E23Rik 68659 -1.57 0.02246 
Wdr7 104082 -1.57 0.026449 
Strn 268980 -1.57 0.005311 
Prpf4b 19134 -1.56 0.005859 
Renbp 19703 -1.56 0.018493 
Ubl4 27643 -1.56 9.72E-05 
Tbl1xr1 81004 -1.56 0.049166 
Bmpr1a 12166 -1.55 0.001585 
Ccdc59 52713 -1.55 0.011403 
St6gal2 240119 -1.55 0.008692 
Dpysl3 22240 -1.54 0.041711 
Akt3 23797 -1.54 0.004841 
2810022L02Rik 67198 -1.54 0.009148 
2810427A07Rik 72767 -1.54 0.037273 
 195 
Prtg 235472 -1.54 0.031536 
Nmi 64685 -1.53 0.027957 
Zfp787 67109 -1.53 0.035728 
Car13 71934 -1.53 0.032171 
Zfp618 72701 -1.53 0.008747 
Hnrnpr 74326 -1.53 0.033721 
Pnpla7 241274 -1.53 0.025188 
Insm1 53626 -1.52 0.029562 
Alg13 67574 -1.52 0.019283 
Fjx1 14221 -1.51 0.001668 
Zfp830 66983 -1.51 0.043395 















































Complete Gene Listings – Micro Array Data 
 








EG653016 653016 10.71 0.000273 
Adm 11535 6.97 0.006384 
Gadd45b 17873 6.94 0.035357 
Ier3 15937 6.57 0.000353 
Txnip 56338 5.84 0.008172 
A2m 232345 5.47 0.001829 
Zc3h6 78751 4.64 0.013729 
Ppp1r3c 53412 4.59 0.002643 
4930583H14Rik 67749 4.42 0.002927 
Dnaic2 432611 4.41 0.008241 
Cadm4 260299 4.23 0.010215 
Lrrc2 74249 4.04 0.00466 
Ndrg1 17988 4.04 0.009897 
Aoc3 11754 3.95 0.008563 
Dynlt3 67117 3.91 0.016584 
Gpi1 14751 3.79 0.000544 
Adm 11535 3.78 0.002924 
Hoxa1 15394 3.43 0.023056 
Cdc42ep2 104252 3.41 0.003107 
Rnf128 66889 3.34 0.018156 
Pdgfrb 18596 3.23 0.019588 
Porcn 53627 3.13 0.009091 
H2-Bl 14963 3.11 0.01823 
Hoxb13 15408 3.11 0.008702 
Sult6b1 73671 3.01 0.012964 
Dhrs7 66375 2.99 0.018137 
Gabbr1 54393 2.97 0.045829 
Frmd4b 232288 2.96 0.010593 
Polr3gl 69870 2.96 0.002411 
Zc3h6 78751 2.96 0.001466 
Arrdc4 66412 2.93 0.005904 
Txnip 56338 2.91 0.00049 
Rnf128 66889 2.9 0.016913 
Dnaic2 432611 2.8 0.005974 
Ppp1r3c 53412 2.78 0.003005 
Bhlhb2 20893 2.75 0.026594 
Ier3 15937 2.71 0.000389 
Bhlhb2 20893 2.7 0.000772 
Pdgfrb 18596 2.66 0.003827 
Etv4 18612 2.63 0.00332 
Dixdc1 330938 2.57 0.008344 
 197 
Tcf19 106795 2.54 0.002402 
Aldh1l2 216188 2.52 0.01821 
Dhrs7 66375 2.51 0.001464 
Slc16a6 104681 2.5 0.00035 
Otub2 68149 2.49 0.01027 
Fkbp1b 14226 2.45 0.0028 
Ero1l 50527 2.43 0.001103 
Lrrc2 74249 2.42 0.028081 
Stag3 50878 2.41 0.014322 
Pygl 110095 2.4 0.002447 
Lyrm5 67636 2.39 0.00494 
Dynlt3 67117 2.38 0.001346 
Krt19 16669 2.38 0.033157 
Asns 27053 2.37 0.000292 
Ccnd2 12444 2.35 0.018804 
Cd68 12514 2.34 0.02154 
Cd47 16423 2.32 0.011272 
Cd99 673094 2.27 0.000192 
Armc8 74125 2.24 0.026344 
Asns 27053 2.24 0.000168 
1810020D17Rik 66273 2.23 0.000743 
Ndrg1 17988 2.23 0.000347 
Ndufs4 17993 2.23 0.009174 
Entpd5 12499 2.21 5.59E-05 
Slc9a3r2 65962 2.19 0.006779 
EG653016 653016 2.17 3.99E-05 
Hoxb13 15408 2.17 0.022618 
Hoxa1 15394 2.16 0.008629 
Matn3 17182 2.14 0.000877 
Nudt12 67993 2.13 0.008692 
Tmem106a 217203 2.13 0.006064 
Acpl2 235534 2.12 0.008781 
Ccnd2 12444 2.12 0.044662 
B230380D07Rik 235461 2.11 0.01962 
Dna2 327762 2.11 0.039302 
4931406C07Rik 70984 2.09 0.000526 
Rab39 270160 2.09 0.013352 
Dna2 327762 2.08 0.003533 
Ndrg1 17988 2.08 0.002102 
Aldh1l2 216188 2.07 0.004112 
Dnmt3a 13435 2.07 0.004359 
Sipa1l1 217692 2.07 0.002547 
Gadd45b 17873 2.06 0.005904 
Lrrc51 69358 2.06 0.018316 
Cadm4 260299 2.04 0.001439 
6030408C04Rik 217558 2.03 2.23E-05 
9130227C08Rik 219094 2.03 0.017057 
A2m 232345 2.03 0.003055 
Krt19 16669 2.02 0.006582 
3110057O12Rik 269423 2.01 0.011358 
 198 
Acpl2 235534 2 0.025816 
Cdc42ep2 104252 2 0.014979 
Gabbr1 54393 2 0.003305 
Snupn 66069 2 0.029402 
Gpi1 14751 1.98 0.005695 
Rab39 270160 1.98 0.003219 
6030408C04Rik 217558 1.96 0.00156 
Arrdc3 105171 1.96 0.033445 
D130020L05Rik 319760 1.95 0.029142 
Etv4 18612 1.94 0.001792 
Ift122 81896 1.94 0.018169 
Cd99 673094 1.93 0.048918 
Cd47 16423 1.92 0.006694 
Dnmt3a 13435 1.92 0.005178 
Papola 18789 1.92 0.014338 
Frmd4b 232288 1.91 0.015018 
Pygl 110095 1.9 0.009339 
Wipi1 52639 1.89 0.043501 
Arrdc3 105171 1.88 0.015682 
Lrrc51 69358 1.88 0.03579 
Tspyl4 72480 1.88 0.001951 
Dixdc1 330938 1.86 0.004225 
Gbe1 74185 1.86 0.017887 
Lyrm5 67636 1.86 0.011213 
4930583H14Rik 67749 1.83 0.001126 
Atp5s 68055 1.83 0.002423 
Aoc3 11754 1.82 0.020256 
Rbks 71336 1.82 0.012451 
Crkrs 69131 1.81 0.010894 
Fkbp1b 14226 1.81 0.000981 
Spg3a 73991 1.81 0.00653 
Spg3a 73991 1.81 0.02979 
9130227C08Rik 219094 1.8 0.023247 
Atp5s 68055 1.79 0.012762 
Ero1l 50527 1.79 0.001683 
Sipa1l1 217692 1.79 0.003231 
B230380D07Rik 235461 1.78 0.000796 
Matn3 17182 1.78 0.009102 
Nudt12 67993 1.78 0.009555 
Plekhh1 211945 1.78 0.011372 
Crkrs 69131 1.77 0.017515 
Stag3 50878 1.77 0.003532 
Lrrc2 74249 1.76 0.013819 
Atp1a3 232975 1.75 0.01029 
Entpd5 12499 1.75 0.002937 
H2-Bl 14963 1.75 0.007363 
Pgm2 72157 1.75 0.007316 
Snupn 66069 1.75 0.012054 
Polr3gl 69870 1.74 0.003656 
Tspyl4 72480 1.74 0.008403 
 199 
D930009K15Rik 399585 1.72 0.020164 
Tcf19 106795 1.71 0.002466 
6720401G13Rik 103012 1.7 0.025637 
Arrdc4 66412 1.69 0.01386 
Plekhh1 211945 1.69 0.002939 
Ppapdc1b 71910 1.69 0.025386 
Ptgr2 77219 1.69 0.0152 
Siae 22619 1.69 0.011741 
Trf 22041 1.69 0.032928 
4931406C07Rik 70984 1.68 0.00235 
Bcap29 12033 1.68 0.018346 
D930009K15Rik 399585 1.68 0.02577 
Rdh11 17252 1.67 0.047991 
Ift122 81896 1.66 0.006838 
Ppapdc1b 71910 1.66 0.01128 
Pter 19212 1.66 0.010471 
Rdh11 17252 1.66 0.038102 
Trf 22041 1.66 0.025571 
Rbks 71336 1.65 0.006665 
Siae 22619 1.64 0.020386 
Papola 18789 1.63 0.038948 
Slc9a3r2 65962 1.63 0.007508 
Armc8 74125 1.61 0.033766 
Bcap29 12033 1.61 0.015003 
Gbe1 74185 1.61 0.000225 
Pter 19212 1.61 0.008718 
Wipi1 52639 1.61 0.040633 
Pgm2 72157 1.6 0.003464 
Sult6b1 73671 1.6 0.001899 
Ptgr2 77219 1.59 0.000646 
Tcte3 21647 1.59 0.039618 
6720401G13Rik 103012 1.57 0.006303 
Cd68 12514 1.56 0.025475 
D130020L05Rik 319760 1.56 0.007154 
Slc16a6 104681 1.56 0.046957 
Atp1a3 232975 1.55 0.029894 
Otub2 68149 1.53 0.00344 
Tmem106a 217203 1.53 0.005295 
1810020D17Rik 66273 1.51 0.03354 
3110057O12Rik 269423 1.51 0.029398 















Complete Gene Listings – Micro Array Data 
 







Igfbp4 16010 6.12 0.022218 
Atp12a 192113 5.2 0.034683 
Nupr1 56312 4.17 0.015656 
LOC624112 624112 3.7 0.040737 
Stra8 20899 3.36 0.014634 
Ypel2 77864 3.34 0.039338 
Selenbp1 20341 3.29 0.038505 
Cidea 12683 3.12 0.011504 
Icam1 15894 3.12 0.030684 
Smarcd3 66993 3.09 0.034352 
Cyp2s1 74134 3.05 0.031639 
Actn3 11474 3.04 0.001613 
Gdpd1 66569 3.04 0.046835 
Anxa2 12306 3.01 0.003859 
Plekha4 69217 3 0.004953 
Irf8 15900 2.96 0.020435 
Mapt 17762 2.94 0.012047 
Stmn2 20257 2.93 0.014065 
Pvr 52118 2.91 0.015788 
Acss2 60525 2.86 0.019339 
Gchfr 320415 2.82 0.018241 
Acp5 11433 2.8 0.001765 
Aldoc 11676 2.78 0.01476 
P4ha1 18451 2.77 0.0427 
Higd1a 56295 2.75 0.020308 
Cox7a1 12865 2.73 0.031978 
Tcfcp2l1 81879 2.72 0.015299 
Hck 15162 2.71 0.034658 
Rmcs5 114888 2.68 0.024608 
Padi2 18600 2.66 0.038446 
H2-Ab1 14961 2.65 0.002661 
Ppp1r3b 244416 2.64 0.046883 
Ankrd37 654824 2.63 0.004227 
Slc1a1 20510 2.63 0.006072 
Cobl 12808 2.59 0.003299 
Esrrb 26380 2.59 0.007544 
Fbxo2 230904 2.59 0.029233 
3100002J23Rik 75429 2.58 0.029909 
Nid1 18073 2.58 0.004186 
Mfge8 17304 2.56 0.039232 
Xpr1 19775 2.56 0.014739 
Anln 68743 2.54 0.011499 
 201 
Tcfap2c 21420 2.53 0.002008 
Gprc5a 232431 2.5 0.001512 
Clgn 12745 2.48 0.001241 
AU015836 385493 2.47 0.021281 
Gstm1 14862 2.47 0.001181 
Pcsk1n 30052 2.47 0.008586 
2600009P04Rik 66572 2.46 0.004789 
Stx12 100226 2.46 0.01343 
Aldh1b1 72535 2.44 0.003883 
Socs3 12702 2.42 0.020476 
Atp4a 11944 2.41 0.035251 
Col5a3 53867 2.39 0.011917 
Pde9a 18585 2.38 0.005756 
Ncan 13004 2.35 0.037107 
Pcolce 18542 2.35 0.042962 
Tnnt1 21955 2.33 0.005799 
Scarb1 20778 2.32 0.004194 
Vegfa 22339 2.31 0.009503 
A430033K04Rik 243308 2.28 0.002621 
Dgat2 67800 2.27 0.047929 
Iqcg 69707 2.27 0.005036 
Ppm1j 71887 2.27 0.005225 
Pycr1 209027 2.25 0.006009 
Rasa4 54153 2.25 0.003958 
Tex14 83560 2.25 0.011632 
Gsn 227753 2.23 0.022017 
Cth 107869 2.21 0.001413 
Immp2l 93757 2.21 0.0172 
Cib2 56506 2.2 0.020862 
Ott 18422 2.2 0.01682 
4933437F05Rik 71275 2.19 0.027026 
BC032203 210982 2.19 0.03356 
Ndufa4l2 407790 2.19 0.004847 
Sat2 69215 2.19 0.049855 
EG432988 432988 2.18 0.003272 
Guca1a 14913 2.18 0.035346 
4930504H06Rik 75040 2.17 0.049715 
2200002K05Rik 69137 2.16 0.004355 
Paqr5 74090 2.16 0.020257 
Sc5d 235293 2.16 0.015719 
Wfdc2 67701 2.16 0.021002 
Pfkfb3 170768 2.15 0.027795 
Stat3 20848 2.15 0.031919 
Selenbp2 20342 2.14 0.0274 
E2f1 13555 2.13 0.029204 
Fstl1 14314 2.13 0.018477 
Sep-06 56526 2.12 0.002222 
Figf 14205 2.12 0.011667 
Specc1 432572 2.12 0.025742 
Stc1 20855 2.12 0.017517 
 202 
Tmem38b 52076 2.12 0.015017 
3632451O06Rik 67419 2.11 0.002186 
Capns1 12336 2.11 0.003017 
Snapc1 75627 2.11 0.006183 
Tpmt 22017 2.11 0.030061 
Ccbl2 229905 2.1 0.020929 
Ldhb 16832 2.09 0.03285 
Abca3 27410 2.08 0.025979 
Ephx1 13849 2.08 0.003231 
Insig1 231070 2.07 0.043779 
Aifm2 71361 2.06 0.015417 
Ccng2 12452 2.06 0.00383 
Exdl2 97827 2.06 0.006268 
Hey1 15213 2.06 0.001701 
Sox15 20670 2.06 0.002339 
Syce1 74075 2.06 0.012615 
Ak7 78801 2.05 0.017344 
Eif2s2 67204 2.05 0.011072 
Bhlhb8 17341 2.04 0.004515 
Rab11fip5 52055 2.04 0.017136 
Acp6 66659 2.03 0.026024 
Hsdl2 72479 2.03 0.038328 
Lrrc34 71827 2.03 0.003325 
Csnk1e 27373 2.02 0.003751 
Hebp1 15199 2.02 0.00523 
Clybl 69634 2.01 0.000462 
Spa17 20686 2.01 0.02366 
Triml1 244448 2.01 0.000372 
Zap70 22637 2.01 0.022789 
Cd74 16149 2 0.005854 
Irgq 210146 2 0.010122 
Lss 16987 2 0.006271 
Stxbp1 20910 2 0.031058 
Slc29a1 63959 1.99 0.005465 
Trim40 195359 1.99 0.02251 
Lgmn 19141 1.98 0.009602 
Psph 100678 1.98 0.008011 
Tbrg1 21376 1.98 0.004715 
Tmem50b 77975 1.98 0.008255 
1700025K23Rik 66337 1.97 0.001485 
4930455F23Rik 74895 1.97 0.029788 
BC028528 229600 1.97 0.017511 
Hsf2bp 74377 1.97 0.024533 
Rad9b 231724 1.97 0.006333 
Hnrnpd 11991 1.96 0.004962 
Smtnl2 276829 1.96 0.007735 
Cntnap2 66797 1.95 0.002582 
Mfap5 50530 1.95 0.021274 
Pik3r5 320207 1.95 0.039169 
Rcn3 52377 1.95 0.010249 
 203 
B4galnt2 14422 1.94 0.00324 
Mad2l2 71890 1.94 0.009165 
Neil1 72774 1.94 0.032404 
1810010H24Rik 69066 1.93 0.041192 
Insl6 27356 1.93 0.027684 
Nptx2 53324 1.93 0.012713 
Zfp383 73729 1.92 0.003421 
4930430E16Rik 73873 1.91 0.008748 
Ccbl1 70266 1.91 0.010579 
Rab27a 11891 1.91 0.007181 
Slc31a1 20529 1.91 0.040794 
Vash1 238328 1.91 0.023742 
Pgrmc2 70804 1.9 0.003811 
2610029I01Rik 77032 1.89 0.00254 
Akap2 11641 1.89 0.016684 
Dock6 319899 1.89 0.015528 
Ucp2 22228 1.89 0.008649 
1810058I24Rik 67705 1.88 0.030583 
Agtr1a 11607 1.88 0.002982 
Glo1 109801 1.88 0.018006 
1110007C09Rik 68480 1.87 0.025206 
Angptl6 70726 1.87 0.032281 
Cnot6l 231464 1.87 0.021588 
Nubpl 76826 1.87 0.00179 
Rage 26448 1.87 0.005516 
1110001A16Rik 68554 1.86 0.044764 
Cdc42 12540 1.86 0.013565 
Elovl2 54326 1.86 0.015013 
Fip1l1 66899 1.86 0.000345 
Pigyl 66268 1.86 0.004214 
Psat1 107272 1.86 0.011776 
D330028D13Rik 231946 1.85 0.008407 
Timp3 21859 1.85 0.008882 
Adamtsl4 229595 1.84 0.0147 
Sccpdh 109232 1.84 0.011449 
Slc7a1 11987 1.84 0.006586 
Tmem146 106757 1.84 0.003951 
1110054O05Rik 66209 1.83 0.030574 
Bcat1 12035 1.83 0.002595 
Nicn1 66257 1.83 0.042381 
4632404H22Rik 78755 1.82 0.001022 
Ahi1 52906 1.82 0.042244 
Cry2 12953 1.82 0.01294 
Hk1 15275 1.82 0.031258 
2610318N02Rik 70458 1.81 0.00042 
Calca 12310 1.81 0.0094 
Hspb11 72938 1.81 0.020496 
Pck2 74551 1.81 0.001846 
Tmed10 68581 1.81 0.001157 
Cdyl2 75796 1.8 0.004146 
 204 
Chrna5 110835 1.8 0.003756 
Elmod2 244548 1.8 0.027534 
Fam126a 84652 1.8 0.002802 
Sox12 20667 1.8 0.014061 
Tm7sf2 73166 1.8 0.008103 
Tnfaip8 106869 1.8 0.009941 
Als2cr2 227154 1.79 0.008427 
Krtap16-7 170656 1.79 0.008619 
Nmnat2 226518 1.79 0.021941 
Syne2 319565 1.79 0.007462 
Prelid2 77619 1.78 0.008813 
Prkcb 18751 1.78 0.011058 
Slc38a4 69354 1.78 0.001146 
EG434402 434402 1.77 0.015788 
Nos1 18125 1.77 0.000234 
Rims3 242662 1.77 0.025583 
Twf2 23999 1.77 0.015661 
1810063B07Rik 67509 1.76 0.022821 
Mef2b 17259 1.76 0.010416 
Pgm1 66681 1.76 0.006415 
Ppp2r5c 26931 1.76 0.007371 
Rad51l1 19363 1.76 0.006263 
Rrm2b 382985 1.76 0.009535 
Tcp11 21463 1.76 0.003093 
Trfr2 50765 1.76 0.010893 
Nrgn 64011 1.75 0.004952 
Rnf19a 30945 1.75 0.001716 
Slc1a5 20514 1.75 0.017482 
1200009F10Rik 67454 1.74 0.045097 
Aldh6a1 104776 1.74 0.00147 
Brp44l 55951 1.74 0.007187 
Gch1 14528 1.74 0.010924 
Nup62 18226 1.74 0.015255 
1700009P17Rik 75472 1.73 0.023309 
Slc13a5 237831 1.73 0.019783 
Idh3a 67834 1.72 0.002847 
Ppp4r2 232314 1.72 0.020654 
Scube2 56788 1.72 0.012785 
Anxa4 11746 1.71 0.001216 
Ctdspl2 329506 1.71 0.014671 
E430028B21Rik 211948 1.71 0.032819 
Ncor1 20185 1.71 0.032632 
Zrsr2 22184 1.71 0.038364 
Chrna9 231252 1.7 0.019961 
Cmtm6 67213 1.7 0.011321 
Gys1 14936 1.7 0.023935 
Itpk1 217837 1.7 0.004879 
Sub1 20024 1.7 0.007947 
Ccs 12460 1.69 0.005756 
Coq3 230027 1.69 0.009128 
 205 
Gpr160 71862 1.69 0.001763 
Lgals8 56048 1.69 0.021231 
Litaf 56722 1.69 0.007004 
Wwtr1 97064 1.69 0.018756 
Zfp277 246196 1.69 0.002789 
Zfyve21 68520 1.69 0.001358 
Nek6 59126 1.67 0.007397 
Prss36 77613 1.67 0.027111 
1810049H13Rik 66431 1.66 0.006666 
Sars 20226 1.66 0.001311 
Slc3a2 17254 1.66 0.00056 
Acyp1 66204 1.65 0.028218 
Efhc1 71877 1.65 0.023729 
Gfpt2 14584 1.65 0.003253 
Mett5d1 76894 1.65 0.027774 
Ostf1 20409 1.65 0.008331 
Aqp11 66333 1.64 0.001954 
Chmp2a 68953 1.64 0.024304 
Cxcl12 20315 1.64 0.015802 
Nars 70223 1.64 0.001036 
Oas1c 114643 1.64 0.029671 
Pde2a 207728 1.64 0.024873 
Slc8a3 110893 1.64 0.00787 
Spns2 216892 1.64 0.048073 
Tsga10 211484 1.64 0.004505 
2210010C17Rik 70080 1.63 0.014964 
2410017P09Rik 69709 1.63 0.017082 
Bnip3 12176 1.63 0.001583 
Gstm3 14864 1.63 0.025601 
Phox2a 11859 1.63 0.033617 
Tmhs 328789 1.63 0.040443 
Cryz 12972 1.62 0.003147 
Mbp 17196 1.62 0.022546 
Zfp185 22673 1.62 0.000785 
Creld1 171508 1.61 0.004894 
Ndrg2 29811 1.61 0.001409 
Psmb9 16912 1.61 0.032814 
Synj2bp 24071 1.61 0.025054 
Gng2 14702 1.6 0.005 
Pdzd8 107368 1.6 0.017999 
1810030N24Rik 66291 1.59 0.002264 
Adamts9 101401 1.59 0.015991 
Asrgl1 66514 1.59 0.014575 
Ccdc77 67200 1.59 0.014364 
Rpl22 19934 1.59 0.004935 
Slc25a12 78830 1.59 0.006434 
Derl3 70377 1.58 0.011386 
Slc6a3 13162 1.58 0.00979 
Cars 27267 1.57 0.045623 
Plod2 26432 1.57 0.024527 
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Tfrc 22042 1.57 0.013896 
Ttll8 239591 1.57 0.027051 
Gstz1 14874 1.56 0.012366 
Phf21a 192285 1.56 0.001687 
Prps1 19139 1.56 0.041858 
Lnp 69605 1.55 0.032316 
Asl 109900 1.54 0.003171 
Bphl 68021 1.54 0.002992 
Gstm4 14865 1.54 0.032619 
Narf 67608 1.53 0.030505 
Sf3b1 81898 1.53 0.004896 
Mlh3 217716 1.52 0.00017 
Rbpj 19664 1.52 0.000515 
Efna1 13636 1.51 0.028847 












































Complete Gene Listings – Micro Array Data 
 







Ovgp1 12659 4.07 0.004275 
1700026D08Rik 75556 4 0.019638 
Atr 245000 2.89 5.46E-05 
BC022960 237246 2.75 0.000608 
Zfpm2 22762 2.69 0.006111 
Ccdc82 66396 2.67 0.002865 
Scd1 20249 2.66 0.004388 
H3f3b 15081 2.5 0.012424 
Scyl1 78891 2.49 0.004529 
Fgf11 14166 2.49 0.007133 
Neil3 234258 2.47 0.003587 
6720463M24Rik 77744 2.41 0.001516 
AI842396 103844 2.33 0.004312 
Ltbp3 16998 2.31 0.006902 
2510009E07Rik 72190 2.31 0.000626 
4921513D23Rik 223989 2.27 0.008547 
Ddit3 13198 2.25 0.010153 
Trpc2 22064 2.22 0.001896 
Pla2g7 27226 2.16 0.001925 
Atxn10 54138 2.13 0.011031 
Rarb 218772 2.1 0.008266 
Chrnb1 11443 2.09 0.000959 
Itga8 241226 2.05 0.013982 
Fkbp7 14231 2.05 0.007565 
6030426L16Rik 628850 2.04 0.001479 
Ccdc58 381045 2.03 0.002476 
Prmt8 381813 2.02 0.010599 
Meg3 17263 1.99 0.000305 
Ppil6 73075 1.98 0.027742 
Mid1 17318 1.97 0.01297 
Nisch 64652 1.96 0.000429 
Greb1 268527 1.96 0.005735 
Ddit4 74747 1.96 0.002082 
Ccdc76 229780 1.96 0.004392 
Gdap10 14546 1.93 0.000671 
Nrcam 319504 1.92 0.044349 
D4Wsu53e 27981 1.92 0.001463 
Chchd7 66433 1.91 0.00192 
Hook1 77963 1.88 0.006116 
4933439C20Rik 66776 1.88 0.01452 
Cryzl1 66609 1.87 0.003032 
5430406J06Rik 73848 1.87 0.004895 
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Mirg 373070 1.85 0.029337 
Kank3 80880 1.85 0.002039 
Dennd4a 102442 1.83 2.10E-05 
Atp5c1 11949 1.83 0.010186 
Sema5b 20357 1.82 0.005647 
Cald1 109624 1.82 0.014786 
Npepps 19155 1.81 0.015435 
2310005E10Rik 67861 1.8 0.014729 
1500012D20Rik 78327 1.79 0.000951 
Tet2 214133 1.78 0.017184 
Ylpm1 56531 1.77 0.031684 
Phf20l1 239510 1.76 0.021539 
5830418K08Rik 319675 1.75 0.006386 
Clk1 12747 1.74 0.005234 
Zfp53 24132 1.73 0.014735 
Appl2 216190 1.73 0.005218 
Lpin1 14245 1.72 0.002979 
Iah1 67732 1.71 0.016962 
Ube2b 22210 1.7 0.005517 
Sbsn 282619 1.69 0.012074 
Mapk4 225724 1.69 0.031152 
Hrbl 231801 1.68 0.036437 
Erdr1 170942 1.68 0.002117 
Timm9 30056 1.67 0.019481 
Senp8 71599 1.67 0.001166 
Nipa1 233280 1.67 0.029954 
Ccdc28b 66264 1.67 0.011386 
Mbnl2 105559 1.66 0.0017 
Hist2h2be 319190 1.66 0.010461 
Rbm25 67039 1.65 0.031137 
Map3k2 26405 1.65 0.025672 
Ndufab1 70316 1.64 0.043186 
Gstt1 14871 1.64 0.001387 
Ctr9 22083 1.63 0.038507 
B630005N14Rik 101148 1.62 0.002384 
2010004M13Rik 76511 1.62 0.003477 
Zfp36l1 12192 1.61 0.002395 
Mfsd11 69900 1.6 0.001594 
4930422N03Rik 76871 1.58 0.001073 
Sf3b2 319322 1.57 0.013359 
Eml5 319670 1.57 0.030955 
Chrnb4 108015 1.56 0.005618 
Uevld 54122 1.54 0.002433 
Cbfa2t2 12396 1.54 0.030809 
Bnip2 12175 1.54 0.004358 
1110006E14Rik 76286 1.54 0.037052 
Suv39h1 20937 1.53 0.000604 
Rbbp4 19646 1.53 0.004865 
Hells 15201 1.53 0.01175 
2810417H13Rik 68026 1.53 0.00143 
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2700097O09Rik 72658 1.53 0.001651 
Ncapd2 68298 1.52 0.013731 
Cdadc1 71891 1.52 0.007863 
Slc43a2 215113 1.51 0.006726 
Six6os1 75801 1.51 0.00298 
Rgs11 50782 1.51 0.027371 
Gmpr2 105446 1.51 0.018461 





















































Micro Array Data 
Genes expressing the greatest fold changes 
From the microarray analysis, a total of 45101 genes were returned of which 1,101 were 
differentially expressed when comparing WTE14 cells with two independently derived 
KIT Null cell lines. Genes were sorted into categories dependent on low and high fold 
changes in the presence or absence of LIF. A “low” fold change indicates that the gene 
expression is lower in KIT Null cells compared with the level of expression in WT E14 
cells and a “high” fold change indicates that the gene is expressed at a higher level in KIT 
null cells compared to controls. Genes that were expressed at a higher or lower level, 
regardless of LIF inclusion, were also identified. 
It is important to realise the limitations of the microarray data that has been presented and 
the theoretical nature of the discussed hypotheses.  This data only gives a snapshot of the 
cells genetic composition at a given time point and is therefore only an estimation of gene 
transcription and expression.  As the RNA was extracted from the cells after 36 hours, 
this time interval may not have been long enough to observe any linage specific 
expression changes.  The cells were also grown in monolayer cultures so may not provide 
the differentiating cells with the correct growth requirements for differentiation.  To add 
support to the genes isolated from micro array analysis and the theories presented, further 
experimentation must be carried out to relate function to gene expression.  This 
experimentation should initially include Q-RT-PCR analysis to confirm expression levels 
of the selected genes a well as differences in protein levels.  However, caution must be 
taken with protein level in this instance as the time taken for RNA expression may not 
equate to the time required for post translation modification at the protein level.    Further 
experimentation on WTE14 cells using „knock down‟ experimentation with siRNA in 
conjunction with clonal assays could confirm the effect of the gene at the biological level. 
Even so, this data search has presented several candidate genes and a potential signalling 
pathway for further study.   
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change p-value Function 
Low LIF+ Serpin  -3.13 2.56E-05 Gametogenesis 
  Lefty2  -2.93 0.00240333 
 
Controls left-right  embryo/heart patterning 
  Dppa3  -2.81 0.00832241 Expressed in primordial germ cells (Alias Stella) 
  Aoah  -2.7 0.000519558 
Prevents prolonged inflammatory reactions to 
Gram-negative bacteria and LPS 
  Enah -2.5 7.38E-05 
Links signal transduction pathways and is required for normal 
neural development 
Always low Mest  -22.89 8.46691E-06 
Expressed in all major fetal organs and tissues 
and is involved in gene imptinting/methylation 
  Kit  -11.27 0.000131969 A receptor tyrosine kinase 
  Tox3  -5.38 0.000510852 Involved in alteration of chromatin structure. 
  Hmga2  -4.48 0.00244546 High mobility group (HMG) 
  Lefty1  -4.39 0.0466286 
Involved in left-right asymmetry determination of organ 
systems during development 
Low LIF- 1300003B13Rik -4.63 0.00452621 Zinc ion binding 
  Hs6st2  -4.37 0.00893246 
A cell surface component that influences cell growth, 
differentiation, adhesion, and migration 
  1110012J17Rik -3.9 0.021317 Expressed during embryonic brain development E6-E9.5 
  Has2  -3.67 0.00288673 
Involved with embryonic development 
leukocyte homing and tumor metastasis. 
  Pftk1  -3.49 0.00921185 
A serine/threonine-protein kinase involved in the control of 
the eukaryotic cell cycle, 
High LIF + Ovgp1  4.07 0.00427506 
Encodes a secreted protein involved with ovulated oocytes, 
blastomeres and spermatozoan acrosomal regions 
  1700026D8Rik  4 0.0196383 Unknown but expressed at E1 and in germ cell of the adult 
  Atr  2.89 5.46E-05 
PI3K family member that signals in response to DNA strand 
breaks/ replication errors to maintain cell 
viability/chromosomal stability 
  BC022960  2.75 0.000608366 Expressed on the postnatal ovary and on the retina 
  Zfpm2  2.69 0.00611125 Regulates haematopoiesis and cardio genesis 
Always high EG653016  10.71 0.000273241 Signals downstream of Oct 4 expressedin pluripotent cell lines 
  Adm  6.97 0.00638398 
A survival factor against hypoxic cell death by suppressing 
reactive oxygen species and is PI3K regulated. 
  Gadd45b  6.94 0.0353568 
Inhibits upstream regulators of JNK 
 
  Ier3  6.57 0.000352653 
This gene functions to protect cells from Fas- or tumor 
necrosis factor type alpha-induced apoptosis. 
  Txnip  5.84 0.00817171 
Functions as a transcriptional repressor and over-expression 
will induce G0/G1 cell cycle arrest. 
High -LIF Igfbp4  4.07 0.00427506 
Encodes an IGF-binding protein that prolongs the half-life of 
the IGFs to stimulate cell culture growth. 
  Atp12a  4 0.0196383 Catalyzes the hydrolysis of ATP 
  Nupr1  2.89 5.46E-05 Responsible for potassium absorption in various tissues 
  LOC624112  2.75 0.000608366 Hypothetical protein 
  Stra8  2.69 0.00611125 
Required for the transition into meiosis for both female and 




Micro Array Data 














Venn diagram showing numbers of differentially expressed  genes in the 
following categories; High gene expression in Kit null cells compared to WT ET 
14 cells (red) Low gene expression in Kit null cells compared to WT E14 
cells(blue) in the presence (+LIF) and absence (- LIF) of LIF. Overlapping areas 
refer to genes that are high or low both in self-renewing (+LIF) and differentiating 

















































Micro Array Data 





Condition Receptor Gene Entrez Fc p-value Function 
 
 
Always high  PDGF Pdgfrb 18596 3.23 0.0195876 
 
Transmembrane receptor tyrosine 
kinase 
High Lif - Flt Vegfa 22339 2.31 0.00950305 
 
Binds and activates Flt 1 
   Figf 14205 2.12 0.0116674 
 
Binds and activates Flt 1 
High Lif + FGF Fgf11 14166 2.49 0.00713286 
 
Induces broad mitogenic and cell 
survival activities 
   Fgfr1op2 77744 2.41 0.00151649 
 
Binds to a transmembrane regions 
of FGF1R to promote  
ligand independent dimerisation 
   Fgf17 103844 2.33 0.00431222 
 
Mitogen that binds to FGFR1-4 
   Fgf13 72190 2.31 0.00062621 
 
Mitogen that binds to FGFR1-4 
   Fgfr4 223989 2.27 0.00854738 
 
Transmembrane receptor tyrosine 
kinase 
   Fgf1 22064 2.22 0.00189606 
 
Mitogen that binds to FGFR1-4 
Low LIF - HGFR Met 17295 -2.09 0.0137854 






Differentially expressed genes with a role in receptor signalling and potential 


























Always high Rab39 270160 2.09 0.013352 
 Cd99 673094 2.27 0.000192 
 Cd68 12514 2.34 0.02154 
 Ero1l 50527 2.43 0.001103 
 Frmd4b 232288 2.96 0.010593 
 H2-Bl 14963 3.11 0.01823 
 Porcn 53627 3.13 0.009091 
 Pdgfrb 18596 3.23 0.019588 
 Rnf128 66889 3.34 0.018156 
 Cdc42ep2 104252 3.41 0.003107 
 Cadm4 260299 4.23 0.010215 
 4930583H14Rik 67749 4.42 0.002927 
 Ier3 15937 6.57 0.000353 
 Ier3 15937 6.57 0.000353 
High LIF+ Timm9 30056 1.67 0.019481 
 Atp5c1 11949 1.83 0.010186 
High LIF- Abca3 27410 2.08 0.025979 
 Figf 14205 2.12 0.011667 
 2200002K05Rik 69137 2.16 0.004355 
 Xpr1 19775 2.56 0.014739 
 H2-Ab1 14961 2.65 0.002661 
 Rmcs5 114888 2.68 0.024608 
 Hck 15162 2.71 0.034658 
 Higd1a 56295 2.75 0.020308 
 Pvr 52118 2.91 0.015788 
 Stmn2 20257 2.93 0.014065 
 Anxa2 12306 3.01 0.003859 
 Selenbp1 20341 3.29 0.038505 
 Atp12a 192113 5.2 0.034683 
Always low Mest 17294 -22.89 8.47E-06 
 Kit 16590 -11.27 0.000132 
 2610528J11Rik 66451 -3.83 0.004605 
 Odz4 23966 -2.24 0.035382 
 Stx3 20908 -2.14 0.001158 
 Marveld1 277010 -1.86 0.015964 


























































 Vwf 22371 -2.49 0.018866 
 Slc23a1 20522 -2.27 0.033908 
 Epha4 13838 -1.77 0.004836 
Low LIF- Dscaml1 114873 -3.31 0.002029 
 Slc16a2 20502 -3.21 0.020233 
 Mcoln3 171166 -3.21 0.00145 
 Cdh9 12565 -2.99 0.010782 
 Peli2 93834 -2.75 0.009335 
 Cacna1b 12287 -2.69 0.00137 
 Cdh2 12558 -2.46 0.003841 
 Plch1 269437 -2.34 0.018138 
 Cachd1 320508 -2.34 0.024622 
 Lrfn4 225875 -2.24 0.001177 
 Slc12a2 20496 -2.21 0.041235 
 Cox7c 12867 -1.88 0.011271 
 Reep3 28193 -1.74 0.020636 
 Lpgat1 226856 -1.65 0.017078 
 Prlr 19116 -1.61 0.042153 
 Aoc3 11754 3.95 0.008563 
 Hs6st2 50786 -4.37 0.008932 
 Marveld3 73608 -2.77 0.002929 
 Lrp2 14725 -2.75 0.020445 
 Gfra1 14585 -2.61 0.003505 
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Condition Gene Entrez Fc p-value Apoptosis  
Always high Adm  11535 6.97 0.00638398 anti 
  Gadd45b 17873 6.94 0.0353568 anti 
High LIF- Nupr1 56312 4.17 0.0156559 anti 
  Vegfa 22339 2.31 0.00950305 pro- 
  E2f1 13555 2.13 0.0292042 pro- 
  Cidea 12683 3.12 0.0115041 pro- 
  Aifm2 71361 2.06 0.0154174 pro- 
  Agtr1a 11607 1.88 0.00298249 pro- 
  1110007C09Rik 68480 1.87 0.0252057 anti 
  Adamtsl4 229595 1.84 0.0146997 pro- 
  Tnfaip8 106869 1.8 0.00994052 anti- 
  Als2cr2 227154 1.79 0.00842711 anti- 
  Rrm2b 382985 1.76 0.00953504 anti 
  1200009F10Rik 67454 1.74 0.0450971 pro- 
  Litaf 56722 1.69 0.00700436 pro- 
  Bcap29 12033 1.68 0.0183457 pro- 
  Nek6 59126 1.67 0.00739737 anti- 
  Efhc1 71877 1.65 0.0237288 pro- 
  Bnip3 12176 1.63 0.00158255 pro- 
  Bnip2 12175 1.54 0.00435788 anti- 
High LIF + Hells 15201 1.53 0.0117503 anti- 
  Ddit3 13198 2.25 0.0101532 pro- 
  Rarb 218772 2.1 0.00826633 pro- 
  Ddit4 74747 1.96 0.00208198 pro- 
Low LIF- Bcl11a 14025 -1.6 0.0421745 anti 
  Smndc1 76479 -1.63 0.00182944 anti 
  Sh3kbp1 58194 -1.7 0.0389175 pro- 
  Notch1 18128 -1.79 0.00769348 anti 
  Map3k5 26408 -2 0.00399269 pro/anti 
  Jmy 57748 -2.02 0.00691351 pro- 
  P2rx7 18439 -2.05 0.00581636 pro- 
  Ripk1 19766 -2.38 0.0272567 pro- 
  Dnase2a 13423 -2.74 0.0455096 pro- 
  Hif1a 15251 -1.65 0.00551823 pro- 
  Map3k7 26409 -1.74 0.0372419 pro/anti 
  Axud1 215418 -1.84 0.0137026 pro 
  App 11820 -1.87 0.000784599 pro- 
  Bclaf1 72567 -1.94 0.0463219 pro- 
  Dapk1 69635 -2 0.00253603 pro- 
  Birc3 11796 -1.51 0.00755898 anti- 















Condition Gene Entrez Fc p-value Function reference 
Always high Adm  11535 6.97 0.00638398 Activates JNK  Oufik 2009 
  Gadd45b 17873 6.94 0.0353568 
Activate MKK4 upstream 
of JNK and P38 Takekawa 1998 
High LIF- Nupr1 56312 4.17 0.0156559 Downregulated by JNK Malicet 2003 
  Als2cr2 227154 1.79 0.00842711 
Antiapoptotic activation 
of JNK Sanna 2002 
  Nup62 18226 1.74 0.0152551 




  Efna1 13636 1.51 0.028847 
Inhibits the EGFR-RAS-
MAPK pathway Neve 2006 
Low LIF - Map3k7(TaK 1) 26409 -1.74 0.0372419 
Activates MAPK8/JNK, 
MAP2K4/MKK4, Takatsu 2000 
  Map3k5 (ASK1) 26408 -2 0.00399269 
Activates the MAPK 
pathway Nakagawa 2008 
  P2rx7 18439 -2.05 0.00581636 
Activates the MAPK 
pathway (ERK1/2 ) Gavala 2008 
  Sh3rf1 59009 -1.57 0.00560794 
A scaffold protei for the 
JNK /c-jun pathway Lyons 2007 
Always low Ndst1 15531 -1.62 0.00872428 
Enhances MAPK 
signalling Pallerla 2007 





































  Cell Size uM   
Replicate WT E14 KIT Null 
1 540 215 
  590 153 
  520 141 
2 870 213 
  870 266 
  642 213 
3 701 215 
  730 240 
  700 276 
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